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Abstract 
The tendency for breast cancer cells in the primary tumour to spread to other parts of the 
body and form new tumours in vital organs, termed metastasis, is the main cause of breast 
cancer-related mortality. Therapies that target highly metastatic cells have proved 
successful in the clinic, but the development of therapeutic resistance to these targeted 
therapies significantly limits clinical efficacy. Therefore, new anticancer therapies that 
target invasive tumour cells while minimising systemic toxicity are required. The 
urokinase plasminogen activator receptor (uPAR) is recognised as a biomarker for 
metastasis in breast cancer. Targeting uPAR in breast cancer can be achieved by attaching 
plasminogen activator inhibitor-2 (PAI-2) to the surface of drug-loaded liposomes in 
order to facilitate liposome uptake into uPAR-positive cells. This thesis aimed to develop 
and evaluate novel uPAR-targeted liposomes containing a potent anti-mitotic cytotoxin, 
N-alkylisatin (N-AI), for the treatment of metastatic breast cancer. 
 
Novel N-AI-loaded PAI-2-functionalised (N-AI PAI-2) liposomes were prepared and 
characterised for the first time using optimisations to previously reported methods. N-AI 
PAI-2 liposomes were 141.1 ± 5.0 nm in diameter, were monodisperse (polydispersity 
index of 0.086 ± 0.030), had a zeta potential of –4.66 ± 0.52 mV and contained N-AI at a 
concentration of 2.2 mM, equating to 43.1% drug loading (% w/w). PAI-2 conjugation to 
the surface of N-AI-loaded liposomes was confirmed using size-exclusion 
chromatography and Western blotting. A PAI-2 inhibitory activity assay confirmed that 
PAI-2 attached to the surface of liposomes remained active against urokinase 
plasminogen activator after conjugation, making N-AI PAI-2 liposomes suitable for 
further in vitro and in vivo evaluation against breast cancer cells. 
 
In vitro, cellular uptake of fluorescently labelled PAI-2 liposomes into MDA-MB-231 
breast cancer cells (uPAR-positive) was increased (P < 0.01) relative to MCF-7 breast 
cancer cells (uPAR-negative) as measured by flow cytometry. Confocal microscopy 
confirmed uptake of PAI-2 liposomes and localisation within lysosomes. N-AI PAI-2 
liposomes showed a potent cytotoxic effect against MCF-7 and MDA-MB-231 cells 
grown in 2D after 72 h (IC50 values of 31.84 ± 8.20 µM and 5.40 ± 1.14 µM, respectively) 
and in 3D as multicellular tumour spheroids after 96 h (IC50 values of 40.2 ± 4.0 µM and 
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60.4 ± 7.1 µM, respectively). In vivo, N-AI PAI-2 liposomes had a plasma half-life of 
5.82 h and showed an increased accumulation at the primary tumour site in an orthotopic 
MDA-MB-231 BALB/c-Fox1nu/Ausb xenograft mouse model relative to non-
functionalised liposomes at the 10 min, 3 h and 6 h post-injection time points (P < 0.001). 
However, N-AI PAI-2 liposomes did not have a significant effect on primary tumour 
growth or metastatic burden in the lungs and liver relative to non-functionalised N-AI-
loaded liposomes or empty control liposomes in the two breast tumour mouse models 
used.  
 
Finally, quantification of PAI-2 attached to the surface of liposomes was achieved using 
single-molecule fluorescence microscopy. Liposome and protein signals showed a high 
degree of colocalisation, indicating that proteins were bound to intact liposomes. The 
average number of attached PAI-2 molecules per liposome was determined to be 11 ± 4. 
Imaging of dual-functionalised liposomes revealed stoichiometries of the two attached 
proteins in accordance with the molar ratios of protein added during preparation. For dual-
ligand liposomes, the post-insertion method generated liposomes with a more equal ratio 
of the two ligands than the conventional method (2.1 ± 2.5 and 17 ± 18, respectively). 
This work demonstrated, for the first time, the practical utility of single-molecule 
fluorescence microscopy to quantify the density and stoichiometry of ligands attached to 
the surface of liposomes. 
 
Together, the findings in this thesis support the rationale for targeting uPAR-positive 
breast cancer cells using N-AI-loaded PAI-2-functionalised liposomes. The results 
provide a basis for the further development of dual-ligand liposomes that can target 
heterogeneous tumour cells within the HER2-positive and triple-negative breast cancer 
subtypes in which uPAR has been shown to play a key role in driving metastasis. The 
development of novel liposomal drug carriers that can target uPAR to deliver cytotoxic 
drugs to heterogeneous populations of breast cancer cells is a promising therapeutic 
strategy to improve the treatment of metastatic breast cancer. This thesis will guide future 
work exploring targeting of the urokinase plasminogen activator system as a strategy to 
overcome breast cancer metastasis.  
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1.1 Introduction 
The development of therapeutic resistance to targeted anticancer therapies remains a 
significant clinical problem in the treatment of breast cancer, with intratumoural 
heterogeneity playing a key role. In this context, improving the therapeutic outcome 
through simultaneous targeting of multiple tumour cell subtypes within a heterogeneous 
breast tumour is a promising approach. Liposomes have emerged as useful drug carriers 
that can reduce systemic toxicity and increase drug delivery to the tumour site. While 
clinically used liposomal drug formulations show marked therapeutic advantages over 
free drug formulations, ligand-functionalised liposomes that can target multiple tumour 
cell subtypes may further improve therapeutic efficacy by facilitating drug delivery to a 
broader population of tumour cells making up the heterogeneous tumour tissue. Ligand-
directed liposomes enable the active targeting of cell receptors via surface-attached 
ligands that direct drug uptake into tumour cells or tumour-associated stromal cells and 
therefore can increase the selectivity of drug delivery. This literature review will discuss 
the utility of recent ligand-directed liposome approaches, with a focus on dual-ligand 
liposomes for targeting intratumoural heterogeneity, for the treatment of solid tumours. 
 
1.2 Breast cancer growth and metastasis 
Breast cancer is the most common invasive cancer in women worldwide, accounting for 
approximately one quarter of all cancer cases in women, and remains a leading cause of 
cancer-related morbidity and mortality (Jemal et al. 2011). While overall survival rates 
have improved steadily over the last several decades, breast cancer still accounts for 
almost half a million deaths each year (Ward et al. 2015). Breast cancer is a particularly 
deadly disease due to the tendency for cancer cells of the primary tumour to spread to 
other parts of the body and form new tumours in vital organs – most commonly the bones, 
liver, lungs and brain (Lee 1983). This process, termed metastasis, is the leading cause of 
breast cancer-related mortality, with more than 90% of patient deaths resulting from 
metastatic disease (Dolznig et al. 2011). Despite a growing understanding of the 
molecular biology of breast cancer metastasis and several key advancements in treatment 
options, there is currently no cure for metastatic breast cancer (Sledge 2016). 
 
3 
 
Metastasis occurs when tumour cells break away from the primary tumour and form new 
tumours at distant sites (Fig. 1.1). The primary tumour microenvironment is a complex 
heterogeneous structure, consisting of an extracellular matrix (ECM), blood vasculature 
and a collection of cell types that support tumour cell growth, including endothelial cells, 
fibroblasts and immune cells (Thoma et al. 2014). Through the activation or inactivation 
of particular genes, tumour cells acquire the ability to proliferate indefinitely and utilise 
key cellular systems to facilitate their tumourigenic properties (Hanahan & Weinberg 
2011; Klein 2008). One of the key processes facilitating metastasis is the degradation of 
the ECM, the physical barrier separating distinct tissue types in the body. Proteolytic 
enzymes expressed by tumour cells and tumour-associated cells (Section 1.5) degrade 
structural proteins of the ECM and create a passageway that allows the movement of 
tumour cells out of the area (Krueger et al. 2005). Angiogenesis, the process by which the 
tumour creates its own vasculature to obtain vital nutrients and remove waste products, 
facilitates the escape of tumour cells into the bloodstream and lymphatic system (Weidner 
et al. 1991). This process, termed intravasation, enables tumour cells to travel to distant 
sites in the body and form new secondary metastatic tumours. 
 
 
Figure 1.1: Tumour cell invasion and metastasis in breast cancer. Cells of the primary tumour 
produce proteolytic enzymes that degrade components of the extracellular matrix (ECM), allowing 
tumour cells to escape from the area and enter the bloodstream or lymphatic system. Tumour cells can 
then travel to other sites in the body and form secondary tumours. Figure adapted from Liu et al. 
(2005). 
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1.3 Molecular classification of breast cancer 
The identification of tumour biomarkers and the associated molecular classification of 
breast cancer is highly useful for determining the most appropriate treatment course and 
evaluating prognosis. Many important biomarkers and cellular pathways involved in 
tumour progression and metastasis have been identified and assist in the prediction of 
patient responses to hormone-, chemo-, immuno- and molecular-targeted therapies, the 
determination of mechanisms of therapeutic resistance, and the prediction of disease 
progression and likelihood of relapse (Bailey et al. 2016; Schnitt 2010). Overexpression 
of specific cell surface receptors by tumour cells may be exploited to directly target 
tumour cells using antibodies or smaller molecules, or to enable targeted delivery of 
cytotoxic compounds to tumour cells. Such targeted approaches enable more specific 
anti-tumour effects, potentially resulting in enhanced tumour cell kill and/or a reduction 
in off-target effects. 
 
Several important biomarkers involved in breast cancer progression and metastasis have 
been identified, including the estrogen receptor (ER), progesterone receptor (PR) and 
human epidermal growth factor receptor 2 (HER2) (Schnitt 2010). These biomarkers can 
be used to classify breast cancer into broad molecular subtypes (Table 1.1) (Howlader et 
al. 2014), which assist in the prediction of patient responses to chemotherapy treatments, 
the determination of mechanisms of resistance to treatments, the prediction of disease 
course and likelihood of relapse, and provide a possible target for anticancer therapies 
(Dos Anjos Pultz et al. 2014). The following sections will focus on the HER2-enriched 
subtype and the triple-negative breast cancer (TNBC) subtype. For further information 
regarding the hormone receptor-positive breast cancer subtypes, see previously published 
reviews on these topics (Abraham & Staffurth 2016; Basile et al. 2017; De Marchi et al. 
2016). 
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Table 1.1: Breast cancer molecular subtypes. Breast cancer can be broadly divided into four main 
subtypes: Luminal A, Luminal B, HER2-enriched and triple-negative. ER, estrogen receptor; PR, 
progesterone receptor; HER2, human epidermal growth factor receptor 2. 
Clinical Features Luminal A Luminal B HER2-enriched Triple-negative 
ER expression + + – – 
PR expression + + – – 
HER2 expression – + or – + – 
Incidence (%) ~30-70 ~10-20 ~5-15 ~15-20 
Targeted therapies Endocrine Endocrine Anti-HER2 None 
Rate of metastasis Low Low High High 
Prognosis Good Good Poor Poor 
 
1.3.1 Triple-negative breast cancer 
The TNBC subtype is characterised by a lack of expression of ER and PR, and a lack of 
overexpression and/or amplification of HER2 (Gluz et al. 2009). As this subtype lacks 
these three main breast cancer molecular biomarkers, there are no targeted therapy options 
for TNBC, and the use of conventional chemotherapies remains the standard of care 
(Waks & Winer 2019). In addition, TNBC is a markedly heterogeneous subtype at both 
the clinical and molecular scale, which can make treatment difficult. The prognosis of 
TNBC is generally poor, with high rates of disease recurrence and relapse (Liedtke & 
Kiesel 2012). The progression-free survival and overall survival rates of TNBC patients 
are significantly shorter than those of non-TNBC patients (Keam et al. 2007) (Fig. 1.2). 
 
 
Figure 1.2: Probability of survival in triple-negative breast cancer. Kaplan-Meier analyses of (A) 
relapse-free survival and (B) overall survival according to triple-negative and non-triple-negative 
breast cancer. Figure from Keam et al. (2007). 
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In order to develop novel and effective targeted treatment options for TNBC, the 
discovery and validation of genetic targets relevant to the TNBC subtype remains an 
active area of research (Denkert et al. 2017). Research has focused on identifying 
prognostic and predictive markers for this subtype, such as overexpression of the TP53 
gene, mutations in BRCA1/2 and dysregulation of the PI3K/AKT/mTOR pathway 
(Sporikova et al. 2018), and several clinical trials are in progress for novel molecular 
therapies and immunotherapies (Vikas et al. 2018). Therefore, the continued validation 
of further novel molecular targets for TNBC, and breast cancer more broadly, is an 
important area of research (Dos Anjos Pultz et al. 2014). 
 
1.3.2 HER2-positive breast cancer 
HER2 (also known as Erb-B2 receptor tyrosine kinase 2 (ERBB2)) belongs to the 
transmembrane epidermal growth factor receptor subfamily of tyrosine kinases involved 
in the initiation of signal transduction pathways that regulate cell growth and 
differentiation (Yarden 2001). Amplification and overexpression of HER2 (chromosome 
position 17q12) occurs in 15–25% of breast cancers and results in uncontrolled tumour 
cell proliferation (Slamon et al. 1987). The HER2-positive breast cancer subtype is 
associated with an aggressive disease course, increased resistance to chemotherapy, 
increased likelihood of metastasis and recurrence, and is indicative of an overall poor 
patient prognosis (Schnitt 2010). For this reason, HER2 has been identified as an 
important biomarker for breast cancer, as well as for several other cancer types where 
HER2 may be overexpressed, including ovarian, uterine and pancreatic cancers (Asuthkar 
et al. 2013). 
 
Several HER2-targeted therapies have been developed to treat HER2-positive breast 
cancer. Trastuzumab (TZ; trade name Herceptin®) is a humanised monoclonal antibody 
that specifically binds to the extracellular domain of HER2 to prevent tumour cell 
proliferation (Cho et al. 2003). TZ was approved for clinical use in the treatment of breast 
cancer by the US Food and Drug Administration (FDA) in 1998 (Shak et al. 1998). The 
administration of TZ in combination with chemotherapy results in a 5-month median 
increase in survival but with a small increased risk of severe cardiotoxicity due to the 
mechanism of action of doxorubicin (Rossi et al. 2016). Other HER2-targeted therapies 
have been developed to decrease toxicity and improve efficacy, including pertuzumab, 
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another humanised monoclonal antibody that binds to the HER2 extracellular domain, 
and lapatinib, a small-molecule tyrosine kinase inhibitor that targets HER2 kinase activity 
(Higa & Abraham 2007). Current clinical trials are testing the use of a combination of 
these HER2-targeted therapies in an effort to improve overall clinical efficacy and reduce 
the incidence of therapeutic resistance (Ahn & Vogel 2012), which is now recognised as 
a significant clinical problem despite TZ therapy still being the standard of care for 
HER2-positive breast cancer. 
 
Resistance to targeted therapies can develop via a number of mechanisms and may be 
intrinsic to the patient or acquired over time with the progression of treatment. Intrinsic 
resistance can arise from a lack of expression of a drug target, a mutated drug target or 
via target-independent signalling mechanisms (Masoud & Pages 2017). For example, 
some patients are intrinsically resistant to HER2-targeted therapies because of the ability 
of HER2 to form heterodimers with other human epidermal growth factor receptors, 
allowing differential intracellular signalling (Croucher et al. 2016). Intrinsic resistance to 
TZ affects a significant proportion of patients, with only 30% of HER2-positive breast 
tumours responding initially to TZ therapy (Ludyga et al. 2013). In contrast, acquired 
(also known as pleiotropic or evasive) resistance can develop in patients that were once 
responsive to treatment and can arise from de novo mutations or from clonal selection of 
intrinsically resistant clones (Wood 2015). The development of acquired resistance 
renders HER2-targeted therapies ineffective, and subsequent cancer recurrence often 
results in death from metastatic disease (Menyhart et al. 2015). Of the tumours that 
initially respond, acquired resistance to TZ therapy develops in approximately 70% of 
patients within the first year of treatment (Nahta & Esteva 2006). Several mechanisms of 
acquired TZ resistance have been hypothesised, including the expression of truncated 
forms of HER2 that prevent binding of TZ (Scaltriti et al. 2007), the activation of 
alternative signalling pathways (Ludyga et al. 2013) and the clonal selection and 
expansion of HER2-negative tumour cells as a result of the intratumoural heterogeneity 
of breast cancer (Gerlinger et al. 2012). 
 
1.4 Tumour heterogeneity and therapeutic resistance 
The genomic, functional and spatiotemporal heterogeneity that is characteristic of many 
solid tumours plays a key role in the development of resistance to targeted therapies (Fig. 
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1.3) (Alizadeh et al. 2015; Venkatesan & Swanton 2016). Mechanisms of acquired 
resistance to molecular-targeted therapies have been extensively reviewed elsewhere 
(Holohan et al. 2013; Lackner et al. 2012). The intratumoural heterogeneity of tumours 
provides a template for the clonal selection and expansion of target-negative tumour cells 
(Eirew et al. 2015) and is a known mechanism of acquired resistance to targeted therapies 
(Gerlinger et al. 2012; Sebolt-Leopold & English 2006). Individual tumours are 
comprised of a mixture of both target-positive and target-negative tumour cells 
(Solomayer et al. 2006). The administration of a targeted therapy inevitably places a 
selection pressure on a genetically and functionally heterogeneous population of tumour 
cells, resulting in the selection of tumour cells that are no longer responsive to the targeted 
therapy (Gillies et al. 2012). With time and the continuation of therapy, the target-
negative tumour cell population is able to expand so that the tumour becomes 
predominately target-negative, at which point the patient no longer shows a response to 
the original targeted therapy (Zardavas et al. 2015). In this way, the intratumoural 
heterogeneity of cancer can reduce the potential efficacy of targeted therapies and thus 
contributes to cancer recurrence and metastasis (Hayes 2016). 
 
 
Figure 1.3: Schematic representation of tumour heterogeneity. Tumour heterogeneity includes 
intertumoural and intratumoural (biomarker) heterogeneity, receptor heterogeneity and signalling 
heterogeneity. Figure from Belfiore et al. (2018a). 
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The intratumoural heterogeneity of breast cancer suggests that a multiple biomarker 
targeting strategy may be of benefit in order to target a broader range of tumour cell 
subtypes (Doolittle et al. 2015). This concept has been demonstrated by dual knockdown 
of HER2 and the commonly co-overexpressed protein tyrosine kinase 6, which showed a 
reduction of breast cancer cell migration, invasion and proliferation in vitro and a 
reduction of tumour growth in vivo (Ludyga et al. 2013). As the binding of TZ to HER2 
results in the internalisation of the complex through receptor-mediated endocytosis 
(RME), TZ may be used as a targeting ligand to deliver cytotoxin to HER2-positive 
tumour cells. Phase II clinical trials using a TZ-drug conjugate demonstrated selective 
targeting and enhanced efficacy of this approach in HER2-positive breast cancer patients 
(Burris et al. 2011). Simultaneous targeting of another breast cancer biomarker in addition 
to HER2 in a cytotoxin-delivery approach may provide a means to overcome therapeutic 
resistance and improve the efficacy of HER2-targeted therapies. Several potential 
biomarkers of cancer progression have been identified (Weigelt et al. 2005) to help guide 
decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer 
(Harris et al. 2007). Additionally, recent evidence has shown that other cell types that 
support tumour cell growth and play key roles in facilitating metastasis, including 
endothelial cells, fibroblasts and immune cells, may also be potential targets for novel 
multi-targeted therapies (Thoma et al. 2014). For example, the superior efficacy of 
independently targeting both tumour and immune cells in various cancer types has been 
demonstrated previously (Bracci et al. 2014; Emens & Middleton 2015). 
 
As previously mentioned, several receptor-targeted molecular therapies have been 
developed to treat cancer, including a range of monoclonal antibodies and antibody 
fragments that derive an anti-tumour effect through binding to cell surface receptors in 
order to inhibit tumour cell proliferation (Nahta & Esteva 2006) and/or to induce a 
cytotoxic immune response (Verschraegen 2012). Another tumour cell targeting approach 
involves the use of monoclonal antibodies, proteins or other ligands to facilitate targeted 
cell uptake of specific molecules to achieve an anti-tumour effect. For example, if the 
binding of a ligand to its target receptor results in the RME of the ligand-receptor 
complex, the targeting ligand – which may be a currently used targeted molecular therapy 
– can be used for the intracellular delivery of covalently attached cytotoxins or other 
molecules to tumour cells that express the ligand receptor (Perez et al. 2014; Sievers & 
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Senter 2013). This tumour targeting approach may help to circumvent intrinsic resistance 
driven by alternative signalling mechanisms (Menyhart et al. 2015). While the plasma 
half-life of most targeted molecular therapies tends to be relatively short, the association 
of these molecules with larger nanostructures, such as lipid-based nanoparticles or 
liposomes, can significantly extend the plasma circulation time of the targeted therapy 
and increase the therapeutic payload delivered to the tumour site (Vine et al. 2014). Such 
receptor-targeted nanoparticulate therapies may incorporate currently used targeting 
molecules, such as antibodies, onto the surface of the nanoparticle to be used as targeting 
ligands. These targeting ligands can direct the nanoparticle to receptor-positive tumour 
cells and facilitate cellular uptake of the nanoparticle, achieving intracellular delivery of 
the nanoparticle cargo for an anti-tumour effect (Section 1.6). 
 
1.5 Urokinase plasminogen activator system 
The urokinase plasminogen activator system (uPAS) has a demonstrated role in tumour 
cell invasion and metastasis (Fig. 1.4). In this system, the urokinase plasminogen activator 
(uPA), a serine protease, becomes active upon binding to its cell membrane-bound 
receptor, the urokinase plasminogen activator receptor (uPAR) (Didiasova et al. 2014). 
Active uPAR-bound uPA (uPA/uPAR) converts plasminogen, an inactive zymogen, to 
plasmin at the cell surface. Plasmin is a broad spectrum serine protease that degrades a 
range of extracellular proteins to facilitate remodelling of the ECM (Dass et al. 2008). 
The endogenous plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2) specifically 
bind to the active site of uPAR-bound uPA and inhibit the uPA-mediated conversion of 
plasminogen to plasmin (Fig. 1.4). PAI-1, the main physiological inhibitor of uPA, has 
additional cell signalling roles that facilitate tumour cell invasion (Croucher et al. 2008; 
Dass et al. 2008), and overexpression of PAI-1 in cancer is correlated with a poor patient 
prognosis (Cochran et al. 2011; Croucher et al. 2008). In contrast, overexpression of PAI-
2 in cancer is correlated with a good patient prognosis and prolonged survival (Croucher 
et al. 2008). Under normal physiological conditions, the uPA-mediated remodelling of 
the ECM is essential to promote immune cell migration, wound healing and other 
important extracellular processes (Gonias & Hu 2015). However, under pathological 
conditions such as cancer, the degradation of extracellular physiological barriers enables 
tumour cells to migrate out of the region, promoting the invasion of tumour cells into 
surrounding tissues and facilitating metastasis (O'Halloran et al. 2013). 
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Figure 1.4: Urokinase plasminogen activator system. The urokinase plasminogen activator (uPA) 
becomes active upon binding to its receptor, the urokinase plasminogen activator receptor (uPAR). 
Active uPA converts plasminogen to plasmin, a broad-spectrum serine protease that degrades the 
extracellular matrix (ECM) to promote tumour cell invasion and metastasis. Plasminogen activator 
inhibitor-1 and inhibitor-2 (PAI-1 and PAI-2) can bind to uPAR-bound uPA to prevent the uPA-
mediated conversion of plasminogen to plasmin and subsequent downstream effects promoting 
metastasis. Figure adapted from Didiasova et al. (2004). 
 
 
Numerous studies and clinical evidence have indicated a key role for uPAS in breast 
cancer metastasis (Giannopoulou et al. 2007). Amplification and overexpression of uPA 
and uPAR are recognised biomarkers of metastasis and are indicative of an overall poor 
patient prognosis for several cancer types (Dass et al. 2008; Duffy et al. 2014). In breast 
cancer, progression-free survival is inversely correlated with uPA and uPAR expression 
(Duffy et al. 2014; Harris et al. 2007). Patients with high uPA mRNA levels are more 
likely to suffer from metastatic disease (Urban et al. 2006), and overexpression of uPAR 
by tumour cells and/or stromal cells is associated with poor prognosis for metastatic breast 
cancer (Bianchi et al. 1994). In TNBC, uPAR has been shown to increase the malignant 
potential (Huber et al. 2016) and has been identified as a potential novel target for 
treatment of this breast cancer subtype (Al-Mahmood et al. 2018; Aubele et al. 2015). 
Tumour hypoxia has been shown to induce uPAR overexpression, and uPAR 
overexpression can confer tumour cell resistance to chemotherapy (Gonias & Hu 2015). 
In addition, uPAR overexpression can promote tumour cell migration through signal 
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transduction (Carriero & Stoppelli 2011). Intracellular uPAR-dependent signalling can 
promote epithelial-mesenchymal transition, causing changes to tumour cell morphology 
and inducing stem cell-like properties that facilitate a metastatic tumour cell phenotype 
(Indira Chandran et al. 2015). 
 
Within the HER2-positive breast cancer subtype, recent evidence suggests a cooperative 
effect of uPA/uPAR and HER2 on disease progression. In patients with metastatic HER2-
positive breast cancer, amplification of both HER2 and uPAR often occurs in the same 
tumour cells (Pierga et al. 2005), and the overexpression of uPAR in breast cancer cells 
within the HER2-positive subtype facilitates tumour cell invasion and a metastatic 
phenotype (Berg et al. 2012; Meng et al. 2006). In HER2-normal and HER2-amplified 
subsets of breast cancer patients, uPAR overexpression significantly reduced the 
probability of metastasis-free survival, more significantly so in the short-term for HER2 
amplified breast cancer (Indira Chandran et al. 2015). The presence of HER2-
positive/uPAR-negative and HER2-negative/uPAR-positive cells due to the 
intratumoural heterogeneity of in vivo tumours suggests that targeting both HER2 and 
uPAR may be an effective way to target multiple clonal populations of tumour cells and 
improve the efficacy of drug-based treatments for metastatic HER2-positive breast cancer 
(Sugiyama et al. 2013). In vitro studies using RNA interference showed that 
downregulation of both HER2 and uPAR in breast cancer cells was synergistic in 
supressing tumour cell growth and inducing tumour cell death, and was more effective 
than downregulating either receptor alone (Li et al. 2010). Given the role of uPAS in the 
promotion of metastasis, targeting uPA/uPAR may be a promising therapeutic strategy 
for metastatic breast cancer (Matthews 2011; Mazar et al. 2011). The protective effect of 
PAI-2 in breast cancer progression indicates that the use of PAI-2 in uPA-targeted 
therapies for cancer may be a promising novel strategy for targeting uPAR in breast 
cancer. 
 
1.5.1 Plasminogen activator inhibitor-2 
PAI-2, also known as SerpinB2, is a serine protease inhibitor that exists as a 43 kDa 
intracellular form and a 60 kDa extracellular glycosylated form (Fig. 1.5). While PAI-2 
is expressed by most cell types, expression is upregulated in pregnancy, in the immune 
response and in tumour cells (Croucher et al. 2008). As the binding of extracellular PAI-
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2 to uPAR-bound uPA results in the RME of the PAI-2/uPA/uPAR complex, PAI-2 can 
be used as a targeting ligand for the intracellular delivery of covalently attached cytotoxin 
to uPAR-positive tumour cells (Cochran et al. 2011). Previous work has shown PAI-2 to 
be non-toxic, stable and selective for uPA inhibition. It has been shown that the CD-loop 
(a 33 amino acid loop situated between α-helices C and D of the protein) of PAI-2 is not 
relevant in cell targeting of uPA/uPAR. Recombinant ΔCD-loop PAI-2 retains its 
inhibitory activity against uPA, and is also easier to express and purify (Cochran et al. 
2009). ΔCD-loop PAI-2 has four cysteine residues (C5, C145, C161 and C405) that are 
not involved in the inhibitory function of PAI-2 (Wilczynska et al. 2003) and can 
therefore be used as sites of conjugation to other molecules for targeting and delivery to 
uPA/uPAR-positive cells. 
 
 
Figure 1.5: Plasminogen activator inhibitor-2. Plasminogen activator inhibitor-2 (PAI-2) is a serine 
protease inhibitor that exists as a 43 kDa intracellular form and a 60 kDa extracellular glycosylated 
form. As the binding of extracellular PAI-2 to urokinase plasminogen activator receptor (uPAR)-
bound urokinase plasminogen activator (uPA) results in the receptor-mediated endocytosis of the PAI-
2/uPA/uPAR complex, PAI-2 can be used as a targeting ligand via conjugation of molecules to 
cysteine residues C5, C145, C161 or C405. Figure adapted from Wilczynska et al. (2003). 
 
 
ΔCD-loop PAI-2 has been previously used to target uPA/uPAR for drug delivery 
applications. PAI-2 has been successfully conjugated to the alpha-emitting radioisotope 
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Bi213 (Stutchbury et al. 2007) and to an N-alkylisatin (N-AI)-based cytotoxin (Section 
1.6.1), a potent microtubule destabilising agent (Vine et al. 2007) that can evade P-
glycoprotein (P-gp)-mediated efflux in multi-drug resistant cancer cell lines (Vine et al. 
2016). The PAI-2-N-AI conjugate showed selective targeting to and cytotoxicity against 
uPA/uPAR-positive breast cancer cells in vitro and effective inhibition of primary tumour 
regrowth in an in vivo model of breast cancer metastasis at 1/20th of the concentration of 
free N-AI (Vine et al. 2012). The attachment of PAI-2 to larger molecules, such as 
polyethylene glycol (PEG), can significantly extend the plasma half-life of PAI-2 and 
increase tumour retention in vivo (Vine et al. 2014). The use of a PEG-coated drug 
delivery carrier, such as a lipid-based nanoparticle, may further increase the in vivo 
circulation time of PAI-2 bound to the nanoparticle surface to enhance targeting of uPAR-
positive tumour cells in drug delivery applications. 
 
1.6 Liposomes for tumour targeting and drug delivery 
Liposomes have emerged as a useful delivery system for the transport of drugs and other 
molecules to solid tumours (Allen & Cullis 2013). Liposomes are spherical lipid-based 
vesicles, typically 100-200 nm in diameter, comprised of associating phospholipids that 
form a lipid bilayer surrounding an aqueous core (Pattni et al. 2015) (Fig. 1.6). This 
unique structure allows for the encapsulation of hydrophobic or hydrophilic drugs, or 
other small molecules, in the lipid bilayer or aqueous core, respectively (Gubernator 
2011). Encapsulated drugs can then be delivered to target cells for intracellular drug 
release and anti-tumour effect. The circulation time of liposome particles is largely 
dependent on their lipid composition, size, surface charge, morphology and other 
physicochemical characteristics. The dominant mechanism by which liposomes are 
typically cleared from the bloodstream is based on interactions with the phagocytic cells 
of the mononuclear phagocyte system (MPS). The inclusion of hydrophilic polymers, 
most commonly PEG, at the outer surface of the liposome can increase the in vivo 
circulation time by reducing recognition and clearance by the MPS (Uster et al. 1996). 
For this reason, PEGylated liposomes have long been considered a clinically useful 
nanoparticle for drug delivery applications. 
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Figure 1.6: General structure of liposomes. Drug-loaded liposomes may be non-ligand (passively 
targeted), single-ligand or dual-ligand (actively targeted). Phospholipids associate to form a 
hydrophobic lipid bilayer surrounding a hydrophilic aqueous core. Drugs may be encapsulated in the 
liposome bilayer or core, depending on solubility. Polyethylene glycol (PEG) is incorporated into the 
bilayer to neutralise surface charge and decrease the rate of clearance from the bloodstream. Targeting 
ligands may be covalently attached to the terminal ends of PEG chains to enable selective binding of 
the liposome to cell surface receptors for targeted drug delivery. 
 
 
Liposome-based drug formulations can offer several distinct advantages over free drug 
formulations in addition to an increased in vivo circulation time, including improved 
stability and solubilisation of the encapsulated drug, reduction in systemic toxicity of the 
drug and increased drug delivery to the tumour site (Estanqueiro et al. 2014). The superior 
activity of drug-loaded liposomes relies on a multi-step process involving both passive 
and active targeting mechanisms. Passive targeting is primarily mediated by the enhanced 
permeability and retention (EPR) effect (Fig. 1.7), defined as the extravasation and 
retention of particles less than 380-780 nm in size into the tumour interstitial space due 
to highly porous tumour vasculature and poor lymphatic drainage from the tumour site 
(Gerlowski & Jain 1986; Matsumura & Maeda 1986). The encapsulated drug can be 
released from liposomes in the tumour interstitium and can then be taken up by the tumour 
cells, or liposomes containing the drug can be internalised by the tumour cells or other 
tumour-associated cells (Barenholz 2012). Therefore, in theory, passive targeting enables 
targeting to tumours via the EPR effect. In addition, liposome formulations reduce 
exposure of normal tissues to the drug as liposomes cannot pass through intact continuous 
endothelium (except for the liver and spleen, which have a different anatomy of 
vasculature) and so do not localise there, minimising associated off-target effects while 
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simultaneously providing a mechanism for enhanced accumulation in the tumour site 
(Abdalla et al. 2018). 
 
 
Figure 1.7: The enhanced permeability and retention effect. The extravasation and retention of 
nanoparticles into the tumour interstitial space occurs due to highly porous tumour vasculature and 
poor lymphatic drainage from the tumour site. Figure from Abdalla et al. (2018). 
 
 
1.6.1 N-alkylisatins 
N-alkylisatins are a class of molecules derived from isatin (1H-indole-2,3-dione) with a 
broad range of cytotoxic and anticancer properties (Matesic et al. 2008). The N-alkyl-5,7-
dibromoisatins, including 7-dibromo-N-(p-hydroxymethylbenzyl)isatin (N-AI) (Fig. 1.8), 
are microtubule-destabilising cytotoxins with a potent anti-tumour cell effect against 
cancer cell lines in vitro (Vine et al. 2007), and an anti-tumour growth effect in vivo (Vine 
et al. 2012). The potency of these compounds against tumour cells is comparable to 
clinically used drugs such as doxorubicin and paclitaxel, but unlike many clinically used 
drugs, the N-alkylisatins are not substrates for P-gp-mediated efflux, meaning that this 
class of compounds has potential application in the treatment of multi-drug resistant 
cancers (Vine et al. 2016). 
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Figure 1.8: Chemical structure of N-alkylisatin. 5,7-dibromoisatin and the N-alkylisatin derivative 
5,7-dibromo-N-(p-hydroxymethylbenzyl)isatin. 
 
 
N-AI has been previously conjugated to PAI-2 in order to target uPA/uPAR-positive 
tumour cells for targeted drug delivery. The N-AI-PAI-2 conjugate, which had an average 
of 1-2 cytotoxin molecules per PAI-2 molecule, demonstrated a selective increased 
cytotoxic effect against uPA/uPAR-positive tumour cells in vitro, and was efficacious in 
vivo in reducing primary tumour growth in mice (Vine et al. 2012). Given the potency 
and previous validation of N-AI as a cytotoxin for use in anticancer applications, N-AI is 
a promising candidate for further development in drug delivery research. As a 
hydrophobic molecule, N-AI has a low aqueous solubility that limits the amount of drug 
that can be administered intravenously (Grimaldi et al. 2016). However, N-AI is amenable 
to encapsulation within liposomes in order to improve solubility and physicochemical 
stability. While liposomal formulations of N-AI have not been previously reported in the 
literature, the loading of similar hydrophobic anticancer drugs, such as paclitaxel and 
colchicine, into the liposome bilayer has been achieved (Koudelka & Turánek 2012; 
Kulkarni et al. 1997). 
 
1.6.2 Ligand-directed liposomes for active tumour cell targeting 
In addition to their versatile drug encapsulation capabilities, liposomes permit the active 
targeting of specific cell types via the conjugation of ligands, such as monoclonal 
antibodies, antibody fragments, proteins, peptides, carbohydrates, glycoproteins, 
aptamers and small molecules, to the liposome surface for drug delivery to cells 
expressing the target surface receptor(s) of interest (Messerschmidt et al. 2008). Active 
targeting using liposomes is achieved via conjugation of one or more ligands to the 
liposome surface to form liposomes that bind to a target receptor expressed on the tumour 
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cell surface. Following liposome extravasation into the tumour interstitial space, 
subsequent ligand-directed surface binding and internalisation (usually via RME) 
promotes liposome and drug entry into specific cell types. As actively targeted liposome 
formulations combine both passive and active drug delivery mechanisms, ligand-directed 
liposomes should show superior drug delivery compared to non-ligand liposomes, 
depending on the tumour type (Wilhelm et al. 2016). 
 
Currently, all clinically approved liposome drug formulations are non-ligand directed, 
with efficacies relying solely on passive targeting to achieve tumour accumulation. 
Despite extensive research into nanomedicine-based therapeutics, and the preclinical 
development of dozens of liposome drug formulations spanning several decades, less than 
a dozen liposomal drug formulations have been approved by the FDA for clinical use to 
date (Bobo et al. 2016; Shi et al. 2017). Of these FDA-approved liposomes, only several 
distinct formulations have been approved for the treatment of cancer, including Kaposi’s 
sarcoma, acute lymphoblastic leukaemia, pancreatic cancer, ovarian cancer, multiple 
myeloma and metastatic breast cancer (Table 1.2). Evidently, there is a bottleneck in the 
translation of liposomes from preclinical development through to clinical utility, with 
many preclinical formulations never proceeding to clinical trials and only a small 
percentage of those that do eventually making it onto the market. This bottleneck is even 
more profound for the development of ligand-directed liposomes, where there are 
currently no clinically approved formulations available (van der Meel et al. 2013). 
 
Active targeting strategies using ligand-directed liposomes have been explored 
extensively in the preclinical setting, showing improved efficacy over non-ligand 
liposomes in in vitro and in vivo models. For example, in vitro testing of doxorubicin-
loaded liposomes (analogous to Doxil®) that were surface-functionalised with an anti-
HER2 monoclonal antibody fragment demonstrated effective binding to breast cancer 
cells expressing HER2 and a 700-fold increase in drug uptake compared to non-ligand 
directed liposomes in vivo (Park et al. 2001). MM-302, a HER2-targeted liposomal 
formulation of doxorubicin, showed efficacy in xenograft models of breast cancer and 
proceeded through to clinical trials (Espelin et al. 2016). A phase II/III clinical trial of TZ 
therapy in combination with either MM-302 or chemotherapy of physician’s choice was 
recently terminated as the TZ/MM-302 treatment did not show improved efficacy over 
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the current standard of care for HER2-positive breast cancer (Miller et al. 2016). This 
may be due to the current lack of understanding around how actively targeted liposomes 
behave in immune-competent animals (i.e. humans). While the development of actively 
targeted liposomes to improve the efficacy of their passively targeted predecessors has 
been explored preclinically, there has been limited progression of such formulations 
through to clinical trials (Table 1.2) (van der Meel et al. 2013). Given the long history of 
ligand-directed liposome development and the significant investment of research into this 
area, it is important to explore the reasons why there has been limited translation of 
actively targeted liposomes in the field of cancer therapy. Following an overview of 
previous research in the field, we will highlight and discuss some of the likely reasons for 
this bottleneck in clinical progression. 
 
1.6.3 Dual-ligand liposomes for dual-targeting of tumour cells 
Liposomes have been used for tumour targeting for several decades, and while no single-
ligand or dual-ligand liposomes have yet been clinically adopted, actively targeted 
liposome formulations have been reported extensively in the literature. The utilisation of 
a dual-targeted approach has a range of reported purposes: most commonly, for 
overcoming intratumoural heterogeneity by targeting multiple tumour cell subtypes and 
targeting tumour-associated cells; for targeting tumour vasculature as a means to halt 
tumour growth; and for facilitating nanoparticle delivery across biological barriers, such 
as the blood-brain barrier (BBB), for drug delivery to the brain. 
 
Given the demonstrated performance of non-ligand liposomes in drug delivery and the 
large number of studies describing the design of ligand-bearing liposomes to target 
tumour-associated receptors, the development of liposomes that can target more than one 
tumour cell subtype in a heterogeneous tumour may help to overcome therapeutic 
limitations of current therapies (Fig. 1.9). Previous in vitro and in vivo studies have 
demonstrated that ligand-directed liposomes targeting two different cell surface receptors 
can increase the total amount of liposomes binding to the cancer cells within a tumour as 
the liposomes are able to bind to any target cell expressing either receptor, which 
increases the breadth of targeting. 
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Figure 1.9: Targeting multiple tumour cell subtypes using ligand-directed liposomes. Dual-
ligand-directed liposomes may help overcome therapeutic limitations caused by intratumoural 
heterogeneity of cancer. Liposomes bearing two disparate ligands enable liposome uptake via 
receptor-mediated endocytosis by tumour cells bearing either (or both) target receptors, thus increasing 
the range of tumour cell targeting. Single-ligand liposomes only enable targeting of the tumour cells 
bearing the single target receptor. Given the intratumoural heterogeneity of cancer, some tumour cells 
will not be targeted by the single-ligand liposome, and instead that tumour cell population may be able 
to expand. Ligand-directed liposomes may also be designed to target stromal cells for an intended anti-
tumour effect. Figure from Belfiore et al. (2018a). 
 
 
Several preclinical studies have successfully modified liposomes with two surface-bound 
moieties to create dual-ligand-directed, drug-loaded liposomes that show specific binding 
to receptor-bearing tumour cells and a resultant higher tumour cell uptake and kill than 
non-targeted or single-ligand liposomes (Lukyanov et al. 2004). For example, the cellular 
uptake and cytotoxicity of dual-ligand liposomes targeting lymphoma biomarkers CD19 
and CD20, or an equal combination of the two single-ligand liposomes at equal antibody 
amounts, were greater than for either single-ligand liposome alone (Sapra & Allen 2004). 
Similarly, a pH-sensitive doxorubicin-loaded liposome formulated to promote 
intracellular drug release was surface-functionalised with folic acid and AS1411 aptamer 
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(targeting the folate receptor and nucleolin, respectively), and showed increased cancer 
targeting and efficacy relative to single-ligand and non-ligand liposomes (Lale et al. 
2014). Dual-ligand liposomes showed enhanced cellular uptake, higher intracellular 
delivery of doxorubicin and greater apoptosis in human breast and pancreatic cancer cell 
lines than single-ligand liposomes, and had no adverse doxorubicin-related effects on a 
non-cancerous human cell line. Using a murine model of human B-cell lymphoma, drug-
loaded liposomes functionalised with antibodies targeting CD19 or CD20 showed an 
improved outcome compared to non-ligand liposomes, with a trend of increased 
therapeutic efficacy for a combination of the two compared to each alone (Sapra & Allen 
2004). 
 
Liposomes containing paclitaxel and bearing both a cell ligand peptide and cell 
penetrating peptide to target lung cancer showed greater liposome internalisation in lung 
cancer cells, greater accumulation of paclitaxel in tumour spheroids, and significantly 
greater inhibition of tumour growth in a mouse model of lung cancer than single-ligand 
and non-ligand liposomes (Wang et al. 2015). Dual-ligand paclitaxel-loaded liposomes 
containing the integrin avβ3 peptide and an anti-microbial peptide showed increased 
cellular toxicity and improved tumour growth inhibition in a colon carcinoma mouse 
model relative to single-targeted liposomes (Zhang et al. 2016). This improved delivery 
effect of dual-ligand over single-ligand targeting was also demonstrated using a 
nanostructured lipid carrier containing plasmid DNA that was surface-functionalised with 
both transferrin and hyaluronic acid, which showed increased transfection efficiency over 
single-ligand or non-ligand carriers in a mouse model of lung cancer (Zhang et al. 2017). 
While the ligand density and stoichiometry were not quantified in any examples, ligand-
directed liposomes targeting two different cell surface receptors may be able to increase 
the total amount of liposome binding to the tumour cell surface within a heterogeneous 
tumour as the liposome is able to bind to any target cell expressing either receptor (Fig. 
1.9). This is likely to increase the breadth of cellular targeting beyond a single receptor 
or cell type, subsequently enhancing drug uptake, dose and hence the anti-tumour effect 
(Laginha et al. 2005). Furthermore, dual-ligand liposomes could act to unify the 
pharmacokinetic and biodistribution properties of different ligand-functionalised 
liposomes for precise delivery to target cells, rather than using two individual ligand-
functionalised liposomes with disparate targeting moieties and pharmacological profiles. 
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In the context of glioma treatment, ligand-directed liposomal drug formulations may 
enhance drug transport across the BBB for drug delivery to the brain (Gulati & Wallace 
2012). Dual-ligand liposomes containing daunorubicin and surface-functionalised with 
both transferrin and p-aminophenyl-α-D-manno-pyranoside showed increased transport 
across the BBB, increased cellular uptake and increased survival compared to treatment 
with free daunorubicin in a rat model of brain glioma (Ying et al. 2010). Another study 
using doxorubicin-loaded liposomes surface-functionalised with both transferrin and one 
of two different cell-penetrating peptides showed improved delivery of doxorubicin 
across the brain-endothelial barrier (BEB) compared to single-ligand and non-ligand 
liposomes in vitro, and efficient translocation across the BEB in an in vitro brain tumour 
model (Sharma et al. 2014). Similarly, docetaxel-loaded nanoparticles that were surface-
functionalised with IL-13 and RGD peptide to target both tumour cells and 
neovasculature showed greater uptake in a glioma cell line than single-ligand and non-
ligand nanoparticles, and the dual-ligand nanoparticle induced higher apoptosis of cells 
in the glioma site in vivo, indicating an improvement in cell uptake and anti-tumour effect 
by dual-targeting (Gao, H. et al. 2014). This was further supported by experiments using 
dual-ligand liposomes bearing both an aptamer and a peptide moiety to target glioma and 
the BBB in an in vitro glioma model designed to recapitulate the tumour 
microenvironment (Gao, Huile et al. 2014). Collectively, the aforementioned studies 
demonstrate the potential utility of dual-ligand-directed liposomal drug formulations for 
cancer therapy, with an increased degree of liposome uptake acting to improve the anti-
tumour effect. 
 
1.6.4 Dual-ligand liposomes for targeting the tumour microenvironment 
The tumour microenvironment, which consists of fibroblasts, immune cells, vasculature, 
and ECM components such as collagen and fibrin, is increasingly being found to play a 
key role in tumour progression, metastasis and response to therapy. Treatment strategies 
that target aspects of the tumour microenvironment, such as anti-angiogenic and 
immunostimulatory therapies, show promising preclinical and clinical results; however, 
factors such as lack of drug penetration into the tumour, non-specific drug delivery, rapid 
clearance from serum, or toxic side effects contribute to the failure of many conventional 
therapies to completely eliminate the tumour. Dual-ligand liposomes offer a potential 
solution to some of the aforementioned problems, as many recent studies have shown 
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encouraging results using nanomedicines to target the tumour vasculature, the ECM and 
cancer-associated immune cells (Siegler et al. 2016). 
 
For example, Doolittle et al. (2015) described the creation of dual-ligand liposomes 
targeting two different angiogenesis-specific receptors overexpressed at different stages 
of metastatic disease. Given that tumours display a dynamic, heterogeneous 
microenvironment that undergoes spatiotemporal changes in the expression of cell-
surface biomarkers during disease progression, the authors reasoned that targeting P-
selectin and αvβ3 integrin would target the liposome towards blood vessels associated 
with metastases at different stages of disease progression. Here, a metastatic site 
transitions, after initial adhesion of circulating tumour cells onto the endothelium, from 
P-selectin-dependent cell rolling on the endothelium to firm attachment that is αvβ3 
integrin-mediated (McCarty et al. 2000). In a resectable mouse model of metastatic 
TNBC, their dual-ligand strategy achieved complementary targeting of different tumour 
sites that was missed using two independent single-ligand liposomes. This was attributed 
to poor colocalisation of both single-ligand liposomes at metastatic sites at the same point 
in time (Doolittle et al. 2015). This approach was similarly demonstrated by Kluza et al. 
in the context of magnetic resonance imaging of angiogenesis (Kluza et al. 2010).  
 
Spatiotemporal changes in the expression of cell-surface molecular markers are also 
observed in cancer stem cells (CSCs), a small population of cells within a tumour with 
the ability to undergo both self-renewal and differentiation. These cells are now 
recognised for their role in driving the initiation, invasion, metastasis, resistance and 
recurrence of a tumour, and the development of targeted nanotherapies that disrupt the 
maintenance and survival of CSCs are the subject of intense research (Chen et al. 2013). 
For example, a multi-functional nanoparticle conjugated to a ligand targeting a specific 
CSC marker and a chemosensitiser (such as an ABC transporter inhibitor) to overcome 
drug resistance has been proposed (Chen et al. 2013). Altogether, these studies further 
support the potential advantage of a multiple receptor-targeting strategy using dual-ligand 
liposomes to better target the spatiotemporal changes in receptor expression that occur 
during metastatic disease progression. Additional examples of potential target 
combinations for the design of dual-ligand liposomes are listed in Table 1.3. 
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Table 1.3: Dual receptor targeting using liposomes. Potential target receptors for the design of dual-
ligand liposomes with the ability to concomitantly target the tumour and its dynamic 
microenvironment. 
Cancer Biomarker 1 Cell population targeted  Biomarker 2 Cell population targeted  
Breast  HER2 
ER  
EGFR  
Tumour (Ross et al. 2009) 
Tumour (Ariazi et al. 2006) 
Tumour (Diéras et al. 2003) 
ALDH-1  
CTLA-4  
uPAR  
 
 
CSC (Pan et al. 2015) 
CSC (Velasco-Velazquez 
et al. 2011) 
Activated fibroblasts and 
tumour-associated 
macrophages (Grondahl-
Hansen et al. 1995), 
invasive tumour cells 
(LeBeau et al. 2013) and 
CSC (Jo et al. 2010) 
Pancreatic EGFR  
uPAR 
CD109  
Tumour (Troiani et al. 2012) 
Tumour (Nielsen et al. 
2005) 
Tumour (Haun et al. 2014) 
CD133 
CD44  
CD24 
CSC (Hermann et al. 2007) 
CSC (Li et al. 2015) 
CSC (Sagiv et al. 2008) 
Melanoma  AXL receptor 
tyrosine 
kinase  
Tumour (Boshuizen et al. 
2018) 
CD20+  
 
 
VEGFR 
Tumour-associated B cells 
(in cutaneous melanoma) 
(Garg et al. 2016) 
Endothelial cells (Mehnert 
et al. 2007) 
Prostate PSMA Tumour and new blood 
vessels (Ghosh & Heston 
2004) 
CD44/CD133 
 
CSC (Collins et al. 2005) 
 
Colorectal uPAR 
 
Tumour and tumour-
infiltrating macrophages 
(Pyke et al. 1994) 
VEGFR 
EpCAM 
Endothelial cells (Shaheen 
et al. 1999) 
CSC (Dalerba et al. 2007) 
HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; EGFR, epidermal growth 
factor receptor; ALDH-1, aldehyde dehydrogenase 1; CTLA-4, cytotoxic T-lymphocyte-associated 
protein 4; uPAR, urokinase plasminogen activator receptor; CSC, cancer stem cell; CD, cluster of 
differentiation; VEGFR, vascular endothelial growth factor receptor; PSMA, prostate-specific 
membrane antigen; EpCAM, epithelial cell adhesion molecule. 
 
 
1.7 Thesis rationale 
Despite a growing understanding of the molecular biology of breast cancer metastasis, 
there is currently no cure for metastatic breast cancer. The HER2-positive and TNBC 
subtypes have high rates of metastasis and disease recurrence, and a generally poor 
prognosis, and therefore effective therapies are urgently required. HER2-positive breast 
cancer is characterised by high levels of intratumoural heterogeneity, which makes 
resistance to targeted therapies a common problem affecting the success of treatment. In 
contrast, TNBC is characterised by a lack of validated biomarkers and therefore limited 
effective treatment options for this breast cancer subtype. Targeting uPAS in metastatic 
cancer is a promising approach, given the role of this system in breast cancer progression 
and the cooperative effect of uPA and HER2 in the HER2-positive breast cancer subtype. 
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This thesis tested the hypothesis that targeting uPAS using drug-loaded liposomes is an 
advantageous way to enable targeting and delivery of potent anticancer drugs to tumour 
cells via uPAR-directed ligands at the liposome surface. Therefore, the rationale of this 
thesis was the development and evaluation of drug-loaded liposomes targeting uPAS as 
a novel way of treating breast cancer, and for the future development of dual-targeted 
(uPA/HER2) liposomes for targeting heterogeneous tumour cell populations to overcome 
therapeutic resistance of HER2-positive breast cancer treatment. 
 
1.8 Aims 
The overall aim of this thesis was to create and characterise novel N-AI-loaded liposomes 
surface-functionalised with PAI-2 as a ligand for targeting uPAR, and to evaluate the 
targeting ability and anti-tumour efficacy of these liposomes using various in vitro and in 
vivo models of uPAR-positive breast cancer. Therefore, the specific aims of this thesis 
were to: 
1. Prepare and characterise, for the first time, N-AI-loaded PAI-2-functionalised 
(N-AI PAI-2) liposomes by optimising previously reported methods (Chapter 2); 
2. Determine the cellular uptake, cellular localisation and receptor-dependent 
cytotoxicity of N-AI PAI-2 liposomes using monolayer cell culture and 
multicellular tumour spheroid models of breast cancer (Chapter 3); 
3. Evaluate the biodistribution, pharmacokinetic profile and anti-tumour efficacy of 
N-AI PAI-2 liposomes in human xenograft mouse models of primary and 
metastatic breast cancer (Chapter 4); and 
4. Develop a single-molecule fluorescence microscopy technique to determine the 
density and stoichiometry of protein ligands attached to the surface of 
functionalised liposomes to support the future development of uPAR and HER2 
dual-ligand liposomes (Chapter 5).  
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Chapter 2: 
Preparation and Characterisation of 
N-alkylisatin-Loaded Liposomes Targeting the 
Urokinase Plasminogen Activator System 
 
 
 
 
Nanoparticle tracking analysis of liposomes 
 
 
 
 
Portions of this chapter have been included in the following work for publication: 
 
Belfiore, L, Saunders, DN, Ranson, M & Vine, KL 2019, ‘N-alkylisatin-loaded 
liposomes targeting the urokinase plasminogen activator system in breast cancer’, 
manuscript in preparation. 
 
Author contributions: LB, DNS, MR and KLV designed the experiments; LB and KLV 
performed the experiments and analysed the data; LB wrote the manuscript; DNS, MR 
and KLV edited the manuscript for submission. 
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2.1 Introduction 
The first clinically approved liposome formulation, Doxil®, has been in use for over 20 
years and is still regarded as an effective and safe treatment for several cancer types. 
However, the liposome field has not evolved into translating effective actively targeted 
liposomes as all current clinically used liposomes are passively targeted (Chapter 1, 
Section 1.6). In the context of cancer therapy, the utility of liposome technologies is 
promising as ligand-directed liposomes have the potential to further increase the 
selectivity of therapy, improving efficacy and reducing the potential for harmful side 
effects. Therefore, the development of novel drug-loaded liposomes with surface-bound 
targeting ligands for active tumour targeting is warranted. Central to the successful 
evaluation of novel actively targeted liposomes is the use of high-throughput and scalable 
methods to produce and characterise them prior to in vitro and in vivo testing. This chapter 
explored and developed these methods to produce and characterise novel actively targeted 
liposomes for tumour cell targeting. 
 
2.1.1 Preparation of drug-loaded liposomes 
Liposomes have emerged as a useful delivery system for the transport of drugs and other 
molecules to solid tumours (Allen & Cullis 2013). Liposomes are spherical lipid-based 
vesicles, typically 100-200 nm in diameter, comprised of associating phospholipids that 
form a lipid bilayer surrounding an aqueous core (Pattni et al. 2015). This unique structure 
allows for the encapsulation of hydrophobic or hydrophilic drugs, or other small 
molecules, in the lipid bilayer or aqueous core, respectively (Gubernator 2011). Drug-
loaded liposomes can be produced using a range of methods, including the thin film 
hydration method, the solvent injection method, and more recently, automated production 
using microfluidic devices (Pattni et al. 2015). The thin film hydration method involves 
dissolving liposome constituents and a hydrophobic drug in organic solvent, which is then 
evaporated to form a dry lipid thin film that is reconstituted in aqueous solution and 
extruded to create unilamellar liposomes with the encapsulated hydrophobic drug within 
the liposome bilayer (Fig. 2.1). For hydrophilic drug encapsulation, alternative methods, 
such as the ammonium sulfate active loading method, can be used for the encapsulation 
of hydrophilic drugs in the liposome core (Zhigaltsev et al. 2010). 
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Figure 2.1: Preparation of drug-loaded liposomes using thin film hydration. Phospholipids and 
the anti-mitotic drug (N-AI) are dissolved in an organic solvent, which is then removed by rotary 
evaporation. The resultant thin film is hydrated with an aqueous buffer and stirring results in the 
formation of drug-loaded liposomes. Serial extrusion of the heterogeneous multilamellar liposome 
mixture through a 100 nm pore filter produces a homogenous solution of unilamellar liposomes 
approximately 100 nm in diameter. 
 
 
2.1.2 Preparation of actively targeted liposomes 
Actively targeted liposomes can be prepared by utilising simple coupling chemistry 
methods to covalently attach ligands to the liposome surface, typically via polyethylene 
glycol (PEG) chains present on the surface of the liposome (Cheng & Allen 2010). For 
example, free sulfhydryl groups of a protein ligand can covalently attach to maleimide-
functionalised PEG phospholipids, which places the targeting ligand at the terminal end 
of the PEG chain at the liposome surface, allowing uninhibited access of the liposome-
bound ligand to its target receptor on the cell surface (Allen et al. 1995). This coupling 
technique is used in two different methods of targeted liposome preparation (Fig. 2.2). 
The conventional (CO) method uses maleimide-functionalised PEG phospholipid groups 
in the initial liposome formulation, and subsequent thiolation of the ligand and incubation 
with preformed liposomes permits covalent attachment of the ligand to the terminal ends 
of the liposome PEG chains (Allen et al. 1995). Alternatively, the post-insertion (PI) 
method first utilises small micelles composed of maleimide-functionalised PEG 
phospholipids to covalently bind to the thiolated ligand before the micelles are incubated 
with preformed liposomes at a high temperature to facilitate insertion of the PEG 
phospholipid-bound targeting ligands into the outer leaflet of the liposomes (Moreira et 
al. 2002). The PI method forms stable liposomes with negligible drug leakage during the 
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post-insertion step, and similar in vitro cytotoxicity and in vivo therapeutic efficacy to 
liposomes prepared using the CO method (Iden & Allen 2001). The PI method also offers 
a practical approach to creating liposomes that bear two or more different targeting 
ligands to further enhance the targeting selectivity of the liposome. Dual-ligand or multi-
ligand liposomes can be created by incubating liposomes with differently functionalised 
micelles at varying concentrations to control ligand stoichiometry (Saul et al. 2006). 
 
 
Figure 2.2: Conventional and post-insertion methods for ligand conjugation. The conventional 
method involves incubation of preformed liposomes with thiolated ligands, which attach covalently to 
the liposome surface via terminal maleimide-functionalised polyethylene glycol (PEG) groups. The 
post-insertion method involves attaching thiolated ligands to maleimide-functionalised PEG 
phospholipid micelles, which are then incubated with preformed liposomes at 60°C to facilitate the 
transfer of micelle phospholipids with covalently attached proteins into the outer leaflet of the 
liposome bilayer. 
 
 
2.1.3 Characterisation of targeted liposomes 
It is well understood that the biophysical characteristics of targeted liposomes influence 
their stability, in vivo circulation time, clearance properties, tumour uptake and 
therapeutic efficacy. Therefore, various methods for liposome characterisation have been 
reported (Honary & Zahir 2013). Commonly measured characteristics include liposome 
size and polydispersity by dynamic and static light scattering, surface charge by 
measuring zeta potential, degree of drug encapsulation by spectrophotometry or high-
performance liquid chromatography (HPLC), and morphology and physical state by 
cryogenic-transmission electron microscopy (cryo-TEM) or atomic force microscopy 
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(Kang et al. 2015). While the methods for characterisation of passively targeted liposomes 
are relatively well developed, characterisation methods for more complex liposomes, 
particularly ligand-directed liposomes, are lacking, and this may be a potential barrier to 
the feasible and practical development of actively targeted liposomes for clinical utility 
(Saul et al. 2006). Therefore, the validation of methods to comprehensively characterise 
actively targeted liposomes is an important aspect of actively targeted liposome 
production and evaluation. 
 
2.1.4 Experimental rationale 
Previous research has shown that plasminogen activator inhibitor-2 (PAI-2) can be used 
to target urokinase plasminogen activator/urokinase plasminogen activator receptor 
(uPA/uPAR)-positive breast cancer cells in vitro and in vivo. PAI-2 has been conjugated 
to the potent anti-tumour cytotoxin and anti-mitotic agent N-alkylisatin (N-AI) (Chapter 
1, Section 1.6.1). The N-AI-PAI-2 conjugate, which had an average of 1-2 N-AI 
molecules per PAI-2 molecule, showed targeting of and a selective cytotoxic effect 
against uPA/uPAR-positive cells in vitro, and anti-tumour growth effects in vivo (Vine et 
al. 2012). In order to increase the in vivo circulation time and payload of N-AI to the 
tumour site for increased anti-tumour effect, N-AI can be encapsulated in the bilayer of 
PEGylated liposomes for drug delivery, and PAI-2 can be attached to the liposome 
surface in order to actively target and deliver N-AI to uPAR-positive tumour cells. As N-
AI-encapsulated liposomes have not been reported previously, there is a need to utilise 
and build upon previous liposome preparation methods to formulate and characterise 
novel N-AI-loaded PAI-2-functionalised liposomes before proceeding to in vitro and in 
vivo evaluation. 
 
2.1.5 Aims 
The overall aim of this chapter was to prepare and characterise novel N-AI-loaded PAI-
2-functionalised (N-AI PAI-2) liposomes. Specifically, the aims of this chapter were to: 
1. Prepare N-AI PAI-2 liposomes using modifications to previously published 
methods for forming ligand-directed, drug-loaded liposomes; and 
2. Determine the biophysical characteristics of N-AI PAI-2 liposomes, including 
liposome size, particle concentration, surface charge, drug encapsulation 
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efficiency, PAI-2 ligand attachment to the liposome surface and the ability of 
PAI-2 liposomes to inhibit uPA activity. 
 
2.2 Methods 
2.2.1 Liposome preparation 
Liposomes were prepared using the thin film hydration method, as described previously 
(Ishida et al. 1999). Liposomes were composed of 20 mM soy PC (L-α-
phosphatidylcholine) and 0.6 mM mPEG2000-DSPE (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[(polyethylene glycol)-2000]) (Avanti Polar Lipids, AL, USA), 
with the addition of either 5 mM cholesterol (Sigma-Aldrich, MO, USA) to form empty 
liposomes, or 5 mM 5,7-dibromo-N-(p-hydroxymethylbenzyl)isatin (N-AI) (prepared in-
house (Vine et al. 2016)) to form N-AI-loaded liposomes. Reagents were weighed out 
into a round-bottom flask and dissolved in a 2:1 (v/v) mixture of chloroform/methanol 
(Sigma-Aldrich, MO, USA). Organic solvents were removed by rotary evaporation and 
subsequent freeze drying to form a lipid film. Dried liposome films were rehydrated in 
deoxygenated 25 mM HEPES buffer (115 mM NaCl, 20 mM HEPES, 2.4 mM K2PO4, 
1.2 mM CaCl2, 1.2 mM MgCl2; pH 7.4) at a phospholipid concentration of 20 mM by 
shaking for 1 h at room temperature (RT) with intermittent sonication. Once reconstituted, 
liposomes were passed through a 0.22 µm polyvinylidene fluoride (PVDF) membrane 
(Merck Millipore, Germany) and then serially extruded 11 times through a 0.1 µm PVDF 
membrane using a syringe-driven extruding apparatus (Avanti Polar Lipids, AL, USA) at 
RT. 
 
2.2.2 PAI-2 conjugation to liposomes 
Liposomes were surface-functionalised with PAI-2 using either the conventional (CO) 
method or post-insertion (PI) method (Allen et al. 2002). Human recombinant PAI-2, 
ΔCD-loop, prepared as described previously (Cochran et al. 2009), has free cysteine 
residues for conjugation to terminal maleimide groups of maleimide-functionalised PEG 
(Oswald et al. 2016). For the CO method, preformed liposomes were incubated with PAI-
2 at a molar ratio of 3333:1 liposome phospholipid:protein for 2 h at RT. For the PI 
method, micelles composed of 0.8 mM mal-PEG2000-DSPE (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000]) and 0.2 mM 
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mPEG2000-DSPE were prepared as per previously reported methods (Moreira et al. 2002), 
and PAI-2 was added to the micelles at a molar ratio of 10:1 (mal-PEG2000-DSPE:protein) 
to form PAI-2-functionalised micelles. PAI-2-functionalised micelles were added to 
preformed liposomes and heated to 60°C for 1 h to facilitate the post-insertion of micelle 
lipids into the outer leaflet of the liposomes. Following the liposome functionalisation 
steps, unbound PAI-2 was removed from liposomes by either size-exclusion 
chromatography (SEC) using Sepharose CL-4B (Sigma-Aldrich, MO, USA) according to 
the manufacturer’s protocol, or repeated centrifugation at 20,000 x g for 1.5 h at 4°C. 
 
2.2.3 Liposome characterisation 
2.2.3.1 Dynamic light scattering 
Liposome size distribution, peak intensity and polydispersity index (PDI), as well as 
stability over time using repeated measurements, were determined by dynamic light 
scattering (DLS) using a Zetasizer APS instrument (Malvern Instruments, UK). Liposome 
samples (60-100 µL) in phosphate-buffered saline (PBS) or HEPES were added to 96-
well plates and analysed at 25°C using the manufacturer’s measurement protocol for 
liposomes (13 reads per sample, triplicate measurements). Data were presented as the 
intensity distribution for liposomes and the number distribution for micelles in order to 
enable visualisation of small particles. Zeta potential (surface charge) of liposomes was 
determined by DLS using a Zetasizer Nano ZS instrument (Malvern Instruments, UK) 
(10-100 reads per sample, triplicate measurements). 
 
2.2.3.2 Nanoparticle tracking analysis 
Liposome size distribution and particle concentration were determined using a NanoSight 
LM 10 instrument (Malvern Instruments, UK) according to the manufacturer’s protocol. 
Liposomes were diluted to a concentration of between 1×108 and 25×108 particles/mL in 
PBS to ensure an optimal concentration for accurate analysis of samples (NanoSight Ltd, 
UK). Imaging of 20-100 particles per field of view was performed using an optical 
microscope fitted with a charge-coupled device camera at 25°C. Particle movement was 
recorded at 20 frames per second for 60 seconds. Average particle size and concentration 
were calculated using Nanoparticle Tracking Analysis (NTA) software (version 2.3, 
NanoSight Ltd, UK) from triplicate measurements. 
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2.2.3.3 Phospholipid assay 
Liposome phospholipid concentration was determined using a commercial phospholipid 
kit (Sigma-Aldrich, MO, USA), as per the manufacturer’s instructions. Briefly, 
phosphatidylcholine standards were prepared 0-20 µM, 20 µL of each standard was added 
to a 96-well plate in duplicate, as well as 20 µL of each liposome sample (at various 
dilutions). 80 µL of reaction mix containing assay buffer, enzyme mix, phospholipase D 
enzyme and dye reagent, was added to each well and incubated at RT for 30 min. 
Absorbance was measured at 570 nm using a Spectramax spectrophotometer (Molecular 
Devices, CA, USA). The absorbance values of the phospholipid standards were used to 
create a standard curve and unknown sample concentrations were determined by 
interpolation. 
 
2.2.3.4 N-AI encapsulation in liposomes 
Drug encapsulation efficiency was determined by high-performance liquid 
chromatography (HPLC). N-AI-loaded liposomes were mixed with water/acetonitrile 
(60:40 v/v) and centrifuged. The N-AI concentration was determined using an Atlantis 
T3 reverse-phase C18 analytical column (Waters, UK) and a Waters HPLC machine 
(Waters, MA, USA). Analysis was performed using an injected volume of 10 µL with a 
gradient elution and monitored with a photodiode array at 435 nm. Concentration was 
determined by interpolating from a standard curve after analysis of standards and samples 
using Empower Pro V2 software (Waters, UK). 
 
2.2.3.5 Lowry assay 
Protein concentration of PAI-2 and PAI-2-functionalised liposomes was determined 
using the DC Protein Assay kit (Bio-Rad Laboratories, CA, USA) according to the 
manufacturer’s protocol. Bovine serum albumin (BSA) was used as a standard (0-2 
mg/mL) and 5 µL of standard or sample was added to a 96-well plate. Bio-Rad reagent A 
(25 µL) and reagent B (200 µL) were added to each well, the plate incubated at RT for 
10 min, and the absorbance measured using a Spectramax spectrophotometer (Molecular 
Devices, CA, USA) at 750 nm. The absorbance values of the BSA were used to create a 
standard curve and unknown sample concentrations were determined by interpolation. 
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2.2.3.6 BCA assay 
The Bicinchoninic Acid (BCA) assay is one of the most sensitive colourimetric protein 
assays and can detect protein at concentrations as low as 5 µg/mL (Walker 1996). Due to 
phospholipid interference in the Lowry analysis of liposome samples, protein 
concentration of PAI-2-functionalised liposomes was additionally determined using the 
BCA assay according to previously published methods. Solution A, consisting of 20 g/L 
sodium carbonate, 9.5 g/L sodium bicarbonate and 1.6 g/L sodium tartrate, was brought 
to pH 11.25 with the addition of 1 M sodium hydroxide. Immediately prior to use, 0.5 g 
BCA powder (Sigma-Aldrich, MO, USA) was dissolved in 50 mL of solution A. Solution 
A was combined with solution B, which was made up of 4% (w/v) copper sulfate in water, 
in a ratio of 50:1 to produce BCA working reagent (solution C). BSA protein standards, 
ranging in concentration from 0-1 mg/mL, were prepared in PBS, and 10 μL of each 
protein standard was added to a 96-well plate in triplicate. Various dilutions of samples 
in PBS were prepared and 10 μL of each solution was added to the plate in triplicate. 80 
μL of solution C was added to each well and the plate incubated at 60°C for 15 min. The 
absorbance of the solutions within the wells was determined using a FLUOstar OPTIMA 
plate reader (BMG Labtech, Germany) at a wavelength of 544 nm. The absorbance of the 
BSA was used to create a standard curve and unknown sample concentrations were 
determined by interpolation. 
 
2.2.3.7 SDS-PAGE 
For sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis, 
loading buffer (containing 50% (v/v) glycerol, 2% or 6% (w/v) sodium dodecyl sulfate 
and 0.02% (v/v) bromophenol blue in distilled water) was added to samples. For reducing 
conditions, 5 μL of β-mercaptoethanol (Sigma-Aldrich, MO, USA) was added to samples. 
Samples were denatured by heating to 100°C for 5 min and were then loaded into a 10% 
gel to run by SDS-PAGE at 100 V for 2 h. 
 
2.2.3.8 Western blotting 
Western blotting was used to detect and quantify PAI-2 conjugated to liposomes. Proteins 
in SDS-PAGE gels were transferred to PVDF membranes using Bio-Rad transfer 
equipment (Bio-Rad Laboratories, CA, USA) at 100 V for 1.5 h. Membranes were rinsed 
in TBST (1X TBS buffer with 0.05% v/v Tween-20) and blocked using 10% skim milk 
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in TBST for 1 h at RT. After rinsing membranes twice with TBST, membranes were 
incubated with primary antibody (anti-SerpinB2; Abcam, Cambridge, UK) at 1:2000 
dilution in 2% skim milk/TBST at 4°C overnight. Membranes were washed with TBST 
four times (10 min each wash) and then incubated with secondary antibody (anti-rabbit-
HRP; Abcam, Cambridge, UK) at 1:5000 dilution in 2% skim milk/TBST for 2 h at RT. 
Membranes were then washed in TBST three times for 5 min and then in TBS (no Tween-
20) three times for 5 min. Membranes were developed using ECL peroxidase reaction 
(Pierce PicoWest ECL reagent; Thermo Fisher Scientific, MA, USA), according to the 
manufacturer’s instructions. Membranes were visualised using x-ray film after 
developing and fixing (Bio-Rad Laboratories, CA, USA) or using a Gel Logic 2200 
Digital Imager (Carestream Molecular Imaging, CT, USA). Band intensities were 
quantified using ImageJ (National Institutes of Health, MD, USA). 
 
2.2.3.9 Flow cytometric analysis of liposomes 
Flow cytometry was used to further assess liposome size and quantify the efficiency of 
micelle insertion into preformed liposomes. Fluorescent liposomes were prepared by 
loading with rhodamine-123 (R123) (Sigma-Aldrich, MO, USA) or by post-inserting 
micelles that were prepared in the absence or presence of varying percentages of FITC-
DSPE-PEG (Avanti Polar Lipids, AL, USA). Events (50,000) were collected using an 
LSR II flow cytometer (BD Biosciences, NJ, USA; excitation 488 nm, emission collected 
with a 515/20 band-pass filter). Data were analysed using FlowJo software version 10 
(FlowJo LLC, OR, USA). 
 
2.2.3.10 Fluorogenic uPA activity assay 
To determine whether PAI-2 conjugated to the surface of liposomes retained inhibitory 
activity against uPA, the activity of PAI-2-functionalised liposomes was quantified using 
a fluorogenic uPA activity assay, as described previously (Cochran et al. 2009). Briefly, 
liposomes were diluted in 100 μL reaction buffer (20 mM HEPES, pH 7.6, 100 mM NaCl, 
0.5 mM EDTA, 0.01% (v/v) Tween 20) containing 0.25 mM uPA fluorogenic substrate 
(Z-Gly-Gly-Arg-AMC; Merck Millipore, MA, USA). After a brief pre-incubation at 37 
ºC, high molecular weight urokinase plasminogen activator (HMW-uPA) (final 
concentration 0.675 nM) was added to start the reaction and fluorescence emission was 
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measured at 37 ºC using a microplate reader (POLARstar Omega; BMG Labtech, 
Germany). All assays were performed in triplicate and values corrected by subtracting 
the background well values (reaction buffer and substrate only). 
 
2.2.4 Data analysis 
All data analysis, including the generation of graphs and statistical tests, was performed 
using GraphPad Prism version 7 for Windows (GraphPad Software, CA, USA), unless 
stated otherwise. Data are presented as the mean ± standard deviation (s.d.) or standard 
error of the mean (s.e.m.) as stated. Pairwise comparisons were made using Student’s t-
test and multiple comparisons were made using one-way ANOVA with Tukey’s post-
test. 
 
2.3 Results 
2.3.1 Preparation of empty and N-AI-loaded liposomes 
Modifications to previously reported methods (Allen et al. 1995) were used to prepare 
and characterise soy PC PEGylated liposomes containing the potent microtubule-
destabilising cytotoxin N-alkylisatin (N-AI). Empty and N-AI-loaded liposomes were 
prepared by the thin film hydration method and were analysed by dynamic light scattering 
(DLS) (Table. 2.1). Empty (EMP) liposomes were 137.6 ± 5.6 nm in diameter, while N-
AI-loaded liposomes were 139.9 ± 3.9 nm in diameter. The polydispersity index (PDI) 
for both liposomes was < 0.1 for both samples, indicating monodispersity. Both 
liposomes had a peak intensity of 100%, further indicating the liposome populations were 
monodisperse and the absence of aggregation or large particle populations in the samples. 
EMP and N-AI liposomes exhibited an equivalent zeta potential (small negative surface 
charge) and equivalent phospholipid concentrations. 
 
Table 2.1: Characterisation of empty and N-AI PEGylated liposomes. Empty (EMP) liposomes 
and N-AI-loaded liposomes were prepared by the thin film hydration method and analysed by dynamic 
light scattering. Values are means ± s.d. (n = 3). 
Liposome 
Diameter 
(nm) 
Polydispersity 
index 
Intensity 
(%) 
Zeta potential 
(mV) 
Phospholipid 
(mM) 
EMP 137.6 ± 5.6 0.067 ± 0.035 100 –3.63 ± 0.80 16.44 
N-AI 139.9 ± 3.9 0.093 ± 0.023 100 –3.64 ± 0.59 16.45 
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The size and morphology of N-AI liposomes were further confirmed by cryogenic 
transmission electron microscopy (cryo-TEM), performed by Delfine Cheng at the 
Sydney Microscopy & Microanalysis Facility of the University of Sydney. Cryo-TEM 
indicated that the N-AI liposomes had an average diameter of 138.7 ± 18.4 nm (Fig. 2.3). 
Cryo-TEM additionally revealed N-AI liposomes to be spherical, monodisperse and 
unilamellar. The N-AI loaded in the liposome bilayer showed no evidence of 
crystallisation. The concentration of N-AI encapsulated in the liposomes could not be 
determined by spectrophotometry and interpolation from a standard curve as the liposome 
phospholipid interfered with the peak absorbance of N-AI at 310 nm and 435 nm 
(Appendix A). Therefore, the concentration of N-AI loaded into liposomes was 
determined by high performance liquid chromatography (HPLC), which revealed an N-
AI concentration of 2.2 mM, equating to 43.1% drug loading (% w/w) based on the 
starting amount of N-AI used in the liposome preparation (Appendix B). 
 
 
Figure 2.3: Cryo-TEM of N-AI-loaded liposomes. N-alkylisatin (N-AI)-loaded liposomes were 
prepared using the thin film hydration method, and cryogenic transmission electron microscopy (cryo-
TEM) was performed to visualise liposome size and morphology. (A) Representative image of N-AI-
loaded liposomes. (B) Determination of average liposome diameter from cryo-TEM image analysis. 
 
 
2.3.2 Preparation of recombinant human PAI-2 
Recombinant human PAI-2 for covalent attachment to the liposome surface was prepared 
using established protocols (Cochran et al. 2009). SDS-PAGE analysis showed that the 
PAI-2 produced was pure, with a single band corresponding to the size of PAI-2 of 
approximately 45 kDa (Fig. 2.4A). Prior to conjugating PAI-2 to liposomes, a fluorogenic 
uPA activity assay was used to confirm that the recombinant PAI-2 was active. PAI-2 
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activity was indicated by the complete inhibition of uPA at a 2-fold molar excess of PAI-
2:uPA compared to the positive control (no PAI-2) (Fig. 2.4B). 
 
 
Figure 2.4: Production of recombinant human PAI-2. (A) SDS-PAGE analysis of purified 
plasminogen activator inhibitor-2 (PAI-2) fractions (1, 2); M = marker. (B) Urokinase activity assay 
to confirm inhibitory activity of purified PAI-2 over 30 min. + = positive control, - = negative control. 
 
 
2.3.3 Conjugation of PAI-2 to liposomes using the conventional method 
To attach PAI-2 to the surface of liposomes using the conventional method, recombinant 
human PAI-2 was incubated with preformed liposomes for 2 h at RT, and unconjugated 
PAI-2 was removed using size-exclusion chromatography (SEC) (Fig. 2.5). Analysis of 
fractions by spectrophotometry at 280 nm to detect protein revealed the presence of two 
peaks, indicating that unconjugated PAI-2 had separated from PAI-2 that had covalently 
attached to liposomes. 
 
 
Figure 2.5: Size-exclusion chromatogram of liposomes after PAI-2 conjugation. After 
conjugation, free plasminogen activator inhibitor-2 (PAI-2) was removed from PAI-2 liposomes using 
size-exclusion chromatography. The absorbance of the fractions at 280 nm was used to detect PAI-2. 
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Following SEC, the fractions corresponding to the liposome peak were pooled and the 
sample was analysed by DLS. DLS revealed that the average diameter of the N-AI-loaded 
PAI-2-functionalised (N-AI PAI-2) liposomes was 141.1 ± 5.0 nm, while that of the 
empty PAI-2-functionalised (EMP PAI-2) liposomes was 139.7 ± 4.9 nm (Table 2.2). The 
diameter and the PDI of both samples remained similar to the measurements before the 
PAI-2 conjugation step (Table 2.1). The peak intensity of both liposome preparations was 
100%, indicating that the final liposome formulations were monodisperse. The zeta 
potential of the PAI-2-functionalised liposomes became more negative (Table 2.2), 
shifting slightly for both empty and N-AI-loaded liposomes. The phospholipid 
concentration of both EMP PAI-2 and N-AI PAI-2 liposomes was equivalent at 16.67 
mM and 16.62 mM, respectively. 
 
Table 2.2: Characterisation of liposomes prepared by the conventional method. Empty 
plasminogen activator inhibitor-2 (PAI-2)-functionalised liposomes (EMP PAI-2) and N-alkylisatin 
(N-AI)-loaded PAI-2-functionalised liposomes (N-AI PAI-2) were prepared by the conventional 
method and analysed by dynamic light scattering. Values are means ± s.d. (n = 3). 
Liposome 
Diameter 
(nm) 
Polydispersity 
index 
Intensity 
(%) 
Zeta potential 
(mV) 
Phospholipid 
(mM) 
EMP PAI-2 139.7 ± 4.9 0.109 ± 0.017 100 –4.05 ± 0.53 16.67 
N-AI PAI-2 141.1 ± 5.0 0.086 ± 0.030 100 –4.66 ± 0.52 16.62 
 
 
2.3.4 Quantification of PAI-2 bound to liposomes by protein assays 
The quantification of PAI-2 attached to liposomes was attempted using two common 
laboratory assays: the BCA assay and the Lowry assay. Empty non-functionalised and 
empty PAI-2-functionalised liposomes at an equivalent phospholipid concentration were 
analysed to determine protein concentration according to the manufacturer’s protocols for 
the assays. The protein concentration resulting from interpolation of a standard curve 
(using bovine serum albumin) revealed the protein concentration of both liposome 
preparations to be just over 1 mg/mL in both assays, with protein concentration between 
the non-functionalised and PAI-2-functionalised liposomes not significantly different in 
both assays (Fig. 2.6). This indicated a high degree of interference in the assay from the 
liposome phospholipid. Therefore, the PAI-2 concentration of liposome samples could 
not be determined using biochemical protein assays. 
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Figure 2.6: Phospholipid interference in protein assays. Non-functionalised (NF) and plasminogen 
activator inhibitor-2 (PAI-2) liposomes were analysed via the BCA assay and Lowry assay, and protein 
concentration was determined by interpolation from a bovine serum albumin standard curve. ns = not 
significant. Data are the mean ± s.d. (n = 3). 
 
 
2.3.5 Detection of liposome-bound PAI-2 by Western blotting 
As PAI-2 could not be detected or quantified using commercial biochemical protein 
assays, Western blotting was used to confirm successful conjugation of PAI-2 to 
liposomes and to attempt to quantify protein amount post-conjugation. Following SEC to 
remove free PAI-2 from PAI-2 liposomes, fractions corresponding to the PAI-2 liposome 
(peak 1) and free PAI-2 (peak 2), as well as a sample of unpurified PAI-2 liposomes, were 
analysed via Western blotting (Fig. 2.7). Covalent conjugation of PAI-2 to liposome 
phospholipid (PEG-DSPE; molecular weight ~2940 kDa) to form PAI-2-PEG-DSPE was 
confirmed by a lag in gel migration of PAI-2 in the peak 1 fraction (Fig. 2.7, sample #1) 
relative to the peak 2 fraction (Fig. 2.7, sample #2), which corresponded with the 45 kDa 
molecular weight of free PAI-2. The absence of a band corresponding to free PAI-2 in 
peak 1 indicated that removal of unbound PAI-2 was successful. The bands revealed in 
the unpurified PAI-2 liposome sample (Fig. 2.7, sample #3) appeared as a combination 
of the two former, further indicating separation via size-exclusion was successful. It was 
observed that liposome-bound PAI-2 migrates differently through a gel compared to pure 
PAI-2, causing a smearing effect and multiple PAI-2 bands, limiting the accuracy of 
densitometry for quantification of liposome-bound protein using a PAI-2 standard curve. 
Estimates using densitometry indicated that the ratio of mean grey value between the PAI-
2 bands in peaks 1 and 2 was 53:47 (Appendix C). This ratio was roughly reflected in the 
OD280 peak height of the size-exclusion chromatogram (56:44). The amount of protein 
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in sample 2 (unconjugated PAI-2) was determined to be 37 ng (via BCA assay), which 
indicated that the amount of PAI-2 associated with the liposome fraction in sample 1 was 
approximately 42 ng, based on the densitometry ratio between the two samples. 
 
 
Figure 2.7: Western blot analysis of PAI-2 liposomes. (A) Size-exclusion chromatograph of PAI-2 
liposome fractions after, including PAI-2 liposomes (peak 1) and unbound PAI-2 (peak 2). (B) 
Western blot detection of PAI-2 in size-exclusion fractions (1, 2), unpurified liposomes (3), and 
purified PAI-2 (50, 25 and 12.5 ng). OD = optical density, M = marker, PEG = polyethylene glycol. 
Data are representative from two experimental repeats. 
 
 
2.3.6 Fluorogenic urokinase plasminogen activator inhibition assay 
To confirm that the PAI-2 attached to the surface of liposomes was still able to inhibit 
uPA activity, a fluorogenic uPA activity assay was performed (Cochran et al. 2009). 
Empty (EMP) liposomes were used instead of N-AI-loaded liposomes as N-AI is slightly 
fluorescent and may interfere with the assay (Chapter 3, Section 3.3.2). Liposome 
phospholipid had a positive interfering effect in fluorescence measurements, with both 
EMP and EMP PAI-2 liposomes showing a shift above baseline at the start of 
measurements. The rate of fluorescence (RFLU) was 4026.9 ± 206.2 FLU/min for EMP 
liposomes and 43.5 ± 24.9 FLU/min for EMP PAI-2 liposomes, and the mean 
fluorescence intensity of the EMP liposomes was 3.7-fold higher than the EMP PAI-2 
liposomes at the 30 min time point (Fig. 2.8). The 92.6-fold reduction in RFLU for EMP 
PAI-2 liposomes relative to EMP liposomes indicates that the former inhibits uPA activity 
whereas the latter does not, demonstrating that PAI-2 is present and active in the PAI-2 
liposome sample. 
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Figure 2.8: Fluorogenic uPA activity assay of PAI-2 liposomes. Liposomes were prepared and 
added to assay to see if PAI-2 bound to the surface of liposomes would still be active in inhibiting 
uPA over a period of 30 minutes at 37°C as compared to unconjugated PAI-2. Values are means ± s.d. 
(n = 3). 
 
 
2.3.7 Centrifugation of liposomes to remove unbound PAI-2 
SEC is the most commonly used method to remove free protein from liposomes following 
conjugation. Although standard in the field, research has noted that liposome loss using 
SEC may be a concern as liposomes may non-specifically adsorb to the resin (Ruysschaert 
et al. 2005). Further, this method causes dilution of the sample, takes time if performed 
by gravity, and only allows for analysis of one sample at a time. There are reports in the 
literature of using high-speed centrifugation to spin and pellet liposomes, primarily for 
the purpose of removing unencapsulated soluble drug (Zhigaltsev et al. 2010). As small 
soluble protein ligands, such as 45 kDa PAI-2, do not pellet out of solution under high-
speed centrifugation, it was posited that unbound PAI-2 could be removed from 
liposomes by high-speed centrifugation, which would increase the efficiency of liposome 
production and potentially increase liposome recovery. 
 
Firstly, to determine how liposomes pellet under different centrifugal forces, EMP 
liposomes were spun at 20,000 x g for 0-4 h, with phospholipid in the pellet measured by 
spectrophotometry at 350 nm. The results showed a time-dependent increase in OD350 
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signal in the liposome pellet and a corresponding decrease in OD350 signal in the 
supernatant (Fig. 2.9). Liposome size remained constant in the pellet, deviating little from 
the starting diameter of 145 nm. However, size decreased linearly with time up to the 2 h 
time point as larger particles settled to form the pellet first, leaving smaller particles 
behind in the supernatant and leading to a smaller average diameter. All samples 
displayed 100% peak intensity, as determined by DLS. 
 
 
Figure 2.9: Centrifugation of liposomes over time. (A) Liposomes were centrifuged at 20,000 x g 
for up to 4 h and OD350 measured of pellet and supernatant to locate which fraction the phospholipid 
(liposome) resided. (B) Liposome samples taken at different time points from either the supernatant 
or pellet were analysed by dynamic light scattering to determine changes in average liposome diameter 
with high-speed centrifugation. Data are the mean ± s.e.m. (n = 3). 
 
 
To examine the effect of centrifugation on empty PAI-2-functionalised liposomes, 
liposomes were centrifuged for 4 h and then analysed by nanoparticle tracking analysis 
(NTA) to determine average particle diameter and concentration relative to non-
centrifuged liposomes (Table 2.3). The centrifuged liposomes showed a small but not 
significant (P > 0.05) increase in average diameter from 148.0 ± 4.2 nm to 153.9 ± 5.9 
nm and a significant (P < 0.01) 22.9% reduction in particle concentration relative to non-
centrifuged liposomes. NTA images revealed the distributions and monodispersity of the 
centrifuged and non-centrifuged liposomes to be similar (Fig. 2.10). 
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Table 2.3: Effect of centrifugation on liposome diameter and particle concentration. Liposomes 
were centrifuged at 20,000 x g at 4°C for 4 h and analysed by nanoparticle tracking analysis. Data 
are the mean ± s.d. (n = 3). 
Liposome 
Diameter 
(nm) 
Concentration 
(particles/mL) 
Non-centrifuged PAI-2 liposomes 148.0 ± 4.2 2.40 x 1013 ± 4.24 x 1011 
Centrifuged PAI-2 liposomes 153.9 ± 5.9 1.85 x 1013 ± 1.36 x 1012 
 
 
Figure 2.10: Nanoparticle tracking analysis of liposomes after centrifugation. Liposomes were 
centrifuged at 20,000 x g for a total of 4 h. (A) Control (non-centrifuged) and (B) centrifuged 
liposomes were analysed using nanoparticle tracking analysis (NTA) to determine particle size and 
concentration. Images are representative frames from 60 second analysis via NTA. Images are 
representative from triplicate measurements. 
 
 
2.3.8 Conjugation of PAI-2 to liposomes using the post-insertion method 
The post-insertion method of liposome functionalisation requires the formation of 
functionalised micelles that are then inserted into preformed liposomes (Fig. 2.2). 
Micelles were prepared using PEG2000-DSPE and analysed by DLS. Prior to 0.22 µm 
filtration, the average diameter of the micelles was approximately 300 nm, and this was 
reduced following filtration to remove large aggregates, where the average diameter was 
14.1 nm (Table 2.4). Size distributions of the filtered micelles showed the presence of 
larger peaks in the intensity distribution but a single peak in the volume and number 
distributions, indicating the presence of small micelles as the predominant population 
with some larger aggregates (Fig. 2.11). To form PAI-2-functionalised micelles, PAI-2 
was added to PEG2000-DSPE micelles containing 20% maleimide-functionalised PEG2000-
DSPE to enable attachment of PAI-2 via cysteine residues to the terminal end of PEG. 
DLS analysis of PAI-2 micelles showed that the average diameter was 15.9 nm. Micelles 
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before and after PAI-2 conjugation showed similar PDI values of 0.165 and 0.178, 
respectively (Fig. 2.11). 
 
Table 2.4: Characterisation of PEG2000-DSPE micelles. Micelles were prepared by thin film 
hydration, filtered using a 0.22 µm membrane and analysed by dynamic light scattering. Values are 
means ± s.d. (n = 3). NF = non-functionalised. 
Micelle Diameter (nm) Polydispersity index 
NF micelle 14.1 ± 0.526 0.165 ± 0.014 
PAI-2 micelle 15.9 ± 0.273 0.178 ± 0.031 
 
PAI-2 micelles were then added to preformed N-AI-loaded liposomes to create PAI-2-
functionalised liposomes. Following the post-insertion step, liposomes were purified by 
SEC as for conventional liposomes. DLS revealed 100% peak intensity across all 
distributions, indicating no remaining micelles were present in the liposome sample (Fig. 
2.12).  
 
 
Figure 2.11: Dynamic light scattering analysis of PEG2000-DSPE micelles. Micelles were 
prepared by thin film hydration, filtered using a 0.22 µm membrane and analysed by dynamic light 
scattering to determine average liposome diameter. Traces are replicate measurements (n = 3). 
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There was a noticeable and significant (P < 0.01) increase in average liposome diameter 
from 141.2 ± 4.7 nm to 154.1 ± 1.3 nm following N-AI-loaded liposome incubation with 
PAI-2 micelles (the post-insertion step) (Fig. 2.13). A small increase in diameter was 
observed for N-AI liposomes that were incubated with maleimide-PEG micelles alone 
(145.0 ± 1.7 nm) or with a mixture of micelles that contained non-maleimide-
functionalised PEG and PAI-2 (145.4 ± 4.7 nm), but this was not significantly different 
to the liposome diameter prior to the post-insertion step. 
 
 
Figure 2.12: Dynamic light scattering analysis of post-insertion liposomes. Liposomes were 
prepared using the post-insertion method and analysed by dynamic light scattering. Traces are 
replicate measurements (n = 3). 
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Figure 2.13: N-AI PAI-2 liposomes prepared by the post-insertion method. Liposomes were 
functionalised with PAI-2 via the post-insertion method using micelles. Dynamic light scattering was 
used to determine average liposome diameter. Values are the mean ± s.d. (n = 3). ns = not significant; 
** = P < 0.01. 
 
 
2.3.9 Flow cytometric analysis of micelle post-insertion into liposomes 
To further confirm the insertion of micelle phospholipids into the liposome bilayer using 
the post-insertion method, the transfer of fluorescent micelles into liposomes was detected 
using flow cytometry (Mack et al. 2012). Firstly, to determine whether liposomes could 
be detected using the flow cytometer and to optimise settings, empty liposomes and 
fluorescent rhodamine-123 (R123)-loaded liposomes were prepared and analysed by DLS 
(Table 2.5) before being run on the flow cytometer to detect fluorescence of the particles 
(Fig. 2.14). R123-loaded liposomes were slightly larger than empty liposomes, but both 
had low polydispersity and 100% peak intensity of the particle population. Flow 
cytometry revealed the liposome populations of both samples, with similar forward and 
side scatter profiles. The R123 liposome population (MFI = 43.8 ± 0.5) showed a peak 
shift and 20.7-fold increase in MFI relative to that of empty liposomes (MFI = 2.1 ± 1.3), 
indicating that the fluorescence of R123 liposomes could be detected by flow cytometry. 
Analysis of PBS only showed a minimal presence of small particles at the detection 
settings used to analyse the liposomes. 
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Table 2.5: Characterisation of R123-loaded liposomes. Empty liposomes and liposomes containing 
rhodamine-123 (R123) were prepared by the thin film hydration method and analysed by dynamic 
light scattering. Values are means ± s.d. (n = 3). 
Liposome Diameter (nm) Polydispersity index Intensity (%) 
Empty 135.3 ± 6.0 0.080 ± 0.038 100 
R123-loaded 148.1 ± 3.6 0.066 ± 0.010 100 
 
 
Figure 2.14: Detection of R123-loaded liposomes by flow cytometry. (A) Empty or (B) rhodamine-
123 (R123)-loaded liposomes were analysed by flow cytometry using a 515 band-pass filter for 
detection of rhodamine. (C) PBS was used to adjust the threshold for the detection of particles and to 
minimise signal noise. (D) Fluorescent signal of R123 was detected as a peak shift relative to empty 
liposomes and PBS samples. Data are representative from n = 3 samples. FSC, forward scatter; SSC, 
side scatter. 
 
 
Once it was confirmed that liposomes could be detected by flow cytometry using the 
optimised settings, micelles composed of 0%, 10% or 30% FITC-labelled phospholipid 
(FITC-PEG-DSPE; 30% of total micelle phospholipid) were incubated with preformed 
empty liposomes as per the post-insertion method of targeted liposome preparation (Allen 
et al. 2002). DLS analysis revealed a small increase in average liposome diameter for all 
three preparations following the post-insertion step relative to liposomes that had not been 
incubated with micelles (Table 2.6). The PDI of the three post-insertion preparations 
increased slightly, but peak intensity remained at 100%, indicating the absence of 
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unincorporated micelles in the liposome preparations. Analysis of the liposomes by flow 
cytometry revealed a significant increase (P < 0.01) in the mean fluorescence intensity 
(MFI) for liposomes that had been incubated with 10% or 30% FITC-labelled micelles 
compared to liposomes incubated with non-fluorescent micelles (Fig. 2.15). There was 
no significant difference in MFI between the 10% FITC and 30% FITC liposome 
preparations. 
 
Table 2.6: Characterisation of FITC-labelled liposomes. Liposomes were prepared by the thin film 
hydration method, and micelles composed of 0%, 10% or 30% FITC-PEG2000-DSPE were 
incorporated into the liposomes using the post-insertion method. Liposomes were analysed by 
dynamic light scattering. Values are means ± s.d. (n = 3). 
Liposome Diameter (nm) Polydispersity index Intensity (%) 
No micelle 136.0 ± 2.1 0.055 ± 0.033 100 
0% FITC micelle 140.6 ± 2.4 0.089 ± 0.003 100 
10% FITC micelle 140.1 ± 2.4 0.086 ± 0.041 100 
30% FITC micelle 143.1 ± 2.7 0.079 ± 0.021 100 
 
 
Figure 2.15: Detection of post-insertion of FITC micelles into liposomes. Liposomes were 
incubated with (A) 0% FITC micelles, (B) 10% FITC micelles or (C) 30% FITC micelles and analysed 
by flow cytometry (FSC = forward scatter; SSC = side scatter). (D) PBS only was used to select an 
appropriate voltage to minimise the signal from small non-liposome particles and noise signal. (E) 
Histograms of the mean fluorescence intensity (MFI) of the samples. (F) MFI values for each sample. 
Values are means ± s.e.m. (n = 3). ns = not significant; ** = P < 0.01. FSC, forward scatter; SSC, side 
scatter; FITC, fluorescein isothiocyanate. 
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2.4 Discussion 
In this chapter, N-AI-loaded PAI-2-functionalised (N-AI PAI-2) liposomes were prepared 
and characterised for the first time using optimisations to previously reported methods. 
N-AI PAI-2 liposomes were 141.1 ± 5.0 nm in diameter, monodisperse (PDI of 0.086 ± 
0.030), had a zeta potential of –4.66 ± 0.52 mV and contained N-AI at a concentration of 
2.2 mM, equating to 43.1% encapsulation efficiency. PAI-2 conjugation to the surface of 
N-AI-loaded liposomes was achieved using conventional and post-insertion methods of 
liposome functionalisation and was confirmed using SEC and Western blotting. A PAI-2 
inhibitory activity assay confirmed that PAI-2 attached to the surface of liposomes 
remained active against its target uPA after conjugation, which indicated that N-AI PAI-
2 liposomes are suitable for further in vitro and in vivo evaluation against breast cancer 
cells. 
 
The empty (non-drug-loaded), empty PAI-2-functionalised, N-AI-loaded and N-AI-
loaded PAI-2-functionalised liposomes prepared in this work ranged between 130 nm and 
150 nm in diameter, which is in the size range of previously reported PEGylated 
phosphatidylcholine liposomes (Chang & Yeh 2012). This liposome size range has been 
reported to avoid rapid clearance by the mononuclear phagocyte system (MPS) in 
circulation and to utilise the enhanced permeability and retention effect to extravasate and 
accumulate at the site of tumours for drug delivery (Maeda 2015). The zeta potential, or 
surface charge, of liposomes is dependent on a number of factors, including the 
composition of the liposome (Smith et al. 2017). It has been reported that while PEG itself 
does not affect the surface charge of liposomes, PEG-DSPE introduces a negative surface 
potential due to the phosphate diester moiety (Barenholz 2012). This is reflected by the 
zeta potential measurements of the four liposome formulations reported in this chapter, 
which ranged between –3.63 mV and –4.66 mV (Tables 2.1 and 2.2). This indicates that 
the liposomes have a slightly negative, but near-neutral, surface charge, which did not 
vary greatly with N-AI encapsulation and/or PAI-2 conjugation to the liposome surface, 
although it was noted that PAI-2-functionalised liposomes had a slightly more negative 
surface charge than non-functionalised liposomes (Tables 2.1 and 2.2). This is expected, 
given that PAI-2 has a predicted isoelectric point of 5.4 and therefore a negative charge 
at physiological pH (Croucher et al. 2007). Liposomes with mildly charged or near-
neutral surfaces have a propensity to aggregate faster than liposomes with a strong surface 
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charge as the latter have greater particle-particle repulsion and hence are more 
electrostatically stabilised in suspension (Safhi et al. 2017). However, strongly positively 
charged particles lead to rapid elimination by the MPS (Litzinger et al. 1996), whereas 
near-neutral liposomes have an increased circulation half-life (Allen & Cullis 2013). 
Importantly, histological analysis of the localisation of liposomes within in vivo tumours 
has shown that negatively charged and neutral liposomes are able to extravasate at the 
site of the tumour, while positively charged liposomes remain associated with the 
vascular endothelium, limiting their suitability for tumour targeting applications (Krasnici 
et al. 2003). 
 
The successful encapsulation of a hydrophobic drug into liposomes can greatly enhance 
the aqueous solubility and bioavailability of the molecule, and therefore increase the 
suitability for its use in drug delivery applications. In this work, the thin film hydration 
method was used to load N-AI into the bilayer of soy phosphatidylcholine PEGylated 
liposomes. The N-AI loading into liposomes appeared to be stable and not crystallise out 
of the liposomes (Fig. 2.3), and the encapsulation efficiency was determined to be 
approximately 43.1% of the starting amount of N-AI used in the formulation. Drug 
loading into liposomes depends on many factors, and in the case of loading into the 
bilayer, liposome size is a key factor (Swenson et al. 2001). One of the drawbacks of the 
thin film method is the typically low drug loading, as compared to other methods, as the 
space in the bilayer limits how much drug can be loaded (Pattni et al. 2015). In this work, 
N-AI was substituted for cholesterol in the formulation of N-AI-loaded liposomes in order 
to increase the drug-loading capacity of the bilayer. As the molecular weights of N-AI 
and cholesterol are similar (425.07 g/mol and 386.65 g/mol, respectively) and both are 
hydrophobic molecules that act to stabilise the liposome bilayer (Leonenko et al. 2004), 
a greater encapsulation of N-AI in the liposomes was achieved without affecting liposome 
size or surface charge (Table 2.1). Alternative methods can be used to load drugs into the 
liposome core, which typically has a larger volume and therefore a greater capacity for 
drug loading (Gubernator 2011). For example, the commonly used anticancer drug 
docetaxel, which is strongly hydrophobic and poorly water soluble, has previously been 
loaded into the bilayer of liposomes. This was achieved by creating a weak base derivative 
of the drug molecule, and the use of ion gradients in the liposome formulation were used 
to actively load the drug into the liposome core, increasing the trapping efficiency to close 
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to 100% at a drug-to-lipid ratio of up to 0.4 mg/mg (Zhigaltsev et al. 2010). Such an 
approach could be explored in the future to increase the loading of N-AI in liposomes if 
required. 
 
The main advantage of the thin film method is that it is relatively straightforward and 
easy to produce reasonable and consistent quantities of liposomes for laboratory testing. 
However, upscaling of liposome production – as required for clinical use – is challenging 
since lab-based liposome production methods are generally not amenable to scale up 
beyond the millilitre scale. The formation of liposome thin films via the use of rotary 
evaporation is limited by the size of the flask used to create the film, and flask overloading 
may increase liposome polydispersity and alter other physicochemical characteristics of 
the resultant sample (Wagner & Vorauer-Uhl 2011). The extrusion of liposomes through 
membranes as required to achieve a desired size distribution is another labour-intensive 
step in the production process as preparations need to be passed repeatedly across a 
membrane and usually on a 1-20 millilitre scale. In the laboratory setting, the preparation 
of multiple separate batches of liposomes can be used to overcome these issues, although 
batch-to-batch variability must be considered. This is particularly important for ligand-
functionalised liposome formulations as variations in the physicochemical characteristics 
of the preparation may influence stability, in vivo circulation time, clearance properties, 
tumour uptake, therapeutic efficacy and toxicity (Honary & Zahir 2013). Therefore, 
adequate characterisation of liposomes intended for further in vitro and in vivo evaluation 
is essential. 
 
The conjugation of PAI-2 to the surface of empty and N-AI-loaded liposomes via PEG 
was performed using standard coupling chemistry as described previously (Vine et al. 
2014). Removal of unconjugated PAI-2 was achieved using SEC, as is standard in the 
liposome field (Grimaldi et al. 2016). When unconjugated PAI-2 was removed from PAI-
2 liposomes following the conjugation step by SEC, the absorbance at 280 nm revealed 
the presence of two distinct peaks (Fig. 2.5). The first peak corresponded to the largest 
particles eluting from the column: PAI-2-functionalised liposomes. The second peak 
corresponded to the smaller, unconjugated PAI-2 molecules, which had a longer elution 
time. This pattern was also observed in the OD350 readout, where liposome phospholipid, 
but not protein, showed absorption. Phospholipid signal was observed for the first peak 
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(fractions 4-9) but not in the second peak (fractions 34-40), corroborating the OD280 
readout and suggesting that liposomes eluted from the column first, followed by 
unconjugated protein (Fig. 2.5). However, due to the broad absorbance spectrum of 
phospholipids, including at 280 nm (Appendix A), it was impossible to determine whether 
PAI-2 was covalently attached to those liposomes. 
 
The quantification of covalently attached PAI-2 in the liposome samples was attempted 
using two biochemical copper-based protein assays. However, protein could not be 
detected due to the following factors: 1) liposomal phospholipid interferes in both Lowry 
and BCA assays, resulting in an overestimation of protein concentration (Kessler & 
Fanestil 1986) (Fig. 2.6); 2) the amount of protein in the liposome sample is expected to 
be low and therefore is likely below the limit of detection (the minimum amount of protein 
that can be detected in the Lowry and BCA assays is reported as 5 µg/mL and 8 µg/mL, 
respectively); and 3) after SEC, the liposome sample is diluted considerably, further 
compounding the former two factors. Therefore, Western blotting of the size-exclusion 
fractions was performed to detect PAI-2 in those fractions as an indirect measure of 
successful PAI-2 conjugation to the liposomes. 
 
Western blot detection of PAI-2 in fractions from the two size-exclusion peaks confirmed 
that PAI-2 was conjugated to the liposome phospholipid (PEG-DSPE) in the first peak, 
while the second peak contained unconjugated PAI-2 (Fig. 2.7). The latter peak presented 
as a band at 45 kDa, the same as the molecular weight observed for purified PAI-2 
(positive control). In the liposome fraction, PAI-2 presented at a molecular weight higher 
than 45 kDa. This shift upwards in the gel is the consequence of a lag in migration of the 
PAI-2-PEG-DSPE molecules through the gel due to steric hindrance of the PEG and 
interaction with SDS. Therefore, PAI-2-PEG-DSPE does not migrate through the gel as 
quickly as free PAI-2, resulting in a higher apparent molecular weight (Vine et al. 2014). 
The appearance of a second higher molecular weight band in the liposome sample 
suggests the presence of PAI-2 bound to two or more PEG-DSPE molecules, which is 
possible since PAI-2 has four available cysteine residues that can bind to the maleimide 
group of PEG-DSPE (Chapter 1, Section 1.5.1). Native PAGE eliminates the PEG-SDS 
interaction and provides a higher band resolution, so this technique could be used as an 
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alternative to SDS-PAGE for further analysis of ligand-functionalised PEG liposomes 
(Zheng et al. 2007).  
 
The Western blot of size-exclusion samples showed that there was no detectable band at 
45 kDa, indicating that unconjugated PAI-2 was successfully removed from the liposome 
sample by SEC (Fig. 2.7). Quantification of PAI-2 on liposomes was attempted using 
densitometry of Western blots, and although an approximate ratio of bound and unbound 
PAI-2 was determined to be 50:50 (Appendix C), the irregular pattern of the liposome 
PAI-2 band on the blot indicated that densitometry was not a reliable tool to quantify PAI-
2 conjugation. However, as outlined above, Western blotting was successful in 
qualitatively confirming the conjugation of PAI-2 to liposomes and in confirming the 
absence of unconjugated PAI-2 in the purified liposome sample prior to further testing. 
These findings highlight a distinct limitation in the research field of actively targeted 
liposomes: the lack of robust methodology to quantify small amounts of liposome-bound 
protein in liposome formulations (Belfiore, L. et al. 2018). In this chapter, quantifying 
small amounts of PAI-2 was not achieved using biochemical assays due to phospholipid 
interference, although it is important to note that even if such methods were successful, 
they could only provide a quantification of the total protein in a liposome sample rather 
than a quantification of the average number of protein ligands bound to each liposome. 
This lack of published methods necessitates the development of alternative methods to 
quantify protein conjugation of actively targeted liposome formulations.  
 
As outlined in Chapter 1, Section 1.6, the majority of clinically approved nanotherapies 
are arguably quite simplistic in their composition and structure. In the context of ligand-
directed liposomes, controlling for batch-to-batch variability is difficult without effective 
methods for characterisation, and the inability to control or correct for variability in ligand 
attachment to liposomes may become an issue in the regulatory processes required for 
clinical translation of a novel formulation. Without robust methods to enable detection of 
ligand conjugation and quantification of surface ligands, variation between batches may 
lead to deviations in the physicochemical characteristics of the preparation, which would 
ultimately influence stability, in vivo circulation time, clearance properties, tumour 
uptake, therapeutic efficacy and toxicity of a targeted liposome formulation (Honary & 
Zahir 2013). Adequate methods for the confirmation and quantification of ligand 
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attachment to liposomes have not been developed (Saul et al. 2006), which poses a larger 
challenge for dual-ligand and multi-ligand liposomes, where the determination of 
stoichiometry of ligand attachment, in addition to density, is an important step in the 
characterisation process. Theoretical values of ligand conjugation and ligand ratios have 
been reported, but this has not been demonstrated empirically for most liposome 
formulations as the methods used to generate such data are technically challenging. The 
development of new methods to quantify ligand attachment to liposomes will enable a 
more complete characterisation of targeted liposome formulations to facilitate 
optimisation and assist with standardising nanoparticle characterisation in the research 
field more broadly (Faria et al. 2018). This concept is explored further in Chapter 5, where 
single-molecule fluorescence microscopy was evaluated as a method to quantify ligands 
attached to the surface of liposomes. 
 
An important step in characterising ligand-functionalised liposomes is to confirm whether 
the targeting ligand(s) conjugated to the liposome surface retain activity against the target 
receptor once bound to the liposome surface and following all the processes of production 
and purification. In a fluorogenic activity assay, PAI-2 liposomes successfully inhibited 
the enzymatic activity of uPA, while non-functionalised liposomes did not show 
inhibition, as expected (Fig. 2.8). While there was no observed uPA inhibitory effect due 
to liposome phospholipid alone, there was an observed interference effect from the 
presence of the liposome phospholipid in the assay for both non-functionalised and PAI-
2-functionalised liposomes, which was revealed as a positive shift from the baseline in 
both samples. Despite this, the rate of inhibition as indicated by fluorescence (RFLU) of 
4026.9 ± 206.2 FLU/min for non-functionalised liposomes was significantly reduced to 
43.5 ± 24.9 FLU/min for PAI-2 liposomes, which confirms that PAI-2 bound to the 
surface of liposomes retains its inhibitory action against uPA. This is a crucial aspect for 
utilising PAI-2 liposomes for uPA/uPAR targeting in vitro and in vivo. 
 
Given that SEC results in considerable dilution of liposome samples, centrifugation was 
explored as a potential method to concentrate liposomes and remove unconjugated 
protein from liposomes in a high-throughput manner. Centrifugation of liposomes is 
reported in the literature, particularly in the context of removing unencapsulated soluble 
drug from liposomes, such as in protocols for the active-loading method of drug 
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encapsulation (Gubernator 2011). In this study, centrifugation of liposomes for up to 4 h 
showed a time-dependent pelleting of liposomes, with a plateau after 2 h of centrifugation 
at 20,000 x g (Fig. 2.9). In the supernatant of these samples, DLS revealed that while the 
pelleted liposome diameter remained relatively constant, the average diameter of the 
liposomes remaining in the supernatant decreased over time. As centrifugation causes the 
largest particles in a solution to pellet before the smallest particles, the largest liposomes 
pelleting between 0 h and 2 h of centrifugation corresponded with the smallest liposomes 
remaining in solution, shifting the size distribution considerably. DLS analysis of pelleted 
liposomes after 4 h of centrifugation revealed a small but not significant (P > 0.05) 
increase in the average diameter compared to non-centrifuged liposomes (153.9 ± 5.9 nm 
and 148.0 ± 4.2 nm, respectively) and a 77.1% retention of liposomes after 4 h of 
centrifugation (Table 2.3). The centrifuged liposomes appeared to remain intact and had 
not aggregated as determined by nanoparticle tracking analysis (Fig. 2.10). While these 
results indicate that centrifugation of empty liposomes does not change the liposome 
population significantly, it is unknown whether prolonged centrifugation of N-AI-loaded 
liposomes would affect drug loading. This would need to be determined specifically for 
N-AI-loaded liposomes prior to adopting centrifugation as a standard purification method 
for drug-loaded liposomes. Additionally, the development of a robust method to quantify 
PAI-2 attachment to liposomes is needed in order to elucidate whether centrifugation 
results in changes to PAI-2 ligand attachment on the surface of liposomes. 
 
As outlined in Section 2.1.2, the post-insertion method is an alternative method of 
conjugating ligands to the surface of liposomes, with the greatest advantage of this 
method being the ease with which a range of dual-ligand or multi-ligand liposomes can 
be produced from a single batch of liposomes (Moreira et al. 2002). Previous work 
comparing these two methods indicates that liposomes prepared by conventional and 
post-insertion methods are equivalent (Iden & Allen 2001). In this chapter, PAI-2-
functionalised liposomes prepared via the post-insertion method were significantly larger 
(P < 0.05) in diameter than those prepared by the conventional method (154.1 ± 1.3 nm 
and 141.1 ± 5.0 nm, respectively) (Fig. 2.13). This appears to be a result of the post-
insertion step specifically, as N-AI liposomes incubated with maleimide-PEG micelles 
alone (145.0 ± 1.7 nm) or with a mixture of micelles that contained non-maleimide-
functionalised PEG and PAI-2 (145.4 ± 4.7 nm) did not show a significant increase in 
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diameter compared to the liposome diameter prior to the post-insertion step (141.2 ± 4.7 
nm). It is possible that the post-insertion method led to more efficient conjugation of PAI-
2 and mal-PEG compared to the conventional method, perhaps due to the higher 
temperature of the conjugation step, meaning that the observed increase in liposome size 
could be due to post-insertion liposomes having a greater average number of PAI-2 
proteins attached to the surface than conventional liposomes. This was further explored 
in Chapter 5 (Section 5.3.6). DLS analysis of micelles alone prior to the post-insertion 
step showed small amounts of aggregation in the sample (Fig. 2.11). However, following 
the post-insertion step and SEC of liposomes, DLS analysis revealed 100% peak intensity 
(Fig. 2.12), indicating the absence of unincorporated micelles or aggregates. 
 
Flow cytometry was used as an indirect confirmation that post-insertion of micelle 
phospholipids (and any covalently conjugated ligands) into the liposome outer leaflet was 
successful, as per previously reported methods (Mack et al. 2012). Rhodamine-123-
loaded liposomes showed a 20.7-fold increase in MFI (43.8 ± 0.5) relative to non-
fluorescent liposomes (2.1 ± 1.3), indicating that fluorescently labelled liposomes could 
be detected by flow cytometry (Fig. 2.14). Analysis of post-insertion liposomes by flow 
cytometry revealed a significant increase (P < 0.01) in MFI for liposomes that had been 
incubated with 10% or 30% FITC-PEG-DSPE micelles compared to liposomes incubated 
with non-fluorescent micelles (Fig. 2.15). This work detected the association of 
fluorescent micelle phospholipids in liposomes after the post-insertion step, indirectly 
confirming successful post-insertion. However, as this method is only semi-qualitative, it 
remains unknown if and how well protein ligands are transferred into the outer liposome 
bilayer using the post-insertion method. 
 
As the post-insertion method requires the extra step of firstly preparing ligand-
functionalised micelles, the conventional method is more straightforward for preparing 
single-ligand liposomes. The post-insertion step also involves heating, which may affect 
the structure or activity of some protein ligands, so this would need to be determined for 
the individual ligands used. The main advantage of the post-insertion method is in the 
context of creating dual-ligand liposomes to target multiple tumour cell receptors, such 
as in the case of liposomes targeting tumour heterogeneity (Chapter 1, Section 1.6). As 
dual-ligand liposomes can increase the number of targetable receptors at the cell surface, 
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a greater number of liposomes can bind to tumour cells to enhance the therapeutic efficacy 
of the encapsulated drug (Laginha et al. 2005). Therefore, the findings presented in this 
chapter can be considered in future work exploring the creation of dual-ligand liposomes 
using the post-insertion method. 
 
2.5 Conclusion 
The work presented in this chapter demonstrates the successful preparation and 
characterisation of liposomes encapsulating the N-AI cytotoxin, with PAI-2 covalently 
attached to the liposome surface as a targeting ligand for binding to uPAR-positive cells. 
Previously published liposome analysis methods were optimised in order to allow the 
successful characterisation of liposomes as required for in vitro and in vivo evaluation. 
N-AI-loaded PAI-2-functionalised liposomes were monodisperse, contained 
encapsulated N-AI, had PAI-2 successfully conjugated to the liposome surface, and 
importantly, were active in inhibiting target uPA in an activity assay. Therefore, further 
testing of these liposomes against uPAR-positive breast cancer cells using in vitro and in 
vivo models is warranted.
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Chapter 3: 
In Vitro Evaluation of N-alkylisatin-Loaded 
Liposomes Targeting the Urokinase Plasminogen 
Activator System 
 
 
 
 
 
N-AI-loaded liposome-mediated destruction of a multicellular tumour spheroid 
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3.1 Introduction 
The work described in Chapter 2 of this thesis detailed the preparation and 
characterisation of N-alkylisatin (N-AI)-loaded plasminogen activator inhibitor-2 (PAI-
2)-functionalised (N-AI PAI-2) liposomes. In order to evaluate how these liposomes 
interact with and affect breast cancer cells, N-AI PAI-2 liposomes were tested against 
breast cancer cells in vitro. This is an important step to confirm the cellular uptake, 
cellular localisation and cytotoxicity of N-AI PAI-2 liposomes before evaluating their 
potential as an anticancer therapeutic using more complex in vivo models of breast cancer. 
 
3.1.1 Cell-based models of cancer 
A diverse range of cancer cell lines derived from tumour biopsies have been established 
in the laboratory and retain many – but not all – of the genotypic and phenotypic 
properties of the original tumour cells, making them useful representative models for 
testing targeted therapies (Holliday & Speirs 2011; Subik et al. 2010) and for studying 
mechanisms of therapeutic resistance (Boulbes et al. 2015). Cells grown on dishes are 
amenable to high-throughput approaches for determining morphological changes and 
cytotoxicity resulting from treatment with novel drugs, and endpoint cell viability assays 
can be used to measure changes in cell proliferation and metabolism in a high-throughput 
manner. In vitro cell-based models of cancer are also useful for measuring the targeting 
ability of novel nanotherapies and the localisation of nanoparticles within cells. 
 
Cancer cells can be grown as two-dimensional (2D) cell monolayers or three-dimensional 
(3D) cell aggregates or spheroid structures. While 2D cell culture is high-throughput, 
robust and widely validated, 3D cell culture better recapitulates several key elements of 
in vivo tumours, including tumour architecture, tumour cell interactions, tumour-stroma 
interactions, and the various proliferative and metabolic gradients that form when tumour 
cells exist as a 3D structure (Li & Lu 2011). Multicellular tumour cell spheroids are 
cancer cells that are grown in a large spherical association, resembling small tumours and 
micrometastases (Senavirathna et al. 2013) (Fig. 3.1). The ability of cancer cells to form 
spheroids is strongly related to the expression of several cell-cell adhesion molecules 
(Ivascu & Kubbies 2007), and spheroid formation can be facilitated by culturing cells in 
conditions that prevent adherence to cell culture plates (Friedrich et al. 2009). Changes in 
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spheroid morphology and diameter in response to a drug treatment can be measured using 
manual or automated imaging techniques (Karacali et al. 2007), and end-point 
biochemical assays allow for the determination of cell viability (Friedrich et al. 2007). As 
drug sensitivities of cell lines can vary depending on whether the cells are grown in 2D 
or 3D (Godugu et al. 2013), it is important to utilise 3D cell culture models in the 
screening of novel drug formulations. 
 
 
Figure 3.1: Cross-section view of a multicellular tumour cell spheroid. Spheroids recapitulate 
several key elements of in vivo tumours, including three-dimensional (3D) tumour architecture, cell-
cell interactions and the various proliferative and metabolic gradients that form when tumour cells 
exist as a 3D structure. Figure adapted from Lin et al. 2008. 
 
 
3.1.2 Experimental rationale 
The targeting ability, cellular localisation and cytotoxicity of N-AI PAI-2 liposomes can 
be determined using 2D monolayer cell culture and 3D multicellular tumour spheroid 
models (Thoma et al. 2014). The commonly used breast cancer cell lines MCF-7 (Soule 
et al. 1973) and MDA-MB-231 (Olivé et al. 1974) serve as representative urokinase 
plasminogen activator receptor (uPAR)-negative and uPAR-positive cells (Huber et al. 
2016), respectively, for the testing of uPAR-targeted liposomes. The in vitro evaluation 
of N-AI PAI-2 liposomes will serve to justify and guide further evaluation in vivo. 
 
3.1.3 Aims 
This chapter tested the hypothesis that N-AI-loaded PAI-2-functionalised (N-AI PAI-2) 
liposomes exhibit increased cellular uptake and increased cytotoxic effect in uPAR-
positive breast cancer cells relative to uPAR-negative breast cancer cells. Therefore, the 
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overall aim of this chapter was to evaluate the in vitro properties of N-AI PAI-2 liposomes 
in two breast cancer cell lines that vary in expression of uPAR. The specific aims of this 
chapter were to: 
1. Determine the cellular uptake of N-AI PAI-2 liposomes in breast cancer cells; 
2. Elucidate the cellular localisation of N-AI PAI-2 liposomes in breast cancer 
cells; and 
3. Characterise the cytotoxicity of N-AI PAI-2 liposomes against breast cancer 
cells grown as either monolayers or multicellular tumour spheroids. 
 
3.2 Methods 
3.2.1 Cell lines and culture conditions 
The human mammary epithelial invasive ductal carcinoma cell lines MCF-7 and MDA-
MB-231 were originally purchased from the American Type Culture Collection (ATCC, 
VA, USA). Cells were cultured in RPMI-1640 medium (Life Technologies, CA, USA) 
containing 24 mM NaHCO3 and supplemented with 10% (v/v) heat-inactivated fetal 
bovine serum (FBS; Thermo Fisher Scientific, MA, USA). Cells were maintained in 
culture at 37°C in a 95% humidified atmosphere with 5% CO2 in a HERAcell incubator 
(Kendro Laboratory Products, Germany). For passaging, cells were harvested by 
treatment with 0.05% trypsin-EDTA (Life Technologies, CA, USA), followed by 
centrifugation at 300 x g for 5 min. For experiments, cells were harvested by treatment 
with PBS containing 5 mM EDTA (pH 7.4), followed by centrifugation at 300 x g for 5 
min. Viable cells were counted with a haemocytometer using the Trypan Blue (Sigma-
Aldrich, MO, USA) exclusion method. Cell lines were routinely tested and confirmed 
negative for mycoplasma contamination (in-house testing conducted by the IHMRI 
Technical Services Unit). Cell lines were confirmed negative for cross contamination by 
short-tandem repeat (STR) sequencing (performed by the Garvan Institute of Medical 
Research, Darlinghurst, Australia). 
 
3.2.2 Cell surface uPA and uPAR expression 
Expression of urokinase plasminogen activator (uPA) and uPAR on the surface of MCF-
7 and MDA-MB-231 cells was determined by flow cytometry. Cells (1 x 105) in 100 µL 
PBS (pH 7.4, with 1% w/v BSA) were incubated with mouse anti-human uPA 
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monoclonal antibody (ADI #394; Alpha Diagnostic International, TX, USA) at 10 
µg/mL, mouse anti-human uPAR monoclonal antibody (DAKO #7294; Agilent 
Technologies, CA, USA) at 10 µg/mL or mouse IgG1 monoclonal antibody (isotype 
control) (Merck #MABC002; Merck, Germany) at 10 µg/mL for 45 min on ice, followed 
by three washes with ice-cold PBS (with 1% w/v BSA) and centrifugation at 300 x g for 
5 min after each wash. Cells were then incubated with donkey anti-mouse IgG-Alexa 
Fluor 488 polyclonal antibody at 2 µg/mL for 45 min on ice, followed by three washes 
with ice-cold PBS (with 1% w/v BSA) as above. Cells were resuspended in 100 µL PBS 
and the fluorescence intensity of the Alexa-488-conjugated antibody analysed by flow 
cytometry (LSR II; BD Biosciences, CA, USA) (excitation 488 nm, emission collected 
with 515/20 band-pass filter). FlowJo software (version 10; Tree Star Inc., OR, USA) was 
used to evaluate cell-surface expression of uPA and uPAR relative to the IgG isotype 
control to account for non-specific antibody binding to cells. 
 
3.2.3 Cellular uptake of liposomes by flow cytometry 
Uptake of fluorescently labelled non-functionalised and PAI-2-functionalised liposomes 
by MCF-7 and MDA-MB-231 cells was assessed using flow cytometry. Cells (2 x 105 
cells per well) were seeded into 12-well plates and allowed to attach for 24 h at 37°C. 
Liposomes containing 1% (mol/mol) FITC-PEG2000-DSPE were prepared as described in 
Chapter 2, Section 2.2 and added to cells in culture media (RPMI-1640 + 10% (v/v) FBS) 
at dilutions ranging from 1:20 to 1:5. At specified time intervals ranging between 15 min 
and 60 min, the supernatant was removed, cells washed once with PBS and then harvested 
using PBS containing 5 mM EDTA (pH 7.4). Cells were then centrifuged (300 x g for 5 
min) and washed three times with PBS before being resuspended in 200 µL PBS for 
analysis. The fluorescence intensity was determined by flow cytometry (LSR II flow 
cytometer; BD Biosciences, CA) (excitation 488 nm, emission collected with 515/20 
band-pass filter). FlowJo software (V10; Tree Star Inc., OR, USA) was used to evaluate 
the mean fluorescence intensity (MFI) to determine cellular uptake of liposomes. 
 
3.2.4 Cellular localisation of liposomes by confocal microscopy 
Uptake and cellular localisation of fluorescently labelled liposomes were determined by 
confocal microscopy as reported previously (Ducat et al. 2011). For monolayer cell 
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culture experiments, 50,000 cells per well were seeded into 8-well µ-Slide chambered 
coverslips (ibidi, Germany) and incubated for 24 h at 37°C. Cells were allowed to reach 
80% confluence before the addition of liposomes. Liposomes containing 1% or 10% 
(mole % of liposome phospholipid) FITC-PEG2000-DSPE, or 0.625% (mole % of 
liposome phospholipid) octadecyl rhodamine B chloride (R18; Invitrogen, CA, USA) 
were prepared as described in Chapter 2, Section 2.2. Liposomes were added to cells in 
culture media (RPMI-1640 + 10% (v/v) FBS) at dilutions ranging from 1:5 to 1:10 and 
incubated for 30 min to 2 h at 37°C. Supernatant was removed and wells were rinsed three 
times with PBS before LysoTracker Green DND-26 (excitation/emission 504/511 nm) or 
LysoTracker Red DND-99 (excitation/emission 577/590 nm) (Thermo Fisher Scientific, 
MA, USA) was added to each well (50 nM final concentration) immediately prior to 
imaging. Live imaging of cells in PBS was performed using a Leica TCS SP5 Confocal 
Microscope (Leica Microsystems, Germany) and images were acquired using a 63X oil 
immersion lens. Images were analysed using Leica Application Suite (V10; Leica 
Microsystems, Germany). 
 
3.2.5 2D monolayer cytotoxicity assays 
In vitro cytotoxicity assays were performed in 96-well flat-bottom microtitre plates as 
described previously (Vine et al. 2016). MCF-7 or MDA-MB-231 cells were seeded at a 
density of 5000 cells per well into sterile 96-well flat-bottom plates and incubated at 37°C 
for 24 h in an IncuCyte Zoom automated imaging instrument (Essen BioScience, MI, 
USA). Empty and N-AI-loaded liposomes were prepared as outlined in Chapter 2, Section 
2.2 and were serially diluted in PBS before being added to cells (each concentration tested 
in triplicate). Liposomes were incubated with cells for 72 h and wells were imaged every 
24 h by the automated IncuCyte imaging system. To determine cell viability at the 
experimental endpoint, CellTiter 96 Aqueous One Solution Cell Proliferation Assay MTS 
reagent (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium; Promega Corporation, WI, USA) was added to each well at a final 
concentration of 10% (v/v). Plates were incubated at 37°C for 3 h and the absorbance at 
490 nm was measured using a Spectramax spectrophotometer (Molecular Devices, CA, 
USA). The IC50 (dose required to inhibit the metabolic activity of 50% of the cell 
population) was calculated from logarithmic sigmoidal dose-response curves fitted to the 
data using GraphPad Prism V7 for Windows (GraphPad Software, CA, USA). The 
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absorbance readings of wells containing media only were subtracted from sample 
readings to correct for background absorbance. Data were normalised to absorbance 
readings for cells treated with PBS only (positive control). 
 
3.2.6 3D multicellular tumour spheroid cytotoxicity assays 
MCF-7 or MDA-MB-231 cells were seeded into ultra-low attachment 96-well plates 
(Sigma-Aldrich, MO, USA) at a density ranging between 625 and 5000 cells per well and 
incubated at 37°C to promote spheroid formation. Empty and N-AI-loaded liposomes 
were serially diluted in PBS and incubated with cells for up to 96 h (each concentration 
tested in triplicate). To determine cell viability at the experimental endpoint, an acid 
phosphatase (APH) assay (Friedrich et al. 2007) or calcein staining (Leary et al. 2016) 
was performed. For the APH assay, spheroids were carefully washed twice with PBS and 
the spheroid plate centrifuged at 400 x g for 10 min after each wash step. The supernatant 
was replaced with 100 µL APH assay buffer (2 mg/mL para-Nitrophenylphosphate and 
0.1% (v/v) Triton-X-100 in 0.1 M sodium acetate). The plate was incubated at 37°C for 
90 min and then 10 µL 1 M sodium hydroxide was added to each well. The absorbance 
of each well at 405 nm was then measured using a Spectramax spectrophotometer 
(Molecular Devices, CA, USA). For calcein staining, calcein-AM (Thermo Fisher 
Scientific, MA, USA) was added to spheroids at a final concentration of 1 µM per well. 
The plate was incubated at 37°C for 30 min and images were acquired using an IncuCyte 
Zoom automated imaging instrument (Essen BioScience, MI, USA), with a 10X objective 
and green filter (excitation 440-480 nm, emission 504-544 nm) to detect calcein 
fluorescence associated with viable cells. 
 
3.2.7 Data analysis 
All data analysis, including the generation of graphs and statistical tests, was performed 
using GraphPad Prism software (version 7), unless stated otherwise. Data are presented 
as the mean ± standard deviation (s.d.) or standard error of the mean (s.e.m.) as stated. 
Pairwise comparisons were made using Student’s t-test and multiple comparisons were 
made using one-way ANOVA with Tukey’s post-test. 
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3.3 Results 
3.3.1 Profiling MCF-7 and MDA-MB-231 cells for uPA/uPAR expression 
Two commonly used breast cancer cell lines, MCF-7 and MDA-MB-231, were profiled 
for cell surface uPA and uPAR expression by flow cytometry prior to liposome testing 
(Fig. 3.2). MDA-MB-231 cells showed positive expression of uPAR, with a significantly 
(P < 0.001) higher (46-fold) MFI (11.82 ± 0.90) than that of uPAR-negative MCF-7 cells 
(0.26 ± 0.03). Both cell lines showed positive expression of uPA, with uPA levels 
significantly (P < 0.05) higher (2.7-fold) for MDA-MB-231 cells compared to MCF-7 
cells (MFI values of 6.66 ± 0.97 and 2.49 ± 0.10, respectively). 
 
 
Figure 3.2: Flow cytometry analysis of surface uPA and uPAR expression. MCF-7 cells and 
MDA-MB-231 cells were incubated with antibodies against human urokinase plasminogen activator 
(uPA), human uPAR (urokinase plasminogen activator receptor) or an isotype control antibody (IgG) 
and analysed by flow cytometry to detect fluorescence of Alexa-488-conjugated secondary antibody. 
MFI = mean fluorescence intensity (fold-increase of IgG control). Data are the mean ± s.d. (n = 3). * 
= P < 0.05; *** = P < 0.001. 
 
 
3.3.2 Measuring cellular uptake of PAI-2 liposomes by flow cytometry 
The cellular uptake of fluorescently labelled liposomes can be determined by flow 
cytometry (Ducat et al. 2011). To decide on an appropriate fluorophore for liposome 
detection by flow cytometry in subsequent experiments, liposomes loaded with either N-
AI (in the liposome bilayer) or rhodamine 123 (in the liposome core), as well as FITC-
labelled liposomes (FITC-PEG-DSPE incorporated into the liposome bilayer), were 
incubated with MDA-MB-231 cells at equivalent phospholipid concentrations (20 mM) 
for 15 min or 60 min before analysis by flow cytometry (Fig. 3.3). Compared to untreated 
control MDA-MB-231 cells, all fluorescently labelled liposomes showed an increase in 
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MFI after 15 min and 60 min, although this difference was only significant for R123 
liposomes. While the percentage of viable cells remained high after 15 min, the 
percentage of cells in the viable gate dropped significantly from that of the untreated 
control cells following the 60 min incubation, with a percentage of 46.8 ± 5.5 %. The 
drop in cell viability was most pronounced for the N-AI and R123 liposomes, with the 
percentage of viable cells at 60 min dropping to 1.5 ± 0.9 % and 0.07 ± 0.02 %, 
respectively. The percentage of viable cells for cells treated with FITC-labelled liposomes 
dropped to 25.6 ± 1.1 % at 60 min, indicating that FITC liposomes were the least cytotoxic 
to cells out of the three fluorescently labelled liposomes. 
 
 
Figure 3.3: Cellular uptake of fluorescently labelled liposomes. Liposomes were fluorescently 
labelled with either N-AI, FITC or R123 and were incubated with MDA-MB-231 cells at an equivalent 
phospholipid concentration (20 mM) for 15 min (left) or 60 min (right). Cells were analysed by flow 
cytometry to determine the mean fluorescence intensity (MFI) (top) and percentage of cells within the 
viable gate (bottom). Control cells were not treated with liposomes. Data are the mean ± s.d. (n = 3). 
*** = P < 0.001, ** = P < 0.01, * = P < 0.05, n.s. = not significant (P > 0.05). 
 
 
As the FITC-labelled liposomes were shown to be the least cytotoxic to MDA-MB-231 
cells at the 60 min time point, FITC-labelled liposomes were further investigated to 
determine the effect of liposome concentration and incubation time on MFI and on cell 
viability. FITC-labelled liposomes (or non-FITC control liposomes at an equivalent 
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phospholipid concentration) were incubated with MDA-MB-231 cells at concentrations 
between 0 mM and 10 mM for either 15 min or 60 min and analysed by flow cytometry 
(Fig. 3.4). The results showed a dose-dependent and time-dependent increase in MFI, 
with significant (P < 0.05) increases in MFI between the 15 min and 60 min time points 
for each concentration of FITC liposome tested. Cell viability was not significantly (P > 
0.05) different at any FITC liposome concentration after either the 15 min or 60 min 
incubation, indicating that MDA-MB-231 cells remained viable after 60 min treatment 
with liposomes up to and including 10 mM concentration. 
 
 
Figure 3.4: Cellular uptake of non-functionalised FITC-labelled liposomes. MDA-MB-231 cells 
were incubated with FITC-labelled liposomes (or non-FITC control liposomes at an equivalent 
phospholipid concentration) for 15 min or 60 min and analysed by flow cytometry. Data are the mean 
± s.d. (n = 3). MFI = mean fluorescence intensity. **** = P < 0.0001, *** = P < 0.001, * = P < 0.05, 
n.s. = not significant (P > 0.05). 
 
 
In order to detect differences in the uptake of PAI-2-functionalised liposomes between 
MCF-7 cells (low uPAR) and MDA-MB-231 cells (high uPAR), non-functionalised (NF) 
FITC liposomes and PAI-2-functionalised FITC liposomes (152.6 ± 8.7 nm and 152.8 ± 
11.7 nm, respectively) were incubated with MCF-7 and MDA-MB-231 cells for 45 min 
and liposome uptake was determined by flow cytometry (Fig. 3.5). For MDA-MB-231 
cells, there was a significant increase in FITC PAI-2 liposome uptake at the 5 mM and 
2.5 mM liposome concentrations (P < 0.0001 and P < 0.001, respectively) relative to NF 
PAI-2 liposomes, but not at the 1.25 mM liposome concentration. For MCF-7 cells, no 
significant differences were observed between the uptake of NF and PAI-2 liposomes at 
any liposome concentrations (P > 0.05). 
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Figure 3.5: Uptake of PAI-2 FITC-labelled liposomes in breast cancer cells. MCF-7 cells (left) 
and MDA-MB-231 cells (right) were incubated with non-functionalised (NF) FITC liposomes and 
PAI-2-functionalised (PAI-2) FITC liposomes for 45 min and analysed by flow cytometry. Data are 
the mean ± s.d. (n = 3). **** = P < 0.0001, *** = P < 0.001, n.s. = not significant (P > 0.05). 
 
 
3.3.3 Cellular localisation of PAI-2 liposomes by confocal microscopy 
Confocal microscopy can be used to detect the uptake and cellular localisation of 
fluorescently labelled liposomes (Ducat et al. 2011). In initial experiments, 1% and 10% 
(mol/mol) FITC liposomes were used, but the fluorescent signal was too low (data not 
shown). Therefore, the intensely fluorescent fluorophore R18 was used to label liposomes 
for the detectable accumulation of liposomes in cells. Non-functionalised (NF) and PAI-
2-functionalised liposomes containing 0.625% (mol %) R18 in the lipid bilayer were 
prepared as outlined in Chapter 2, Section 2.2. Liposomes were analysed by dynamic light 
scattering, which revealed average diameters of 131.3 ± 2.5 nm and 131.2 ± 6.6 nm for 
NF and PAI-2 liposomes, respectively. Liposomes were incubated with MCF-7 and 
MDA-MB-231 cells at a 2.5 mM phospholipid concentration at 37°C for 60 min prior to 
imaging by confocal microscopy. Imaging showed a strong fluorescent signal from R18-
labelled liposomes, which was present at the cell membrane, within the cytoplasm and 
within lysosomes (indicated by colocalisation of liposome and LysoTracker) for both cell 
lines (Fig. 3.6). 
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Figure 3.6: Cellular uptake and localisation of R18-labelled liposomes. Non-functionalised (NF) 
and PAI-2-functionalised (PAI-2) liposomes were labelled with octadecyl rhodamine B chloride (R18) 
and incubated with cells at a liposome concentration of 2.5 mM for 1 h. LysoTracker green was added 
immediately prior to imaging via confocal microscopy to visualise lysosomes. Arrows indicate white 
foci which indicate colocalisation of green and magenta signals. Representative images are shown. 
Scale bars are 25 µm. 
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3.3.4 Cytotoxicity of N-AI PAI-2 liposomes against breast cancer cells 
To determine the cytotoxicity of N-AI-loaded PAI-2-functionalised (N-AI PAI-2) 
liposomes against breast cancer cells in vitro, N-AI PAI-2 liposomes and empty (EMP) 
PAI-2 liposomes at an equivalent phospholipid concentration were tested against MCF-7 
and MDA-MB-231 cells. Treatment with N-AI PAI-2 liposomes showed changes in cell 
morphology for both cell lines, consistent with intracellular delivery of the cytotoxic N-
AI (Fig. 3.7). Treatment with EMP PAI-2 liposomes did not induce a change in cell 
morphology in either cell line. After incubating EMP PAI-2 liposomes or N-AI PAI-2 
liposomes with MCF-7 and MDA-MB-231 cells for a period of 72 h, an endpoint MTS 
cell viability assay showed a dose-dependent cytotoxic effect of the N-AI PAI-2 
liposomes against both cell lines. The cytotoxic effect of N-AI PAI-2 liposomes against 
MDA-MB-231 cells (IC50 of 5.40 ± 1.14 µM) was significantly greater (P < 0.01) than 
that against MCF-7 cells (IC50 of 31.84 ± 8.20 µM). EMP PAI-2 liposomes did not elicit 
a dose-dependent cytotoxic response but showed some degree of cytotoxicity in both cell 
lines at the highest liposome concentrations tested. 
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Figure 3.7: Cytotoxicity of N-AI PAI-2 liposomes. In vitro cytotoxicity testing of empty (EMP) 
PAI-2 liposomes and N-AI PAI-2 liposomes against MCF-7 (low uPAR) and MDA-MB-231 (high 
uPAR) breast cancer cell lines. (A) Representative images showing changes in cell growth and 
morphology 72 h after treatment with liposomes at 62.0 µM N-AI or equivalent phospholipid 
concentration (scale bars are 100 µm). (B) Dose-response cell viability curves via MTS assay at 72 h 
post-treatment. Data are the mean ± s.d. (n = 3). 
 
 
3.3.5 Cytotoxicity of N-AI PAI-2 liposomes against breast cancer spheroids 
A range of cancer cell lines have been reported to spontaneously form spheroids under 
low-attachment growth conditions (Friedrich et al. 2009). To determine whether MCF-7 
and MDA-MB-231 cells could form multicellular tumour spheroids for testing of N-AI 
PAI-2 liposomes, MCF-7 and MDA-MB-231 cells were seeded into ultra-low attachment 
96-well plates at 5000, 2500, 1250 or 625 cells per well. Cells were incubated at 37°C for 
5 days and bright-field images acquired every 24 h (Fig. 3.8). Imaging revealed that both 
MCF-7 and MDA-MB-231 cells formed spheroids at all cell densities tested and spheroid 
diameter at each cell density was comparable between the two cell lines. There were 
notable differences in spheroid morphology between the two cell lines. MCF-7 cells 
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formed tight spheroids with well-defined edges and high circularity compared to MDA-
MB-231 spheroids, which appeared looser with less definition of the spheroid surface. At 
48 h post-cell seeding, the average spheroid diameters for 5000 cells were 488.0 ± 11.3 
µm and 484.3 ± 9.3 µm for MCF-7 and MDA-MB-231 cells, respectively. For 625 seeded 
cells at 48 h, the average spheroid diameters were 285.0 ± 7.6 µm and 230 ± 22.1 µm for 
MCF-7 and MDA-MB-231 cells, respectively. Spheroid diameter measurements revealed 
that MCF-7 spheroids continued to grow in diameter in a linear fashion over the 
experiment. In contrast, MDA-MB-231 spheroid growth was less rapid at the higher cell 
densities tested, and an initial decrease in diameter of the MDA-MB-231 spheroids 
coincided with the observed slower spheroid formation relative to MCF-7 spheroids. 
 
 
Figure 3.8: Cell titre for establishing breast tumour spheroids. MCF-7 and MDA-MB-231 cells 
were seeded at different cell densities (5000, 2500, 1250 and 625 cells per well) to optimise conditions 
for growing spheroids. Spheroids were imaged using light microscopy. (A) Representative spheroid 
images at 48 h post-cell seeding (once all wells had formed spheroids). Scale bars are 100 µm. (B) 
Spheroid diameter measurements for MCF-7 and MDA-MB-231 spheroids over time. Graphs are 
representative from two experimental repeats. Presented data are the mean ± s.d. (n = 3). 
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Once MCF-7 and MDA-MB-231 cells were confirmed to form spheroids, cells were 
seeded in ultra-low attachment 96-well plates at a density of 1000 cells per well and 
incubated at 37°C for 48 h to promote the formation of multicellular tumour spheroids 
prior to liposome testing. As per Section 3.3.4, EMP PAI-2 and N-AI PAI-2 liposomes at 
equivalent phospholipid concentrations were incubated with the preformed spheroids at 
37°C for a period of 72 h, with spheroids imaged every 24 h (Fig. 3.9). MCF-7 and MDA-
MB-231 spheroids treated with N-AI PAI-2 liposomes showed a time-dependent and 
concentration-dependent dissemination of the spheroid structure, with the complete 
destruction of the spheroid by 96 h at N-AI concentrations above 62.5 µM for both cell 
lines. At the 24 h time point, MDA-MB-231 spheroids treated with N-AI PAI-2 liposomes 
appeared to be more greatly dissociated than MCF-7 spheroids. In contrast, MCF-7 and 
MDA-MB-231 spheroids treated with EMP liposomes showed continued growth and an 
increase in spheroid diameter over time. 
 
At the experiment endpoint, an acid phosphatase assay was used to measure the metabolic 
activity of the cells comprising the spheroids to determine the cytotoxic effect of the EMP 
PAI-2 and N-AI PAI-2 liposomes after 72 h. The assay confirmed the cytotoxicity of the 
N-AI PAI-2 liposomes on these spheroids in a dose-dependent manner, and also for the 
EMP PAI-2 liposomes (Fig. 3.10). The IC50 values for N-AI PAI-2 liposomes tested 
against MCF-7 and MDA-MB-231 spheroids were 30.9 ± 5.4 µM and 59.3 ± 7.5 µM, 
respectively, and significantly different (P < 0.01). IC50 values for EMP PAI-2 liposomes 
could not be determined as sigmoidal dose-response curves could not be fitted to the data, 
but the trends indicated a dose-dependent decrease in cell viability with empty liposome 
concentrations equal to and greater than a phospholipid concentration of 375 µM. 
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Figure 3.9: Imaging of breast cancer spheroids treated with N-AI PAI-2 liposomes. Testing of 
empty (EMP) PAI-2 and N-AI PAI-2 liposomes against MCF-7 and MDA-MB-231 multicellular 
tumour spheroids over a period of 72 h at 62.0 µM N-AI or equivalent phospholipid concentration. 
Representative images were captured at the same magnification (n = 3). Scale bars are 100 µm. 
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Figure 3.10: Cytotoxic effect of N-AI PAI-2 liposomes on breast cancer spheroids. Empty (EMP) 
PAI-2 liposomes and N-AI PAI-2 liposomes were tested against MCF-7 and MDA-MB-231 
multicellular tumour spheroids over a period of 72 h. An endpoint acid phosphatase assay was used to 
determine cell viability. Data are the mean ± s.d. (n = 3). 
 
 
As the 2D and 3D cell testing revealed a cytotoxic effect of EMP PAI-2 liposomes at high 
phospholipid concentrations, additional testing was conducted using non-functionalised 
liposomes alongside PAI-2-functionalised liposomes at equivalent phospholipid 
concentrations. MCF-7 and MDA-MB-231 spheroids were treated with empty liposomes 
(EMP), empty PAI-2-functionalised liposomes (EMP PAI-2), N-AI-loaded liposomes (N-
AI) and N-AI-loaded PAI-2-functionalised liposomes (N-AI PAI-2) for 96 h. Images 
indicated that N-AI and N-AI PAI-2 liposomes showed similar effects on spheroid 
morphology, with destruction of the spheroid structure at the experimental endpoint (Fig. 
3.11). EMP and EMP PAI-2 liposomes had a similar effect on spheroids. 
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Figure 3.11: Morphological effect of N-AI PAI-2 liposomes on spheroids. Testing of empty (EMP), 
empty PAI-2 (EMP PAI-2), N-AI and N-AI PAI-2 liposomes against MCF-7 and MDA-MB-231 
multicellular tumour spheroids over a period of 96 h. Representative images (n = 3) of treatment with 
25 µM N-AI liposomes (or empty liposomes at equivalent phospholipid concentration). All images 
were captured at the same magnification. Scale bar is 100 µm. 
 
 
Spheroid diameter was measured every 24 h where spheroids were still intact and had a 
distinct border (Fig. 3.12). Relative to control (untreated) spheroids, MCF-7 and MDA-
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MB-231 spheroids showed a stable or slight increase in diameter over 96 h when treated 
with EMP or EMP PAI-2 liposomes. For MCF-7 spheroids, a time-dependent decrease in 
diameter was observed with treatment of 6.25 µM N-AI or N-AI PAI-2 liposomes. For 
MDA-MB-231 spheroids, there was no trend of diameter decrease for spheroids treated 
with 6.25 µM N-AI or N-AI PAI-2 liposomes. At the 24 h time point, there was a 
significant (P < 0.01) difference in diameter for MDA-MB-231 spheroids treated with N-
AI PAI-2 liposomes (74.5 ± 3.4 µm) relative to N-AI liposomes (91.8 ± 5.1 µm). 
Significant differences in diameter between N-AI and N-AI PAI-2 liposomes were not 
observed at any other time points at the 6.25 µM N-AI concentration, and no significant 
differences were observed at any time points for MCF-7 spheroids. 
 
 
Figure 3.12: Diameter of liposome-treated breast cancer spheroids over 96 hours. MCF-7 
spheroids and MDA-MB-231 spheroids were treated with empty (EMP) liposomes, empty PAI-2-
functionalised (EMP PAI-2) liposomes, N-AI-loaded (N-AI) liposomes and N-AI-loaded PAI-2-
functionalised (N-AI PAI-2) liposomes for 96 h. Images were taken every 24 h and spheroid diameter 
measured at each time point. Data are shown for treatment with a 6.25 µM concentration of liposomal 
N-AI (or equivalent liposome phospholipid concentration for empty liposomes). Data are means ± s.d. 
(n = 3). 
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To determine the viability of the spheroids at the experimental endpoint, spheroids were 
incubated with calcein-AM at the 96 h time point and imaged to detect calcein 
fluorescence (Fig. 3.13). Images indicated a change in cell viability across the different 
liposome concentrations tested, with disseminated but viable clusters of MCF-7 and 
MDA-MB-231 cells after treatment with 100 µM N-AI or N-AI PAI-2 liposomes. EMP 
and EMP PAI-2 liposomes at an equivalent phospholipid concentration also showed 
noticeable changes in the distribution of calcein staining for both cell lines. 
 
Dose-response curves derived from the calcein staining revealed similar trends between 
N-AI and N-AI PAI-2 liposomes for both cell lines, with no significant difference between 
the two liposome treatments (Fig. 3.14). The IC50 values for both N-AI and N-AI PAI-2 
liposomes were not significantly different between MCF-7 and MDA-MB-231 spheroids 
(Table 3.1). The IC50 value for spheroids treated with EMP PAI-2 liposomes was 
significantly (P < 0.05) lower for MCF-7 cells (80.3 ± 7.2 µM) relative to MDA-MB-231 
cells (105.6 ± 12.3 µM). 
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Figure 3.13: Calcein imaging of liposome-treated breast cancer spheroids. (A) MCF-7 spheroids 
and (B) MDA-MB-231 spheroids were treated with empty (EMP) liposomes, empty PAI-2-
functionalised (EMP PAI-2) liposomes, N-AI-loaded (N-AI) liposomes and N-AI-loaded PAI-2-
functionalised (N-AI PAI-2) liposomes for 96 h. Calcein-AM was added to spheroids to visualise 
viable cells. Images are representative of triplicate samples of liposomes tested at three different 
concentrations (0, 25 or 100 µM N-AI, or empty liposomes at equivalent phospholipid concentration). 
Scale bars are 100 µm. 
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Figure 3.14: Calcein viability of liposome-treated breast cancer spheroids. MCF-7 spheroids and 
MDA-MB-231 spheroids were treated with empty (EMP) liposomes, empty PAI-2-functionalised 
(EMP PAI-2) liposomes, N-AI-loaded (N-AI) liposomes and N-AI-loaded PAI-2-functionalised (N-
AI PAI-2) liposomes for 96 h. Calcein-AM was added to spheroids to visualise viable cells. Data are 
green fluorescence intensity means ± s.d. (n = 3). 
 
 
Table 3.1: IC50 values for liposome-treated breast cancer spheroids. MCF-7 spheroids and MDA-
MB-231 spheroids were treated with empty (EMP) liposomes, empty PAI-2-functionalised (EMP 
PAI-2) liposomes, N-AI-loaded (N-AI) liposomes and N-AI-loaded PAI-2-functionalised (N-AI PAI-
2) liposomes for 96 h. Calcein-AM was added to spheroids to visualise viable cells. Total fluorescence 
was used to determine viability and IC50 values (µM). Data are means ± s.d. (n = 3). * = P < 0.05 
(relative to MCF-7 EMP PAI-2 value). 
 EMP EMP PAI-2 N-AI N-AI PAI-2 
MCF-7 not reached 80.3 ± 7.2 52.2 ± 6.2 40.2 ± 4.0 
MDA-MB-231 156.1 ± 20.5 105.6 ± 12.3* 71.5 ± 7.6 60.4 ± 7.1 
 
 
3.4 Discussion 
Determining the in vitro properties of novel nanotherapies using cell-based models is 
important for initially evaluating the cellular effects of a nanoparticle formulation before 
proceeding to in vivo studies. In this chapter, the cellular uptake, localisation and 
cytotoxicity of N-AI-loaded PAI-2-functionalised (N-AI PAI-2) liposomes were 
determined using two breast cancer cell lines that vary in their expression of cell surface 
uPAR. PAI-2-functionalised liposomes showed a significantly greater uptake than non-
functionalised (NF) liposomes in MDA-MB-231 cells (uPAR-positive) but not in MCF-
7 cells (uPAR-negative). Confocal microscopy revealed uptake of both NF and PAI-2 
liposomes into both cell lines, with localisation in the cytoplasm and some accumulation 
within lysosomes. N-AI PAI-2 liposomes showed a significantly increased cytotoxic 
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effect against MDA-MB-231 cells compared to MCF-7 cells after 72 h when grown in 
2D culture. N-AI PAI-2 liposomes were also cytotoxic to MCF-7 and MDA-MB-231 
multicellular tumour spheroids, resulting in dissemination of the 3D structure and 
cytotoxic effect, but with no significant differences in IC50 between the two cell lines after 
96 h. Collectively, the results presented in this chapter form a basis for understanding the 
in vitro properties of N-AI PAI-2 liposomes to guide further in vivo evaluation. 
 
As reported previously, uPA and uPAR expression is low in MCF-7 cells and high in 
MDA-MB-231 cells (Huber et al. 2016; Ma et al. 2001). The profiling results in this 
chapter corroborated this, with MDA-MB-231 cells showing significantly greater uPAR 
expression than MCF-7 cells and the IgG control (Fig. 3.2). This difference in uPAR 
expression was associated with a significant increase in fluorescently labelled PAI-2 
liposome uptake relative to non-functionalised liposomes by MDA-MB-231 cells, but not 
by MCF-7 cells (Fig. 3.5). In these experiments, FITC-labelled empty liposomes were 
used as N-AI is slightly fluorescent (Fig. 3.3) and empty liposomes do not have a 
significantly different size or surface charge as compared to N-AI-loaded liposomes 
(Chapter 2, Section 2.3.1). In addition, both N-AI (Vine et al. 2016) and rhodamine-123 
(Krag et al. 1989) have been shown to be cytotoxic against tumour cells, and this was 
observed as a decrease in the viable cell population after 60 min treatment with N-AI and 
R123-loaded liposomes by flow cytometry (Fig. 3.3). This cytotoxic profile of N-AI and 
R123 make their use in uptake studies unfavourable. In contrast to N-AI and R123 
liposomes, FITC-labelled liposomes did not have a strong cytotoxic effect against MDA-
MB-231 cells at a 20 mM phospholipid concentration, and FITC liposomes at 10 mM did 
not show a significant decrease in cell viability after incubation with cells for 60 min (Fig. 
3.4). Therefore, this fluorophore was chosen to label liposomes for subsequent flow 
cytometry experiments. 
 
Liposomes can be taken into cells via several different mechanisms, including adsorption, 
lipid exchange, intracellular membrane fusion and receptor-mediated endocytosis (RME) 
(Ducat et al. 2011). The presence of a fluorescent signal from cells treated with non-
functionalised (NF) fluorescently labelled liposomes (Fig. 3.3) indicates that NF 
liposomes were taken up by cells, most likely by fusion or other non-specific mechanisms, 
rather than by RME. In contrast, the uptake of PAI-2 liposomes by MDA-MB-231 cells 
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was greater than the uptake of NF liposomes in MDA-MB-213 cells (Fig. 3.5). As the 
average liposome diameters of the FITC-labelled NF and PAI-2 liposomes were 
equivalent (152.6 ± 8.7 nm and 152.8 ± 11.7 nm, respectively), this difference in uptake 
is likely due to the presence of PAI-2 at the liposome surface and interaction with 
uPA/uPAR overexpressed on the surface of MDA-MB-231 cells. Competition binding 
studies using excess PAI-2 or uPAR antibody could be used to further confirm this (Willis 
& Forssen 1998; Xiao et al. 2011). 
 
Confocal microscopy indicated that both NF and PAI-2 liposomes were internalised by 
MCF-7 and MDA-MB-231 cells, which further supports the above flow cytometry uptake 
results. Colocalisation of liposome signal with lysosomes in both cell lines confirmed that 
liposomes were internalised by cells and accumulated in lysosomes, in addition to being 
present elsewhere in the cell (Fig. 3.6). The R18 signal was also observed at the cell 
membrane and within the cytoplasm, with the dispersed signal suggesting that some 
degree of liposome fusion with the cell membrane occurred. This is not an unexpected 
result given that the liposomes were incubated with cell monolayers at a high liposome 
concentration, making it likely that liposomes in solution will passively fuse with cells 
over time (Ducat et al. 2011). Collectively, the results indicate that NF and PAI-2 
liposomes are taken into cells by fusion and potentially also by RME in the case of PAI-
2 liposomes. This could be further explored by using inhibitors of endocytosis to elucidate 
mechanisms of liposome uptake (Lu et al. 2017; Un et al. 2012). 
 
The work presented in this chapter highlights the need for adequate characterisation of 
liposome ligand density to guide and interpret in vitro uptake experiments. For example, 
for the N-AI PAI-2 liposome formulation, the exact number of PAI-2 ligands present at 
the liposome surface and the proportion of liposomes that have one or more PAI-2 ligands 
attached for cell binding is unknown. These factors will affect how the liposome 
formulation behaves in vitro. Previous studies have demonstrated that modulating the 
liposome ligand density by changing the starting maleimide-PEG concentration of the 
formulation affects cellular binding and uptake (Chu et al. 2016; Gayong et al. 2016; Li, 
H et al. 2016). As discussed in Chapter 2, Section 2.4, robust methods to quantify the 
number of ligands present at the liposome surface are needed in order to optimise ligand 
density for cell uptake and functional effect. Chapter 5 reports a novel single-molecule 
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fluorescence microscopy method to quantify liposome ligand density, which could be 
used in future experiments to determine the optimal number of ligands for maximal 
receptor binding, cellular uptake and therapeutic effect (Belfiore, Lisa et al. 2018). 
 
In the cytotoxicity testing against breast cancer cells grown as monolayers, N-AI PAI-2 
liposomes showed a dose-dependent cytotoxic effect that was significantly (P < 0.01) 
more potent against MDA-MB-231 cells compared to MCF-7 cells, with IC50 values of 
5.40 ± 1.14 µM and 31.84 ± 8.20 µM, respectively. This appears to indicate PAI-2-
mediated targeting and an increased cytotoxic effect of PAI-2-functionalised liposomes 
against uPAR-positive MDA-MB-231 cells (Fig. 3.7), which correlates with the flow 
cytometric uptake data showing increased uptake of PAI-2 liposomes relative to NF 
liposomes in MDA-MB-231 cells (Fig. 3.5). The less potent but still cytotoxic effect of 
N-AI PAI-2 liposomes against the uPAR-negative MCF-7 cells indicates that the 
liposomes were still taken up by cells via receptor-independent pathways in this cell line, 
which correlates with the flow cytometry and confocal microscopy findings (Fig. 3.6). In 
addition, EMP PAI-2 liposomes showed a cytotoxic effect against both cell lines at the 
highest liposome concentrations tested, which is likely due to empty liposomes fusing 
with cell membranes at high concentrations, resulting in cell lysis (Lu et al. 2017). 
 
In the multicellular tumour spheroid experiments, imaging of spheroids over the course 
of the experiment indicated a concentration-dependent and time-dependent destruction of 
both MCF-7 spheroids and MDA-MB-231 spheroids when treated with N-AI PAI-2 
liposomes (Fig. 3.9). Treatment with EMP PAI-2 liposomes did not result in 
morphological changes to the spheroid structure. However, the effect of EMP PAI-2 
liposomes on the viability of cells grown in 3D appeared to be greater than that observed 
in the 2D experiments. EMP PAI-2 liposomes showed a dose-dependent cytotoxic effect 
against both cell lines grown as spheroids, as revealed by an acid phosphatase (APH) 
endpoint viability assay (Fig. 3.10). To determine whether this effect was due to the 
phospholipid concentration or the presence of PAI-2 at the liposome surface, both EMP 
(non-functionalised) and EMP PAI-2 liposomes were tested against MCF-7 and MDA-
MB-231 spheroids in a subsequent experiment, which revealed similar effects (Fig. 3.11). 
An endpoint calcein viability stain revealed that the IC50 of spheroids treated with EMP 
PAI-2 was significantly (P < 0.05) lower for MCF-7 spheroids (80.3 ± 7.2 µM) relative 
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to MDA-MB-231 spheroids (105.6 ± 12.3 µM), but no significant differences in IC50 were 
observed for the other liposome treatments (Table 3.1). 
 
MCF-7 and MDA-MB-231 cells have been previously shown to form spheroids, with the 
former developing into compact and highly rounded spheroids, and the latter forming 
looser spheroid structures (Ivascu & Kubbies 2007). Similar findings were observed in 
the cell titre experiment reported in this chapter (Fig. 3.8), with phase-contrast imaging 
revealing that MCF-7 spheroids formed tighter and more circular spheroids, whereas 
MDA-MB-231 spheroids appeared looser and less defined, despite both cell lines forming 
spheroids of similar diameters. This difference in spheroid morphology was further 
highlighted by the calcein imaging of spheroids (Fig. 3.13). Untreated MCF-7 spheroids 
showed a decrease in fluorescence at the spheroid centre, indicative of a necrotic core 
with few viable cells (Fig. 3.1). In contrast, untreated MDA-MB-231 spheroids were 
smaller than MCF-7 spheroids and did not show evidence of a necrotic core via calcein 
imaging. These observed differences in spheroid morphology may have effects on 
liposome penetration and drug performance (Ivascu & Kubbies 2007). While MDA-MB-
231 spheroids treated with N-AI PAI-2 liposomes showed greater destruction of the 
spheroid architecture than MCF-7 spheroids at the 24 h time point (Fig. 3.9), this 
increased spheroid dissociation did not correlate with an increased cytotoxic effect (Fig. 
3.11). The increased destructive effect may be the result of the weaker cell-cell junctions 
that hold the spheroid together, as reported previously for MDA-MB-231 spheroids 
(Ivascu & Kubbies 2007). In order to negate the effect of these inherent differences 
between breast cancer cell lines, it would be advantageous to generate a stably transfected 
cell line that overexpresses uPAR, or a knockout of a uPAR overexpressing line, and 
compare spheroid testing with the parent cell line (Moirangthem et al. 2016). 
 
The APH and calcein viability assays revealed an increase in MDA-MB-231 viability 
above untreated control spheroids at mid-range liposome concentrations. At lower N-AI 
concentrations, it appears that the liposomes did not kill the majority of MDA-MB-231 
cells, but reduced the integrity of the spheroid. It is possible that these cells were still able 
to proliferate in small clusters of the aggregate and remained viable even though the 
spheroid was no longer intact. This light microscopy imaging of spheroids treated with 
liposomes (Fig. 3.11) appears to indicate that the cells are not viable, but the calcein 
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imaging at the experimental endpoint (Fig. 3.14) reveals that viable cell clusters are 
present for MDA-MB-231 spheroids treated with liposomes at a 25 µM N-AI 
concentration. Therefore, at lower N-AI concentrations, there may have been a greater 
number of viable cells than in the untreated spheroids, since the cells were more spread 
out and cell proliferation was not slowed down by the spheroid growing larger in size.  
 
There was a high degree of corroboration between the APH assay and calcein-AM 
staining in the determination of IC50 values for N-AI PAI-2 liposomes tested against 
MCF-7 spheroids and MDA-MB-231 spheroids. The IC50 values for MCF-7 spheroids 
treated with N-AI PAI-2 liposomes were 30.9 ± 5.4 µM (APH assay) and 40.2 ± 4.0 µM 
(calcein staining). The IC50 values for MDA-MB-231 spheroids treated with N-AI PAI-2 
liposomes were 59.3 ± 7.5 µM (APH assay) and 60.4 ± 7.1 µM (calcein staining). While 
the 2D testing indicated that N-AI PAI-2 liposomes are approximately 6-fold more potent 
against MDA-MB-231 cells relative to MCF-7 cells, the 3D testing did not reveal a 
significant difference in potency for N-AI PAI-2 liposomes between the two cell lines 
(Fig. 3.7). The observed differences in IC50 values between 2D and 3D testing is not 
unexpected given the different pathways of liposome diffusion and uptake by cells grown 
in 2D versus 3D (Katt et al. 2016), and the reported differences in cell morphology and 
gene expression in 2D versus 3D cultures that can result in different responses to drug 
treatment (Kenny et al. 2007). For example, the sensitivity of breast cancer cells to 
trastuzumab, pertuzumab and lapatinib changes depending on whether the cells are grown 
as 2D or 3D cultures (Weigelt et al. 2010), and the apparent differences in HER2 
signalling observed between 2D and 3D cell culture models of breast cancer suggest that 
3D models better recapitulate in vivo HER2 signalling pathways (Pickl & Ries 2009). 
While uPAR profiling of other cancer cell lines has indicated that uPAR expression 
remains similar between 2D and 3D culture (Ertongur et al. 2004), it remains unknown 
whether the expression of uPA and uPAR by MCF-7 and MDA-MB-231 cells changes 
when cells are grown as 3D structures. 
 
Despite flow cytometry revealing an increase in the uptake of PAI-2-functionalised 
liposomes over non-functionalised liposomes by MDA-MB-231 cells, the endpoint 
viability assays revealed no significant differences in IC50 values between non-
functionalised and PAI-2-functionalised N-AI liposomes. It is possible that at the 
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experimental endpoints of 72 h or 96 h, any differences in cytotoxicity were masked as 
remaining viable cells continued to proliferate over time. There appeared to be a greater 
destruction of the spheroid structure for MDA-MB-231 spheroids than MCF-7 spheroids 
after treatment with N-AI PAI-2 liposomes at the 24 h time point (Fig. 3.9), and a 
significant decrease (P < 0.01) in the diameter of MDA-MB-231 spheroids treated with 
N-AI PAI-2 liposomes (74.5 ± 3.4 µm) compared to N-AI liposomes (91.8 ± 5.1 µm) at 
the 24 h time point (Fig. 3.12). However, these differences were lost at later time points 
and at the experimental endpoints of 72 h and 96 h. As the flow cytometric uptake showed 
a significant difference in the uptake of PAI-2 liposomes over NF liposomes after a 45 
min incubation, differences in liposome uptake and cytotoxic effect may be apparent 
initially but lost over time. For this reason, analysis of spheroid viability at earlier time 
points and the use of real-time analysis of cell viability rather than (or in addition to) 
endpoint viability assays would be advantageous in future experiments in order to 
determine different mechanisms of liposome uptake into tumour spheroids. This could be 
achieved by using fluorescent dyes that track viable cells to detect differences in viability 
at various time points after liposome treatment (Tario et al. 2018; Yumoto et al. 2014). 
 
A limitation of multicellular tumour spheroid models for testing new drug-loaded 
nanotherapies is that these static models do not reproduce the complex vascular network, 
hypoxia, interstitial fluid pressure and fluid shear observed in the in vivo tumour 
microenvironment. Importantly, static spheroid models do not account for drug transport 
across the vascular endothelium but rely exclusively on passive diffusion of liposomes 
through the culture medium to permeate the spheroid (Li & Lu 2011). The use of high 
local concentrations of drug-loaded liposomes to elicit a dose-dependent cytotoxic effect 
on spheroids grown in vitro is not the best representation of the in vivo context, where the 
enhanced permeability and retention (EPR) effect is at play and vascular permeability is 
a relevant factor in liposome accumulation at the tumour site (Maeda 2015). The 
development and validation of in vitro models that recapitulate aspects of the EPR effect 
is an emerging field of research. Static 3D co-culture models comprised of vascular 
network structures and breast tumour spheroids can be used for incorporating the effect 
of vascularisation in drug testing experiments (Swaminathan et al. 2017). Microfluidic-
based platforms can be used for monitoring nanoparticle delivery in a 3D environment 
that recapitulates circulation, extravasation and delivery to the tumour across the 
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interstitial space (Li et al. 2018). These models also permit examination of tumour cell 
and vascular cell interactions and how these interactions affect drug delivery. For 
example, in a microfluidic drug delivery model recapitulating the EPR effect, MDA-MB-
231 cells were shown to increase vascular permeability to liposomes compared to MCF-
7 cells, likely through the release of VEGF (Tang et al. 2017). The creation of clinically 
relevant models to study the interactions between distinct cell types in the tumour 
microenvironment and to test the effects of novel targeted therapies is vital for improving 
the translation of results from the in vitro to the in vivo setting (Herrmann et al. 2014). 
 
3.5 Conclusion 
The work presented in this chapter confirmed the cellular uptake, cellular localisation and 
cytotoxicity of N-AI PAI-2 liposomes. Liposomes were shown to be taken up by MCF-7 
and MDA-MB-231 cells, with PAI-2-functionalised liposomes showing increased uptake 
over non-functionalised liposomes by the uPAR-positive, but not uPAR-negative, MDA-
MB-231 breast cancer cell line by flow cytometry after 45 min incubation. Liposomes 
were shown to be internalised by MCF-7 and MDA-MB-231 cells, with localisation at 
the cell membrane, within the cytoplasm and some accumulation in the lysosomes. N-AI-
loaded liposomes were cytotoxic to breast cancer cells grown in both 2D and 3D, with 
increased cytotoxicity against MDA-MB-231 cells over MCF-7 cells in 2D culture and 
early time points (24 h) in 3D culture. Collectively, the in vitro results reported in this 
chapter provide a rationale to proceed with pharmacokinetic, biodistribution and efficacy 
testing of N-AI PAI-2 liposomes using clinically relevant in vivo models of uPAR-
positive breast cancer. 
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Chapter 4: 
In Vivo Evaluation of N-alkylisatin-Loaded 
Liposomes Targeting the Urokinase Plasminogen 
Activator System 
 
 
 
 
 
Metastatic human tumour cells in mouse lung tissue 
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4.1 Introduction 
The work described in Chapter 3 of this thesis explored the cellular uptake and cytotoxic 
effect of N-alkylisatin (N-AI)-loaded plasminogen activator inhibitor-2 (PAI-2)-
functionalised (N-AI PAI-2) liposomes on uPAR-positive breast cancer cells grown in 
monolayer culture and multicellular tumour spheroid culture. Despite the approximations 
of these cell models to in vivo tumours, there are limitations to how accurately cells grown 
on tissue culture plates can represent the characteristics of real tumours. In particular, 
modelling of the enhanced permeability and retention (EPR) effect – the primary means 
by which liposomes are thought to accumulate at tumour sites – is not possible in the in 
vitro setting. Additionally, metastatic disease cannot be adequately modelled and studied 
without the use of whole organisms. Therefore, there is a need to use animal models to 
better understand and validate the efficacy of novel anticancer nanotherapeutics in vivo. 
 
4.1.1 In vivo tumour models 
In vitro tumour cell models are informative insofar as they can be physiologically 
relevant, but in certain respects, their utility is limited since they cannot adequately 
replicate the complete nature of actual tumours (Katt et al. 2016). For example, in vitro 
cell models are static models that rely on passive diffusion for drugs to reach and permeate 
tumour cells or spheroids, which does not account for transport across the vascular 
endothelium as happens in vivo. Notably for nanoparticle testing, in vitro models cannot 
reproduce the complex vascular network, hypoxia, interstitial fluid pressure and fluid 
shear observed in the in vivo tumour environment (Velasco-Velazquez et al. 2011). 
Additionally, in order to understand the impact of the complexity of the tumour 
microenvironment, including the extracellular matrix, stromal cells and immune cells, on 
the performance of new drugs, models as similar to the in vivo situation as possible are 
required. While ex vivo tumour models have been reported, such as microfluidic-based 
platforms that recapitulate circulation, extravasation and drug delivery to tumours across 
the interstitial space (Tang et al. 2017), evaluation of new nanotherapies and other drugs 
in whole animals remains the standard for preclinical testing. 
 
In vivo, the EPR effect enables the passive accumulation of liposomes to tumour sites, 
although this effect is reported to be highly variable between different tumour types and 
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is not observed for all solid tumours (Hansen et al. 2015; Wang 2015). Generally, the 
nanoparticle targeting of haematological and lymphoid tumours, particularly for ligand-
directed liposomes, has shown greater success in in vivo tumour models since tumour 
cells in circulation are more directly accessible to liposomes than large solid tumours 
immersed in complex microenvironments (Buxton 2009; Cho & Lee 2014). However, the 
application of nanoparticles in the treatment of some solid tumours may have greater 
potential for use in the adjuvant setting to target vascularised micrometastases rather than 
(or in addition to) the primary tumour (Zhao, M et al. 2017). 
 
Currently, metastatic disease is the leading cause of cancer mortality, accounting for 
approximately 90% of cancer-related deaths, and remains untreatable (Sledge 2016). 
Metastatic disease cannot be adequately modelled and studied without the use of whole 
organisms. Modelling metastatic disease using mice is necessary to evaluate the potential 
effect of a nanotherapeutic on the spread of cancer and growth rates of secondary tumours 
(Fantozzi & Christofori 2006). The generation of such models usually involves the 
injection of human cells into an immunocompromised mouse, forming a xenograft, and 
after primary tumour formation, those human cells may metastasise. Many established 
human cancer cell lines have a low metastatic potential, with the likelihood of 
spontaneous metastasis in an animal being dependent on the model used. For example, 
the standard MDA-MB-231 breast cancer cell line routinely used in vitro has been shown 
to metastasise in an intraductal NODScidIL2gamma-/- (NSG) mouse model (Young et al. 
2016) but remains poorly metastatic in a mammary fat pad BALB/c nude mouse model 
(Stutchbury et al. 2007). This highlights the importance of selecting appropriate tumour 
models for the evaluation of nanotherapies in vivo. 
 
While mouse models are the most frequently used animal models of tumours and other 
disease states, given the high degree of similarity between mice and humans, there are 
several known differences between mouse tumour models and the human context. For 
example, the rate of mouse model tumour growth and resultant angiogenesis is much 
greater than the formation of a tumour in humans, which tends to increase the EPR effect 
(Maeda 2015). Additionally, the lack of an adaptive immune system in 
immunocompromised xenograft mouse models used to study nanotherapies means that 
known immune system effects on tumour growth and metastasis are absent from testing 
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(Budhu et al. 2014). Despite their limitations, mouse models enable the determination of 
key characteristics of new nanotherapies, such as potential toxicity and off-target effects. 
Importantly, mouse models allow the evaluation of pharmacokinetics to determine how 
quickly a nanoparticle formulation is cleared from the bloodstream (plasma half-life), 
which is an important indicator of how likely it is that the nanoparticle will successfully 
reach the site of the tumour. Similarly, biodistribution studies provide information about 
where the nanoparticle localises in the body and how the nanoparticle is cleared. These 
characteristics can be measured by radiolabelling the nanoparticles and then detecting the 
presence of radiolabel in plasma and tissues at various time points post-injection (Vine et 
al. 2014). This information can then guide dosing for efficacy experiments, which can 
help elucidate the effects of repeated nanoparticle treatments on primary tumour growth 
rate and tumour metastases to major organs, giving an indication of potential therapeutic 
effect in a clinical setting. 
 
4.1.2 Experimental rationale 
To better understand the behaviour and potential anti-tumour effects of PAI-2-
functionalised liposomes containing N-AI (N-AI PAI-2 liposomes) in vivo, it is necessary 
to evaluate the properties of the liposomes in animal models of breast cancer. Toxicology 
studies previously performed by our laboratory have shown that N-AI-loaded liposomes 
are non-toxic in mice, with up to 100 mg/kg total dose of liposomal N-AI showing no 
adverse effects (Appendix D). PAI-2 has also been shown to be safe and non-toxic in 
mice when administered intravenously (Hang et al. 1998; Vine et al. 2012). The 
biodistribution and pharmacokinetic properties of N-AI PAI-2 liposomes need to be 
determined to guide treatment schedules for efficacy experiments in mouse breast tumour 
models, which can be used to evaluate the potential therapeutic effect of N-AI PAI-2 
liposomes in uPAR-positive breast cancer. 
 
4.1.3 Aims 
This chapter tested the hypothesis that N-AI-loaded PAI-2-functionalised liposomes (N-
AI PAI-2 liposomes) enhance the tumour cell uptake into and cytotoxic effect of N-AI 
against uPAR-positive breast tumours. Therefore, the overall aim of this chapter was to 
determine the pharmacokinetics, biodistribution and anti-tumour efficacy of N-AI PAI-2 
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liposomes in human xenograft models of primary and metastatic uPAR-positive triple-
negative breast cancer (TNBC) in order to evaluate the scope for future preclinical 
analysis and clinical application of N-AI PAI-2 liposomes. The specific aims of this 
chapter were to: 
1. Determine the pharmacokinetic and biodistribution profiles of N-AI PAI-2 
liposomes in female BALB/c nude mice bearing MDA-MB-231 orthotopic 
breast tumour xenografts; 
2. Determine the anti-tumour (primary tumour) efficacy of multiple doses of N-AI 
PAI-2 liposomes in female BALB/c nude mice bearing MDA-MB-231 
orthotopic breast tumour xenografts; and 
3. Determine the anti-tumour (primary tumour and metastatic tumour) efficacy of 
multiple doses of N-AI PAI-2 liposomes in NOD-SCID-IL2gamma-/- mice 
bearing MDA-MB-231 intraductal breast tumour xenografts. 
 
4.2 Methods 
4.2.1 Pharmacokinetics and biodistribution of N-AI PAI-2 liposomes 
4.2.1.1 Preparation of 3H-CHE-labelled liposomes 
Liposome components (20 mM soy L-α-phosphatidylcholine (124.0 mg), 0.8 mM mPEG-
DSPE (18.7 mg), 0.2 mM mal-PEG-DSPE (4.7 mg), 5 mM hydroxymethylbenzyl-isatin 
(17.0 mg)) were weighed out into glass vials and dissolved in chloroform/methanol (2:1 
v/v). All solutions were transferred to a round-bottom flask using a glass pipette and 400 
µCi tritiated cholesteryl hexadecyl ether [cholesteryl-1,2-3H(N)] (3H-CHE) 
(PerkinElmer, MA, USA) (50 µCi per mL liposome) was added to the solution. Solvents 
were removed by rotary evaporation. The flask was then filled with nitrogen, sealed with 
parafilm and transferred to 4°C overnight. To reconstitute the thin film, 8 mL degassed 
endotoxin-free PBS (pH 7.4; Sigma-Aldrich, MO, USA) was added to the flask. The flask 
was placed in a shaking water bath at room temperature (RT) and left for 1 h to 
reconstitute. The solution was filtered through a 0.22 µm PVDF membrane and extruded 
through a 0.1 µm membrane a total of 11 times at RT using a syringe-driven mini-extruder 
(Avanti Polar Lipids). Liposomes were characterised by dynamic light scattering (DLS) 
analysis (NanoSight) to determine size and monodispersity. N-AI-loaded non-
functionalised liposomes (N-AI) and N-AI-loaded PAI-2-functionalised liposomes (N-AI 
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PAI-2) were prepared by adding 704 µL of either PBS (pH 7.4) or PAI-2 (2.3 mg/mL in 
PBS, pH 7.4), respectively, to 3 mL of liposome solution and incubating at RT for 4 h. 
The radioactivity of the preparations was measured using a scintillation counter (Tri-Carb 
2810 TR Liquid Scintillation Counter; PerkinElmer, MA, USA) (10 µL liposome + 6 mL 
Ultima Gold). Prior to injection, the liposome preparations were sterile-filtered through a 
0.22 µm pore PVDF filter and kept sterile for subsequent in vivo studies. 
 
4.2.1.2 Mice 
Female BALB/c-Fox1nu/Ausb nude immunocompromised mice (5 weeks old) 
(Australian BioResources, Moss Vale) were housed in isolator cages at the University of 
Wollongong animal facility. Mice were given food and water ad libitum and kept on a 12 
h light/dark cycle for the duration of the experiment. Mice were allowed to acclimatise 
for 2 weeks before commencement of the experiment. All experiments were conducted 
in accordance with the ‘NHMRC Australian Code for the Care and Use of Animals for 
Scientific Purposes’, which requires 3R compliance (replacement, reduction and 
refinement) at all stages of animal care and use, and the approval of the Animal Ethics 
Committee of the University of Wollongong (Australia) under protocol AE13/18. MDA-
MB-231 cells (ATCC; mycoplasma negative and STR profiled) were cultured in RPMI-
1640 medium with 10% heat-inactivated FBS (incubated at 37°C). Cells were detached 
from flasks with 0.05% trypsin/EDTA solution (Gibco, MA, USA) and incubated for 3-
5 min at 37°C. Cells were collected in RPMI-1640 medium with 10% FBS and 
centrifuged at 1200 rpm (~300 x g) for 5 min at RT. Cells were resuspended in PBS with 
Ca/Mg (pH 7.4; Sigma-Aldrich, MO, USA) and centrifuged again as above. Cells were 
then resuspended in PBS (no Ca/Mg; pH 7.4; Sigma-Aldrich, MO, USA) and counted 
using Trypan blue (Sigma-Aldrich, MO, USA) and a haemocytometer. A cell suspension 
at a concentration of 4 x 107 cells/mL was prepared to give 2 x 106 cells in a 50 µL 
injection volume. Cell viability was checked after injections had been completed and was 
found to be approximately 90%. 
 
Mice were weighed prior to cell injection. Insulin syringe needles (29-gauge; BD 
Biosciences, NJ, USA) were used to inject 50 µL of cell suspension (containing 2 x 106 
cells) into the upper left mammary fat pad. Mice were injected one cage at a time and the 
injection order of cages was randomised. Mice were monitored closely following 
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injection of cells, and tumours were observed to form at approximately 3 weeks post-
injection. 
 
4.2.1.3 Treatment with liposomes 
All mice were monitored and weighed prior to the start of treatments. Mice did not show 
signs of distress or weight loss in the weeks prior to treatment commencement. Tumours 
were apparent in most mice and were small (< 100 mm3) upon commencement of 
liposome treatment. Mice were randomly allocated to treatment (N-AI liposome or N-AI 
PAI-2 liposome) and time point (10 min, 3 h, 6 h, 24 h, 48 h or 96 h) groups (4 mice per 
cohort). Treatments were administered intravenously via a single lateral tail vein 
injection. Tails were warmed using a heat lamp to dilate the tail vein before injecting 100 
µL (4 µCi) of liposome solution. Following injection, a small amount of pressure was 
placed on the injection site to stem any bleeding. Mice that were deemed significantly (± 
10%) smaller or larger in weight than their cage mates had their dose volume adjusted 
proportionally based on their weight relative to the average of their cage mates. 
 
Cohorts were euthanised at designated time points post-treatment (10 min (0.17 h), 3 h, 6 
h, 24 h, 48 h or 96 h) via CO2 inhalation. Immediately after sacrifice, whole blood was 
collected by cardiac puncture using 29-gauge insulin syringes and transferred into 1 mL 
EDTA animal collection tubes (Greiner, Austria). Blood was centrifuged at 500 x g for 
15 min at RT and 0.1 mL of plasma was transferred to a pre-weighed 7 mL glass 
scintillation vial. Kidneys, liver, spleen, lungs and tumour, as well as the tail (to subtract 
activity remaining at injection site) were removed from each animal and transferred to 
individual pre-weighed 20 mL glass scintillation vials. Vials were sealed and stored at 
4°C until tissues were processed. 
 
4.2.1.4 Blood and tissue analysis 
The 3H-CHE radioactivity (liposome) in the plasma, kidneys, liver, spleen, lungs, tumour 
and tail (for injection correction) was quantified using previously published methods 
(Vine et al. 2014). Vials were equilibrated to RT and the weight of each tissue was 
determined by subtracting the pre-recorded weights of each empty vial. Solvable 
(PerkinElmer, MA, USA) was added to each vial to dissolve the tissues: 0.4 mL for 
plasma; 2 mL for kidneys, spleen, lungs and tail; 5 mL for liver; and 1 mL for tumours 
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(where present). Vials were sealed and incubated at 60°C for 1-3 h with occasional 
agitation to dissolve tissues. Vials were then cooled to RT and hydrogen peroxide (30% 
v/v) was added to bleach the samples: 0.2 mL for plasma, kidneys, spleen, lungs and tail; 
0.5 mL for liver; and 0.1 mL for tumour. Samples were allowed to stand for 30 min at RT 
to complete the reaction. Vials were then sealed tightly and incubated at 60°C for 1 h. 
Vials were cooled to RT and 0.5 mL of each sample (0.25 mL for liver due to residual 
intense colouration) was transferred to a 7 mL glass scintillation vial. To this, 5 mL of 
Ultima Gold LSC (PerkinElmer, MA, USA) was added, vials were inverted to mix and 
samples were temperature-adapted (25°C) and dark-adapted for 1 h prior to counting. 
Samples were analysed using a Tri-Carb 2810 TR Liquid Scintillation Counter 
(PerkinElmer, MA, USA). Separate control vials for each tissue were prepared in parallel 
and contained the same volumes of each reagent but in the absence of tissue. The raw 
counts for each sample were corrected for the amount of radioactivity remaining in the 
tail and are presented as the percentage of injected dose (ID) per gram of tissue (% ID/g) 
or percentage of ID in the whole tumour (% ID). Pharmacokinetic profiles were 
determined by plotting the % ID/mL remaining in the plasma over time and fitted to a 
one phase decay model using GraphPad Prism V7 for Windows (GraphPad Software, 
CA, USA). 
 
4.2.2 Efficacy of N-AI PAI-2 liposomes in a primary tumour model 
4.2.2.1 Liposome preparation 
Liposomes were prepared as outlined in Section 4.2.1.1 in the absence of 3H-CHE. Empty 
non-functionalised (EMP) liposomes were composed of 20 mM soy PC, 1 mM mPEG-
DSPE and 5 mM cholesterol. N-AI-loaded non-functionalised (N-AI) and N-AI-loaded 
PAI-2-functionalised (N-AI PAI-2) liposomes were composed of 20 mM soy PC, 0.8 mM 
mPEG-DSPE, 0.2 mM mal-PEG-DSPE and 5 mM 5,7-dibromo-N-(p-
hydroxymethylbenzyl)isatin (N-AI). Liposomes were serially extruded through a 0.1 µm 
pore PVDF membrane using a thermobarrel batch extruder (Lipex) and characterised by 
DLS (NanoSight). 
 
4.2.2.2 Mice 
Female BALB/c-Fox1nu/Ausb nude immunocompromised mice (5 weeks old) 
(Australian BioResources, Moss Vale) were housed in isolator cages at the University of 
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Wollongong Animal Facility. Mice were given food and water ad libitum and kept on a 
12 h light/dark cycle for the duration of the experiment. Mice were allowed to acclimatise 
for 3 weeks before commencement of the experiment. All experiments were conducted 
in accordance with the ‘NHMRC Australian Code for the Care and Use of Animals for 
Scientific Purposes’, which requires 3R compliance (replacement, reduction and 
refinement) at all stages of animal care and use, and approval of the Animal Ethics 
Committee of the University of Wollongong (Australia) under protocol AE13/18. Mice 
were inoculated with MDA-MB-231 tumour cells as outlined in Section 4.2.1.2. 
 
4.2.2.3 Treatment with liposomes 
All mice were monitored and weighed prior to the start of treatments. Mice did not show 
signs of distress or weight loss in the weeks prior to treatment commencement. Tumours 
were apparent in most mice and were large (~200 mm3) at the start of treatments. Mice 
were randomly allocated to one of three treatment groups (EMP, N-AI and N-AI PAI-2) 
(8 mice per treatment group). Treatments (100 µL) were administered intravenously via 
the lateral tail vein as described in Section 4.2.1.3 for a total of 6 injections over 2 weeks 
(average total dose = 68.1 mg/kg N-AI). Mice that were deemed significantly (± 10%) 
smaller or larger in weight than their cage mates had their dose volume adjusted 
proportionally based on their weight relative to the average of their cage mates. Tumour 
dimensions were measured three times per week using callipers and tumour volume was 
calculated using the equation: volume (mm3) = (length (mm) x width (mm) x width (mm)) 
/ 2. Animals were weighed triweekly for the duration of the experiment. Mice were 
sacrificed by CO2
 inhalation upon reaching tumour end point (tumour dimensions of 15 
mm x 15 mm) or at the experimental end point. Immediately after sacrifice, the kidneys, 
liver, spleen, heart and lungs, and tumour were removed and weighed. 
 
4.2.3 Efficacy of N-AI PAI-2 liposomes in a metastatic tumour model 
4.2.3.1 Liposome preparation 
Liposomes were prepared as outlined in Section 4.2.2.1 in the absence of 3H-CHE. The 
four liposome preparations, empty non-functionalised (EMP), empty PAI-2-
functionalised (EMP PAI-2), N-AI non-functionalised (N-AI) and N-AI PAI-2-
functionalised (N-AI PAI-2) liposomes, were sterile-filtered through a 0.22 µm PVDF 
membrane and kept sterile until treatment. 
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4.2.3.2 Mice 
Female immunocompromised NOD-SCID-IL2gamma-/- mice (5 weeks old) were housed 
in the Biological Testing Facility at the Garvan Institute of Medical Research. Mice were 
given food and water ad libitum and kept on a 12 h light/dark cycle for the duration of the 
experiment. All animal procedures were approved by the Garvan/St Vincent’s Animal 
Ethics and Experimentation Committee (approval number 14/27) according to the Animal 
Research Act 1985, Animal Research Regulation 2010 and the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes, which requires 3R 
compliance (replacement, reduction and refinement) at all stages of animal care and use. 
Intraductal injections of MDA-MB-231 cells were performed by Samantha Oakes at The 
Kinghorn Cancer Centre. 80,000 MDA-MB-231 cells were injected directly into the right 
mammary duct in a total volume of 10 µL, as described previously (Young et al. 2016). 
Mice were monitored twice weekly and tumour growth was measured for the duration of 
the experiment. Tumours were measured immediately prior to each injection and volume 
was calculated using the equation: volume (mm3) = (length (mm) x width (mm) x width 
(mm)) / 2. 
 
4.3.3.3 Treatment with liposomes 
At 5 weeks post-tumour cell inoculation, mice were randomised into one of four treatment 
groups (5 mice per treatment cohort): EMP (empty liposomes), EMP PAI-2 (empty PAI-
2-functionalised liposomes), N-AI (N-AI-loaded liposomes) or N-AI PAI-2 (N-AI-loaded 
PAI-2-functionalised liposomes). Treatments (100 µL, dose of 4.7 mg/kg N-AI) were 
administered intravenously via the lateral tail vein using a 25-gauge needle on a triweekly 
schedule for a total of 3.5 weeks (11 injections in total; total dose of 51.7 mg/kg N-AI). 
At 9 weeks post-tumour cell inoculation, mice were euthanised by CO2 inhalation and 
cervical dislocation. The mammary glands, tumours, lungs and livers were harvested and 
fixed for 4 h in 10% buffered formalin at RT for subsequent histology and/or 
immunohistochemistry analysis. 
 
4.3.3.4 Tissue analysis 
All analyses were performed at The Kinghorn Cancer Centre histology laboratory. 
Mammary glands were whole mounted and processed for histology. After fixation, lungs 
and livers were sectioned and stained with vimentin (1:800; Leica NCL-L-VIM-V9), and 
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tumours were sectioned and stained with cleaved caspase-3 (1:100; CST ASP175 9664) 
using DAKO immunohistochemistry as per the manufacturer’s instructions. Images were 
captured using a Leica DFC 450 microscope using 20X magnification. Images were 
analysed using ImageJ (version 1.51s) with automated algorithms designed for IHC 
analysis (Law et al. 2017). 
 
4.2.4 Data analysis 
All data analysis, including the generation of graphs and statistical tests, was performed 
using GraphPad Prism software (version 7), unless stated otherwise. Data are presented 
as the mean ± standard deviation (s.d.) or standard error of the mean (s.e.m.) as stated. 
Pairwise comparisons were made using Student’s t-test, and multiple comparisons were 
made using one-way ANOVA with Tukey’s post-test, or two-way ANOVA for grouped 
comparisons. 
 
4.3 Results 
4.3.1 Pharmacokinetics and biodistribution 
To determine the pharmacokinetic and organ distribution profiles of N-AI-loaded non-
functionalised liposomes (N-AI) and N-AI-loaded PAI-2-functionalised liposomes (N-AI 
PAI-2) in tumour-bearing mice, liposomes were labelled with tritiated cholesteryl 
hexadecyl ether (3H-CHE) to enable the detection of liposomes in plasma and tissues by 
liquid scintillation counting. Following preparation, liposomes were characterised by 
DLS, which revealed monodisperse populations with average diameters of 115 ± 34 nm 
and 117 ± 39 nm for N-AI and N-AI PAI-2 liposomes, respectively. Scintillation counts 
of the two liposome stock preparations were 319,698 CPM and 312,163 CPM for N-AI 
and N-AI PAI-2 liposomes, respectively. The plasma half-life was determined to be 5.63 
h and 5.82 h for N-AI and N-AI PAI-2 liposomes, respectively (Fig. 4.1). The plasma 
clearance profiles of the two liposomes and the pharmacokinetic parameters from curve 
fitting analysis were not significantly different (P > 0.05) (Table 4.1). N-AI and N-AI 
PAI-2 showed no significant differences in the average final weight of the kidneys, liver, 
spleen or lungs (Appendix E). 
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Figure 4.1: Detection of radiolabelled liposomes in the plasma of mice over time. N-AI and N-AI 
PAI-2 liposomes were labelled with tritiated cholesteryl hexadecyl ether and administered 
intravenously as a single bolus dose. Tritiated signal was measured in plasma at each time point. 
Results are expressed as the percentage of injected dose (ID) per mL of plasma (%ID/mL). Error bars 
are s.d. (n = 4). 
 
 
Table 4.1: Pharmacokinetic parameters of N-AI and N-AI PAI-2 liposomes. N-AI and N-AI PAI-
2 liposomes were labelled with tritiated cholesteryl hexadecyl ether and administered intravenously as 
a single bolus dose. Tritiated signal was measured in plasma at each time point. 
PK Parameter N-AI N-AI PAI-2 
Cmax (% ID/mL) 84.66 (± 9.79) 83.76 (± 9.25) 
Kelim α (fast) min−1 0.061 0.058 
Kelim β (slow) min−1 0.002 0.002 
T1/2 α (fast) min 11.419 12.050 
T1/2 β (slow) min 408.152 410.843 
Correlation coefficient (R2) 0.9629 0.9836 
AUC (% ID/min/mL) 860.3 (± 66.89) 873.4 (± 50.79) 
 
 
Liposome accumulation in the kidneys, liver, spleen and lungs at each time point was 
similar between N-AI and N-AI PAI-2 liposomes (Fig. 4.2). The trends indicated 
increased clearance via the liver and spleen over time and decreased clearance via the 
kidneys and lungs over time. There was no significant difference (P > 0.05) in clearance 
via the kidneys, liver or lungs between the two liposomes at any time point. Clearance 
via the spleen was significantly higher (P < 0.05) at the 48 h time point for N-AI 
liposomes (78.5 ± 32.2 % ID/g tissue) compared to N-AI PAI-2 liposomes (44.2 ± 6.7 % 
ID/g tissue). 
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Figure 4.2: Detection of radiolabelled liposomes in clearance organs. N-AI and N-AI PAI-2 
liposomes were labelled with tritiated cholesteryl and administered intravenously as a single bolus 
dose. Tritiated signal was measured in the (A) kidneys, (B) liver, (C) spleen and (D) lungs at each 
time point. Results are expressed as the percentage of injected dose (ID) per gram of tissue (%ID/g). 
Values are means ± s.e.m. (n = 4). 
 
 
Comparison of the different clearance organs revealed similar patterns between N-AI and 
N-AI PAI-2 liposomes (Fig. 4.3). The primary route of clearance after the 10 min time 
point was via the spleen for both liposome formulations, which was 68.6 ± 19.3 % ID/g 
tissue and 48.1 ± 10.1 % ID/g tissue at the 96 h time point for N-AI and N-AI PAI-2 
liposomes, respectively. Clearance via the liver was also high, with 20.0 ± 2.2 % ID/g 
tissue and 23.6 ± 1.8 % ID/g at the 96 h time point for N-AI and N-AI PAI-2 liposomes, 
respectively. Clearance via the kidneys and accumulation in the lungs were minimal for 
both liposome formulations. 
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Figure 4.3: Comparison of N-AI and N-AI PAI-2 liposome clearance. N-AI and N-AI PAI-2 
liposomes were labelled with tritiated cholesteryl and administered intravenously as a single bolus 
dose. Tritiated signal was measured in the kidneys, liver, spleen and lungs at each time point. Results 
are expressed as the percentage of injected dose (ID) per gram of tissue (%ID/g). Values are means ± 
s.e.m. (n = 4). 
 
 
Where present, tumours were removed from mice and analysed for tritiated liposome 
signal in the same manner as for tissues (Fig. 4.4). The results showed rapid accumulation 
of N-AI PAI-2 liposome signal in tumours compared to N-AI liposomes, as indicated by 
significantly increased %ID at 10 min, 3 h and 6 h post-injection (P < 0.001). At 24 h, 48 
h and 96 h, tumour uptake of N-AI and N-AI PAI-2 liposomes was not significantly 
different (P > 0.05). 
 
 
Figure 4.4: Accumulation of liposomes in uPAR-positive breast tumours. N-AI and N-AI PAI-2 
liposomes were labelled with tritiated cholesteryl hexadecyl ether and administered intravenously as 
a single bolus dose. Tritiated signal was measured in whole collected tumour (where present) for each 
time point. Results are expressed as the percentage of the injected dose (ID) in the whole analysed 
primary tumour. Error bars are s.e.m. (n = 4). 
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4.3.2 Efficacy in a primary breast tumour model 
In order to determine the potential effect of N-AI PAI-2 liposomes on primary tumour 
growth, mice bearing MDA-MB-231 tumours were treated with empty liposomes (EMP), 
N-AI-loaded liposomes (N-AI) or N-AI-loaded PAI-2-functionalised (N-AI PAI-2) 
liposomes three times per week for two weeks. Mice in all cohorts continued to gain 
weight for the duration of the experiment, suggesting no toxic effects of the multiple dose 
schedule of the liposomes (Fig. 4.5). While average animal weights were not significantly 
different between the three cohorts over the course of the experiment, the N-AI PAI-2 
cohort showed a trend of a higher percentage weight gain compared to the other cohorts, 
although this was not statistically significant (P > 0.05). 
 
 
Figure 4.5: Animal weights over the duration of liposome treatment. Mice bearing MDA-MB-231 
uPAR-positive tumours were administered with EMP, N-AI or N-AI PAI-2 liposomes on a triweekly 
schedule for two weeks. (A) Average weight and (B) percentage weight change (relative to experiment 
start) for each cohort for the duration of the experiment. Values are means ± s.e.m. (n = 8). 
 
 
To assess the effect of the liposome treatments on primary tumour growth, tumours were 
measured using callipers three times a week and tumour volume was calculated using the 
equation: volume (mm3) = (length (mm) x width (mm) x width (mm)) / 2. Tumours 
showed relatively linear growth across all cohorts, and the average tumour volume and 
percentage change in tumour volume between the three cohorts was not significantly 
different (P > 0.05) at any experimental time point (Fig. 4.6). 
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Figure 4.6: Primary tumour volume measurements. Mice bearing MDA-MB-231 uPAR-positive 
tumours were administered with EMP, N-AI or N-AI PAI-2 liposomes on a triweekly schedule for two 
weeks. (A) Tumour volume and (B) percentage change in tumour volume (relative to day 0 of 
treatment) for each cohort for the duration of the experiment. Values are means ± s.e.m. (n = 8). 
 
 
At the end of the experiment, the kidneys, liver, spleen, and heart and lungs of each mouse 
were removed in whole and weighed. The final organ weights between the three cohorts 
were not significantly different (P > 0.05), indicating no toxicity from the multiple dosing 
schedule of the treatments (Fig. 4.7). 
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Figure 4.7: Final organ weights of liposome-treated mice. Mice bearing MDA-MB-231 uPAR-
positive tumours were administered with EMP, N-AI or N-AI PAI-2 liposomes on a triweekly schedule 
for two weeks. At the experimental endpoint, mice were euthanised and (A) kidneys, (B) liver, (C) 
spleen and (D) heart and lungs were removed in whole and weighed. Values are means ± s.e.m. (n = 
8). ns = not significant (P > 0.05). 
 
 
Primary tumours were removed in whole and weighed. Primary tumour weights varied 
greatly between individuals within each cohort, but the average primary tumour weight 
between the three cohorts was not significantly different (Fig. 4.8). Comparison of 
primary tumour weights and primary tumour volume (calculated from calliper 
measurements) showed a high level of corroboration, but also showed no significant 
differences between the three treatment cohorts. 
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Figure 4.8: Final primary tumour measurements of liposome-treated mice. Mice bearing MDA-
MB-231 uPAR-positive tumours were administered with EMP, N-AI or N-AI PAI-2 liposomes three 
times per week for two weeks. (A) At the experimental endpoint, mice were euthanised and primary 
tumours were removed in whole and weighed. (B) Final primary tumour volume as determined by 
calliper measurements. Values are means ± s.e.m. (n = 8). ns = not significant (P > 0.05). 
 
 
4.3.3 Efficacy in a metastatic breast tumour model 
To investigate the effect of N-AI PAI-2 liposomes on metastatic tumours, liposomes were 
tested in a metastatic intraductal breast tumour model with mice bearing MDA-MB-231 
tumours. Empty non-functionalised liposomes (EMP), empty PAI-2-functionalised 
liposomes (EMP PAI-2), N-AI-loaded non-functionalised liposomes (N-AI) and N-AI-
loaded PAI-2-functionalised liposomes (N-AI PAI-2) were administered intravenously 
from 5 weeks post-tumour cell inoculation when tumours were small (palpable, not 
measurable) on a triweekly schedule. Tumour volume increased steadily over time in all 
cohorts, with a more rapid increase observed from 20 days post-treatment (Fig. 4.9). 
Primary tumour growth was not significantly different between the four treatment 
cohorts, although mice treated with EMP PAI-2, N-AI or N-AI PAI-2 liposomes showed 
a trend of decreased tumour growth relative to the EMP treatment cohort. 
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Figure 4.9: Primary tumour measurements in an intraductal tumour model. Mice bearing 
intraductal MDA-MB-231 tumours were treated with empty liposomes (EMP), empty PAI-2-
functionalised liposomes (EMP PAI-2), N-AI-loaded liposomes (N-AI) or N-AI-loaded PAI-2-
functionalised liposomes (N-AI PAI-2) (at equivalent N-AI and/or PAI-2 concentrations, where 
applicable) 3 times a week for 5 weeks. Values are means ± s.e.m. (n = 5). 
 
 
Animal weights fluctuated throughout the course of the experiment but did not 
significantly change with progression of liposome treatment (Fig. 4.10). At the final time 
point (25 days post-treatment), the average percentage weight change of the N-AI PAI-2 
cohort was significantly higher than that of the other three cohorts (P < 0.05). 
 
 
Figure 4.10: Animal weights in an intraductal model over duration of treatment. Mice bearing 
intraductal MDA-MB-231 tumours were treated with empty liposomes (EMP), empty PAI-2-
functionalised liposomes (EMP PAI-2), N-AI-loaded liposomes (N-AI) or N-AI-loaded PAI-2-
functionalised liposomes (N-AI PAI-2). (A) Animals were weighed prior to each treatment. (B) 
Animal weights normalised to day 0 post-treatment. Values are means ± s.e.m. (n = 5). 
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At the experimental end point, primary tumours (where present; n = 18), mammary glands 
(where possible; n = 15), lungs and livers were removed in whole. Mammary glands were 
stained with carmine as described previously (Young et al. 2016) and imaged for 
secondary tumour detection in the mammary gland once the primary tumour was removed 
(Fig. 4.11). The proportion of mammary glands with secondary tumours present was 
highest for the EMP cohort (4/5) and lowest for the N-AI PAI-2 cohort (0/2). There were 
no significant differences (P > 0.05) in average positive tumour area between the cohorts 
where secondary tumours were present (EMP, EMP PAI-2 and N-AI). 
 
 
Figure 4.11: Mammary gland whole-mount analysis. Mice bearing intraductal MDA-MB-231 
tumours were treated with empty liposomes (EMP), empty PAI-2-functionalised liposomes (EMP 
PAI-2), N-AI-loaded liposomes (N-AI) or N-AI-loaded PAI-2-functionalised liposomes (N-AI PAI-
2). At the experimental endpoint, mammary glands were removed in whole where possible and 
mounted for carmine staining. (A) Representative carmine-stained mammary gland images. (B) 
Percentage of mice with tumour(s) present in mammary gland at experimental endpoint. (C) Tumour 
area (positive stain) of mammary glands where tumours were present. Values are means ± s.e.m. (n = 
2-4). n.s. = not significant (P > 0.05). 
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To determine the potential cytotoxic anti-tumour cell effect of the N-AI and N-AI PAI-2 
liposome treatments on primary tumours, primary tumour sections were stained with 
cleaved caspase-3 to detect apoptotic cells (Fig. 4.12). Automated imaging analysis of 
positively stained cells showed a considerable degree of variability between individuals 
within each treatment cohort, but no significant differences (P > 0.05) in the average 
positive area between the four cohorts in terms of cleaved caspase-3-positive cells. 
 
 
Figure 4.12: Immunohistochemistry analysis of primary tumours. Mice bearing intraductal MDA-
MB-231 tumours were treated with empty liposomes (EMP), empty PAI-2-functionalised liposomes 
(EMP PAI-2), N-AI-loaded liposomes (N-AI) or N-AI-loaded PAI-2-functionalised liposomes (N-AI 
PAI-2). (A) Tumour sections were stained with cleaved caspase-3 (apoptotic cells). (B) Representative 
total mask (all cells) using automated imaging analysis. (C) Representative positive mask (apoptotic 
cells) using automated imaging analysis. (D) Percentage of cleaved caspase-3-positive area (apoptotic 
cells) relative to total cell area. Values are means ± s.e.m. (n = 5). n.s. = not significant (P > 0.05). 
 
 
To determine the effect of the four liposome treatments on metastasis to the lungs and 
liver, lung and liver sections were stained with vimentin to detect metastatic cells (Fig. 
4.13). Automated imaging analysis of positively stained cells showed a high degree of 
variability between individuals within each cohort, but no significant differences (P > 
0.05) in average positive area between the four cohorts in terms of vimentin-positive cells. 
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Figure 4.13: Immunohistochemistry analysis of lung and liver metastasis. Mice bearing 
intraductal MDA-MB-231 tumours were treated with empty liposomes (EMP), empty PAI-2-
functionalised liposomes (EMP PAI-2), N-AI-loaded liposomes (N-AI) or N-AI-loaded PAI-2-
functionalised liposomes (N-AI PAI-2). (A-B) Lung and liver sections were stained with vimentin 
(metastatic cells). (C-D) Representative total masks (all cells) using automated imaging analysis. (E-
F) Representative positive masks (metastatic cells) using automated imaging analysis. (G-H) 
Percentage of vimentin-positive area (metastatic cells) relative to total cell area. Values are means ± 
s.e.m. (n = 5). n.s. = not significant (P > 0.05). 
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4.4 Discussion 
Determining the in vivo properties of novel nanotherapies using animal models is 
important for evaluating how a new nanoparticle formulation can be expected to perform 
in humans. In this chapter, the pharmacokinetics, biodistribution and anti-tumour efficacy 
of N-AI-loaded PAI-2-functionalised (N-AI PAI-2) liposomes were evaluated using two 
different breast cancer xenograft mouse models. The addition of PAI-2 to the surface of 
N-AI-loaded liposomes did not significantly alter the in vivo clearance properties of the 
formulation but did appear to increase accumulation of liposomes at the primary tumour 
site in an orthotopic MDA-MB-231 BALB/c-Fox1nu/Ausb xenograft mouse model 
relative to non-functionalised liposomes. Despite this increase in tumour uptake, the anti-
tumour efficacy of N-AI PAI-2 liposomes relative to non-functionalised N-AI-loaded 
liposomes and empty control liposomes was not significantly different in the two mouse 
models used. 
 
Understanding the pharmacokinetic properties and tissue distribution of nanoparticle 
formulations is essential to determine circulation time, clearance mechanisms and how 
well the nanoparticle reaches and accumulates at the site of primary and metastatic 
tumours (Allen & Cullis 2013). Importantly, the pharmacokinetic profile reveals the 
circulation half-life of a nanoparticle, a characteristic of particular importance for 
nanotherapies as the enhanced permeability and retention (EPR) effect is the primary 
mechanism by which nanoparticles are thought to target tumours and exhibit anti-tumour 
effects (Maeda 2015). The plasma circulation time of liposomes has been shown to be 
dependent on their lipid composition, size, surface charge, morphology and other 
physicochemical characteristics, as the dominant mechanism by which liposomes are 
typically cleared from the bloodstream is based on interactions with phagocytic cells of 
the mononuclear phagocyte system (MPS). The inclusion of PEG at the outer surface of 
the liposome can increase the in vivo circulation time by reducing recognition and 
clearance by the MPS (Uster et al. 1996). Therefore, PEGylated liposomes reportedly 
have decreased rates of clearance as PEG at the nanoparticle surface helps to shield the 
nanoparticle from the innate immune response. 
 
In this work, N-AI and N-AI PAI-2 PEGylated liposomes both exhibited an average 
plasma half-life in mice of approximately 6 hours (5.63 h and 5.82 h, respectively) (Fig. 
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4.1). This plasma half-life is comparable to other reports of PEGylated liposomes, which 
typically exhibit a plasma half-life of several hours (Krishna et al. 2001; Vijayakumar et 
al. 2016). The organ accumulation of N-AI and N-AI PAI-2 liposomes was in accordance 
with the general clearance pattern typically seen for nanoparticles, with high degrees of 
clearance from the spleen, liver and kidneys (Dams et al. 2000) (Fig. 4.2). The 
biodistribution profile of the two liposome preparations correlates with the known general 
patterns of clearance of PEGylated liposomes from the blood, with a drop in liposome 
plasma concentration at the 6 h time point correlating with increased liposome clearance 
primarily by the spleen (indicative of clearance via the MPS), in addition to the liver, and 
comparatively low clearance by the kidneys and lungs (Litzinger et al. 1996) (Fig. 4.3). 
Clearance via the spleen was significantly higher (P < 0.05) at the 48 h time point for N-
AI liposomes (78.5 ± 32.2 % ID/g tissue) compared to N-AI PAI-2 liposomes (44.2 ± 6.7 
% ID/g tissue), which is not unexpected given that the presence of functional groups on 
the surface of nanoparticles can affect clearance via the MPS (Alexis et al. 2008). While 
the N-AI and N-AI PAI-2 liposomes were equivalent in diameter (115 ± 34 nm and 117 
± 39 nm, respectively), the observed difference in spleen accumulation may be due to the 
difference in surface charge between the liposomes (–3.64 ± 0.59 mV and –4.66 ± 0.52 
mV, respectively) (Chapter 2, Section 2.3.3). However, the result obtained in this study 
contrasts with the general trend observed in previous studies, which report that 
nanoparticles with a greater negative charge show greater clearance via the spleen (He et 
al. 2010) and liver (Xiao et al. 2011). The decreased spleen accumulation of N-AI PAI-2 
liposomes relative to N-AI liposomes at the 48 h time point may be due to the increased 
tumour accumulation of N-AI PAI-2 liposomes at earlier time points. 
 
The accumulation of nanoparticles in tumours via the EPR effect is dependent on a 
number of factors, including interstitial fluid pressure, vascularity of the tumour and the 
in vivo circulation time of the nanoparticle formulation (Nichols & Bae 2014). The results 
presented here indicate a trend of increased tumour uptake of N-AI PAI-2 liposomes over 
N-AI liposomes. Tumour accumulation of N-AI PAI-2 liposomes was significantly higher 
(P < 0.001) than N-AI liposomes at the 10 min, 3 h and 6 h time points (Fig. 4.4). After 
the 6 h time point, the tumour accumulation of N-AI and N-AI PAI-2 liposomes was not 
significantly different. As the plasma half-lives of the two liposomes were equivalent 
(Fig. 4.1), the presence of PAI-2 at the liposome surface may have affected liposome 
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extravasation and uptake at the tumour site. This may have been due to PAI-2 liposomes 
binding to uPAR expressed by tumour cells, as was observed in Chapter 3 in the in vitro 
uptake and cytotoxicity testing of non-functionalised and PAI-2-functionalised 
liposomes. The difference in uptake may also be due to other differences between N-AI 
and N-AI PAI-2 liposomes. For example, as mentioned above, N-AI PAI-2 liposomes had 
a slightly more negative surface charge than N-AI liposomes, and surface charge has been 
shown to affect tumour uptake of nanoparticles (Xiao et al. 2011). 
 
The maximum tumour accumulation of the liposomes was 0.5% of the ID at the 10 min 
time point for N-AI PAI-2 liposomes and 0.02% for N-AI liposomes (Fig. 4.4). These 
values are comparable to other PEGylated nanoparticles, which typically show 
approximately 1% or less of the total ID reaching the site of the primary tumour. 
Generally, the percentage of the total ID of nanoparticles administered intravenously 
reaching the target site is quite low: the median value has been reported as 0.7% (Wilhelm 
et al. 2016). While the circulation time of nanoparticles is typically much longer than that 
of small molecules (as would be expected for free N-AI), a longer half-life is optimal for 
achieving tumour targeting, as the EPR effect relies on the nanoparticles remaining in 
circulation long enough to reach tumours and extravasate at those sites, which in turn 
drives enhanced tumour uptake, and accumulation and retention of liposomes for anti-
tumour effect (Grimaldi et al. 2016). Notably, the high tumour accumulation of Doxil® 
in humans (reported as high as 10% of the ID) is due in large part to the very long 
circulation half-life (up to 45 h) of the formulation (Gabizon et al. 1994). 
 
The biodistribution and pharmacokinetics experiment indicated that N-AI PAI-2 
nanoparticles reached the site of the primary tumour from a single intravenous injection, 
with an apparent increase in tumour localisation of the N-AI PAI-2 liposomes compared 
to N-AI liposomes. To determine whether this tumour accumulation of N-AI PAI-2 
liposomes would translate into a reduction in primary tumour growth rates, mice bearing 
large tumours (approximately 200 mm3) were injected three times per week for 2 weeks 
and tumour volume was measured to detect any changes to the tumour growth rate (Fig. 
4.6). Final organ weights were the same across all treatment cohorts (Fig. 4.7), supporting 
the results of a previous toxicology study that showed N-AI-loaded liposomes were not 
toxic at the multiple dosing schedule used, and that the maximum tolerated dose (MTD) 
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of N-AI-loaded liposomes was not reached at 100 mg/kg, the highest dose tested 
(Appendix D). Despite the lack of toxicity, in this study, no significant differences were 
observed in tumour growth rates, final tumour size or final tumour weight between the 
EMP liposome, N-AI liposome and N-AI PAI-2 liposome treatments (Fig. 4.6 and Fig. 
4.8). There may be several reasons for this observation. 
 
In contrast to the biodistribution study, where the starting tumour volume was 
approximately 100 mm3, tumours in this cohort were higher at the commencement of 
treatment, which may have meant that treatment started too late to result in any significant 
primary tumour growth delay. There was also a large degree of variability between 
tumour volume and growth rates among individual animals within the same cohorts, 
which made it difficult to determine differences between treatments, even with a sample 
size of 8 animals per treatment cohort (Fig. 4.8). Additionally, it is unknown whether 
primary tumours were sufficiently vascularised during the treatment timeframe, which 
would be needed to allow the liposomes to enter and reach the tumour area to exert an 
anti-tumour effect (Nichols & Bae 2014). This is an important factor, because for solid 
tumours that are poorly vascularised, any significant accumulation of nanoparticles in the 
vicinity of the tumour via the EPR effect is unlikely (Bahrami et al. 2017). The high 
degree of variability in starting tumour size may have meant differing degrees of tumour 
vascularisation, which may have translated to different degrees of the EPR effect and 
therefore varied liposome delivery to the tumours. While N-AI and N-AI PAI-2 liposomes 
were shown to accumulate at the site of primary tumours in this mouse model, given that 
the plasma half-life of the liposomes was 6 h, the liposomes may not have accumulated 
at the primary tumour site in large enough numbers to have a significant anti-tumour 
effect at the biweekly dosing schedule used. Therefore, an increased frequency of 
liposome administration may have been more suitable in increasing N-AI at the tumour 
site for an anti-tumour effect. However, in addition to being impractical for the researcher, 
frequent intravenous injections via the lateral tail veins may bring up ethical issues, as the 
injection site should be allowed to heal adequately before additional injections are made 
(Turner et al. 2011). 
 
As uPAR-positive breast cancer cells have a high propensity to metastasise (Chapter 1, 
Section 1.5), a mouse model of metastatic uPAR-positive breast cancer was used to assess 
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the potential anti-tumour effect of N-AI PAI-2 liposomes on both primary tumours and 
on micrometastases (Young et al. 2016). Mice were treated with EMP, EMP PAI-2, N-
AI and N-AI PAI-2 liposomes on a triweekly injection schedule for a total of 5 weeks. 
Previous work has shown that free N-AI has a potent anti-tumour effect on primary 
tumours at a dose of 10 mg/kg (Vine et al. 2012). In this experiment, N-AI or N-AI PAI-
2 liposomes administered at a total dose of 51.7 mg/kg did not demonstrate an anti-tumour 
effect on primary tumours (Fig. 4.9). Further, the N-AI PAI-2 liposome treatment did not 
differ significantly from N-AI liposomes or EMP PAI-2 liposomes, indicating that under 
the treatment conditions used, the combination of N-AI and PAI-2 does not have a 
synergistic anti-tumour effect in this model. As observed in the orthotopic breast tumour 
xenograft model described in Section 4.3.2, this intraductal breast tumour xenograft 
model also showed a high degree of variability in primary tumour growth and formation 
of metastases of individual animals within each cohort (Fig. 4.9 and Fig. 4.13). Original 
reports of this model using a variant of the MDA-MB-231 cell line also showed a high 
degree of variability among tumour growth of mice within treatment cohorts, which was 
reflected by a high variability (approximately 3 weeks) of the time to detection of initial 
primary tumour development in control mice (Young et al. 2016). Therefore, the 
statistical power of this model may have been limited by a high degree of biological 
variability. 
 
Previous experiments using the MDA-MB-231 intraductal xenograft model showed that 
antagonism of the survival factor myeloid cell leukemia-1 suppressed metastasis in 
TNBC xenografts (Young et al. 2016). Analysis of the mammary whole mounts in the 
current work showed no significant differences in secondary tumour formation in the 
mammary gland where the primary tumour was located (Fig. 4.11). This may be due to 
the fact that mammary glands could not be dissected from all mice, only from those where 
the primary tumour had not taken over entire mammary gland, limiting the total numbers 
available for analysis. No significant differences between treatment cohorts were found 
when primary tumours were stained with cleaved caspase-3 (Fig. 4.12), likely because 
the tumours were large at the experimental endpoint and the majority of the tumour core 
contained apoptotic cells. Vimentin was used to detect metastatic human cells in the lungs 
and liver, the tissues where MDA-MB-231 cells have been reported to metastasise in this 
mouse model (Young et al. 2016). While metastatic human cells were detected in the 
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lungs and liver of some mice, the low levels of metastasis in the control mice (EMP 
liposome treated) at the experimental endpoint meant that the number of vimentin-
positive cells detected per animal was relatively low (Fig. 4.13). Due to this, as well as 
the high degree of variability between individual animals in this model, significant 
differences between treatment groups could not be detected. If experiments using this 
model are repeated, an extended time frame should be used to ensure sufficient metastatic 
burden to the lungs and liver in control mice in order to detect potential changes in the 
number of metastatic cells of mice in the treatment groups. A superior way to conduct 
these experiments would be to utilise bioluminescent live imaging techniques (for 
example, using luciferase-tagged tumour cells) so that tumour growth and metastatic 
burden could be monitored in real time, helping to inform the decisions of when to start 
and end liposome treatments (Tung et al. 2016). 
 
An additional rationale for the use of non-invasive imaging techniques in in vivo 
experiments for testing liposomes is to elucidate the degree to which the EPR effect is 
occurring in these models (Chapter 1, Section 1.6). This is important as the EPR effect is 
reported to be highly variable and is not observed for all solid tumours, especially poorly 
vascularised tumours (Nichols & Bae 2014; Wang 2015). The EPR effect is also known 
to be highly variable between different animal models, different disease models, and 
between animals and humans (Hare et al. 2017). As the rate of animal tumour growth and 
resultant angiogenesis are reportedly much greater than the formation of tumours in 
humans (Maeda 2015), this results in a more pronounced EPR effect in animal models, 
which may partially explain why many nanotherapies that show promise in in vivo studies 
fail in clinical trials (Nichols & Bae 2014). Further research is required to better 
understand the EPR effect and elucidate the differences in this phenomenon between 
animal and human tumours, and between different tumour types, in order to increase the 
translation of nanoparticle-based therapeutics into the clinic (Lammers et al. 2016). This 
could be achieved via imaging methods, such as the radionuclide imaging of liposomes 
to determine their fate in vivo (van der Geest et al. 2016). Single photon emission 
computed tomography (SPECT) and positron emission tomography (PET) have 
previously been used to quantify the in vivo distribution of nanoparticles, including 
accumulation of nanoparticles at the tumour site, in a non-invasive manner (Harrington 
et al. 2001). The use of nanoparticles in conjunction with such imaging techniques may 
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also have theranostic applications, whereby both diagnostic and therapeutic agents are 
utilised in order to better guide and monitor treatment (Chen et al. 2017). 
 
While the biophysical properties of a nanoparticle formulation affect the plasma 
circulation time, clearance properties, and therefore tumour accumulation in vivo, it is 
important for future research to consider and evaluate the interactions of nanoparticles 
with cells of the immune system and clearance organs, since nanoparticles that are filtered 
out of the blood and end up in liver and spleen do not reach their intended target, which 
limits the therapeutic effect. The frequent use of xenograft models to allow the study of 
human cancer cells in mouse models means that immunocompromised mice are used in 
order to prevent rejection of the human xenografts. Given the known effect of the adaptive 
immune system in tumour growth and metastasis (Kitamura et al. 2015), there is a need 
for tumour models in immunocompetent animals in addition to the often used 
immunocompromised models that eliminate potential effects of the immune system in the 
evaluation of new anticancer therapies (Gomez-Cuadrado et al. 2017). The increasing use 
of such models lends itself to the improved assessment of targeted therapies in the context 
of cancer treatment (Budhu et al. 2014). 
 
Previous studies have shown that the plasma circulation time is dependent not only on the 
biophysical properties of the liposome formulation but also on the number of injections 
administered (Dams et al. 2000). This phenomenon is relevant to efficacy studies, which 
typically involve administration of multiple doses of a nanoparticle formulation to 
maximise therapeutic effect. The accelerated blood clearance (ABC) phenomenon 
describes how the first dose of a PEGylated nanoparticle may affect the pharmacokinetic 
properties of subsequent doses. Specifically, ABC describes an increased clearance rate 
of PEGylated nanoparticles from the blood with second and subsequent intravenous 
injections of the nanoparticle formulation (Laverman et al. 2001; Oussoren & Storm 
1999), and is dependent on the lipid dose administered and duration of the administration 
interval (Gabizon et al. 2008; Laverman et al. 2001). In this context, reduced circulation 
time correlates with increased liver and spleen accumulation (Laverman et al. 2001). The 
ABC phenomenon has been described for PEGylated liposomes, polymeric nanoparticles 
and PEGylated solid lipid nanoparticles delivered intravenously (Szebeni & Storm 2015). 
While the exact mechanism of the ABC phenomenon remains unknown, a key identified 
 119 
 
mechanism is the production of anti-PEG IgM following the first injection, which 
selectively binds to the surface of subsequently injected PEGylated particles and acts to 
accelerate clearance by substantial complement activation (Szebeni 2014). In 
immunocompromised mice, this mechanism is unlikely. However, Doxil® has been 
reported to activate the complement system (innate immune system) in animals and 
humans, leading to a hypersensitivity reaction known as complement activation-related 
pseudoallergy (CARPA), which can impact upon the pharmacokinetic and 
pharmacodynamic properties of the drug (Szebeni et al. 2016). Such research 
demonstrates that the ABC phenomenon is an important factor to consider in the design 
and development of PEGylated liposomes and other nanoformulations for repeat dosing 
therapeutic applications. 
 
Another key consideration for testing new nanotherapies, particularly those that are 
actively targeted, is the use of models that recapitulate intratumoural heterogeneity. The 
injection of a human cancer cell line into an animal to create an in vivo tumour model 
largely fails to represent the heterogeneity observed in human tumours since cells within 
a cell line are clonally similar (Alizadeh et al. 2015). This means that any treatment tested 
is expected to affect most, if not all, cells in that model in the same way, which is not 
representative of the clinical situation (Zardavas et al. 2015). Therefore, the use of these 
models in developing and testing novel therapies, especially dual-targeted therapies that 
are designed to address intratumoural heterogeneity, is limited as they do not permit 
evaluation of the effects of differential cell targeting and therapeutic resistance when 
determining anti-tumour efficacy. Patient-derived xenografts can be more representative 
of the clinical situation as they capture some elements of intratumoural heterogeneity, as 
well as the diversity observed between patients with cancer (Gomez-Cuadrado et al. 
2017). In addition to intratumoural heterogeneity, the interpatient heterogeneity observed 
in cancer also warrants the development and utilisation of patient-derived cell lines to 
more accurately assess patient responses to novel therapies, particularly in cases where 
resistance to currently used therapies is frequently observed (Shafaee & Ellis 2017). 
 
A final consideration in the testing of novel ligand-functionalised liposomes involves the 
question of what happens to liposome integrity, ligand attachment, ligand function, and 
therefore the biophysical properties of a liposome formulation after intravenous 
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administration, which affects in vivo circulation time and clearance properties. For 
example, the well-documented propensity of biological molecules, especially proteins, 
present in the bloodstream to associate non-specifically with the surface of liposomes in 
vivo and the subsequent formation of a protein corona around the liposome may affect 
numerous biophysical properties of a liposome formulation (Caracciolo et al. 2017). In 
the case of ligand-functionalised liposomes, the physical presence of a protein shield 
around the surface of the liposome, including association of plasma proteins with 
liposome ligands, may act to inhibit binding of the liposome targeting ligand with its 
target receptor, which would affect the targeting success in vivo (Shi et al. 2017). These 
potential changes to the liposome are usually unaccounted for but could have significant 
effects on the anticipated biodistribution, pharmacokinetic and efficacy profiles of a 
liposome formulation, and are therefore important factors to consider when testing 
liposomes in biological systems (Walkey & Chan 2012). 
 
4.5 Conclusion 
The work presented in this chapter reports novel data on the pharmacokinetics and 
biodistribution of N-AI and N-AI PAI-2 liposomes, as well as the efficacy of multiple 
doses of N-AI PAI-2 liposomes in two mouse models bearing orthotopic uPAR-positive 
breast tumour xenografts. While increased tumour uptake of N-AI PAI-2 liposomes over 
N-AI liposomes was observed, further research is needed to clarify if and how the potency 
of N-AI as a cytotoxin can be translated into an anti-tumour growth effect by targeting 
uPAR-positive tumours. The utilisation of more advanced preclinical models and 
methods will enable enhanced evaluation of N-AI PAI-2 liposomes in the in vivo context. 
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Chapter 5: 
Quantification of Ligand Density and 
Stoichiometry on the Surface of Liposomes by 
Single-Molecule Fluorescence Microscopy 
 
 
 
 
 
Single-molecule fluorescence imaging of liposomes 
 
 
 
Portions of this chapter have been published in the following work: 
 
Belfiore, L, Spenkelink, LM, Ranson, M, van Oijen, AM & Vine, KL 2018, 
‘Quantification of ligand density and stoichiometry on the surface of liposomes using 
single-molecule fluorescence imaging’, Journal of Controlled Release, vol. 278, pp. 80-
86. 
 
Author contributions: LB, LMS, MR, AMvO and KLV designed the experiments; LB 
and LMS performed the experiments and analysed the data; LB and LMS wrote the 
manuscript; MR, AMvO and KLV edited the manuscript for submission. 
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5.1 Introduction 
The work described in Chapter 2 of this thesis detailed the preparation and 
characterisation of novel N-alkylisatin (N-AI)-loaded, plasminogen activator inhibitor-2 
(PAI-2)-functionalised liposomes. The confirmation and quantification of PAI-2 ligand 
attachment to the surface of liposomes were attempted using biochemical protein assays, 
size-exclusion chromatography and Western blotting, but these methods could not 
provide direct and robust quantification of the average number of ligands attached to the 
surface of each liposome. This characteristic of an actively targeted liposome formulation 
is essential to enable the optimisation of ligand density to ensure optimal tumour cell 
uptake, as well as for quality control purposes such as accounting for batch-to-batch 
variability. Ligand quantification is particularly important for dual-ligand liposomes, for 
which the quantification of both the number and ratio of multiple different ligands 
attached to the liposome surface is needed to achieve optimal target cell effect. Currently, 
there are no methods to comprehensively characterise actively targeted liposomes in 
terms of precise surface ligand quantification. Therefore, there is a need to develop new 
methods to quantify the density and stoichiometry of ligands on the surface of ligand-
functionalised liposomes to facilitate their preclinical evaluation, pharmaceutical scale-
up and manufacture, and ultimately, their utilisation in clinical applications. 
 
5.1.1 Current approaches for liposome ligand quantification 
Liposomes have been utilised as delivery systems for drugs and other molecules in vivo 
for several decades (Grimaldi et al. 2016). Despite extensive research into the 
development of nanoparticle-based therapeutics, all clinically approved liposome 
formulations are non-ligand-directed, with efficacies relying solely on passive targeting 
and accumulation (Estanqueiro et al. 2014). A comprehensive list can be found in Chapter 
1, Table 1.2, and in the published literature (Shi et al. 2017). Active targeting strategies 
using liposomes have been extensively explored in the preclinical setting, particularly 
liposomes targeting tumour-associated receptors, with many reported formulations 
demonstrating improved efficacy over non-ligand-directed liposomes (Lukyanov et al. 
2004; Park et al. 2001). Given the general movement in the field towards actively targeted 
nanotherapeutics, the lack of translation of ligand-directed liposome formulations into 
clinical practice is somewhat surprising (Anchordoquy et al. 2017). Previous reviews 
 123 
 
have identified some of the likely reasons for this phenomenon, ranging from 
methodological difficulties involved in the large-scale preparation of ligand-directed 
liposomes, to the limitations of evaluating their efficacy in preclinical models that fail to 
adequately recapitulate human tumours (Hare et al. 2017). For example, once liposomes 
are administered intravenously, non-specific interactions of liposomes with a range of 
plasma proteins may result in the formation of a protein ‘corona’ at the liposome surface, 
effectively shielding liposome-bound targeting ligands from interacting with their target 
receptors and therefore negating their intended tumour cell targeting ability (Caracciolo 
et al. 2017). 
 
The absence of molecular tools for the robust characterisation of complex liposomes may 
also be contributing to the lack of clinically approved ligand-directed liposomes. 
Specifically, no methodology exists to quantify the number of ligands covalently bound 
to the surface of liposomes. Estimation of ligand conjugation is possible based on 
preparation parameters, but direct measurement of total surface-bound protein using 
standard biochemical assays has inherent limitations. For example, measurement of 
surface-bound protein in an actively targeted liposome formulation using colourimetric 
biochemical methods is challenging due to phospholipid interference in the measurement 
of very low protein concentrations (Klegerman et al. 2002). Flow cytometric methods that 
detect the insertion of fluorescently labelled micelles into liposomes as a proxy for 
successful liposome functionalisation (Chapter 2, Section 2.3.9) have been reported but 
are indirect and semi-quantitative (Mack et al. 2012). While current methods could 
potentially be used to quantify the total amount of protein in a sample, they cannot provide 
information about the average number of ligands bound to each liposome in a 
formulation. Thus, there is a need for fine-scale, single nanoparticle resolution. 
 
The lack of quantitative methodology poses a particular challenge for the development of 
liposomes with more than one surface-bound ligand, since the determination of ligand 
stoichiometry is important to control for batch-to-batch variability in the laboratory and 
for clinical production (Belfiore, L. et al. 2018). The absence of rigorous quantification 
protocols hinders high-quality large-scale manufacturing of ligand-directed liposome 
formulations, which may introduce regulatory barriers and slow down their introduction 
to the clinic. This is because without quantification methods, it is difficult to ascertain the 
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effects of different liposome preparation or purification methods on the resultant ligand 
density of the liposome formulation. For example, in the laboratory setting, size-exclusion 
chromatography (SEC) is commonly used to remove unconjugated ligands from 
liposomes but is not high-throughput. Alternative methods more amenable to scaling up, 
such as high-speed centrifugation, are more favourable, but it remains unknown whether 
centrifugation changes the ligand density of the final preparation. Such questions may be 
answered using a robust quantitative methodology. 
 
5.1.2 Single-molecule fluorescence microscopy 
Single-molecule fluorescence microscopy is a high-resolution imaging technique that 
removes ensemble averaging, allowing the direct visualisation of population distributions 
and the precise characterisation of subpopulations (Monachino et al. 2017). The single-
molecule fluorescence microscope removes out-of-focus background fluorescence of the 
imaged sample by utilising total internal reflection fluorescence (TIRF), enabling the 
detection of individual fluorescently labelled molecules. Laser light of a specific 
wavelength is coupled into the microscope objective, and the fluorescent signal from the 
sample is detected with an electron-multiplying charge-coupled device (EMCCD) camera 
(Fig. 5.1). By tracking the photobleaching steps of individual fluorescently labelled 
molecules, the number of fluorophores per molecule and the total number of molecules 
can be determined. 
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Figure 5.1: Schematic overview of the single-molecule fluorescence microscope. Laser light of a 
specific wavelength is coupled into the microscope objective. The fluorescent signal from the sample 
is detected with an electron-multiplying charge-coupled device (EMCCD) camera. 
 
 
Single-molecule methods have already proven to be important biophysical tools for 
studying a wide variety of biological processes (Shashkova & Leake 2017), including 
mechanisms of DNA replication (Ticau et al. 2017), conformational changes of enzymes 
(Marchetti et al. 2017) and the composition and assembly of various multiprotein 
complexes (Aggarwal & Ha 2016). However, single-molecule microscopy remains an 
under-utilised technique in therapeutics development. Based on how the technique has 
been previously used to quantify proteins that have been fluorescently labelled with 
fluorophores (Choi et al. 2012; Tessler & Mitra 2011), it should be possible to use the 
technique to count protein ligands bound to liposomes. Liposomes can be labelled with 
fluorescent dyes, such as octadecyl rhodamine B chloride (R18), which only fluoresce 
when bound to lipid membranes (Nunes-Correia et al. 2002). Lipid vesicles have 
previously been imaged using single-molecule fluorescence microscopy in the context of 
studying protein-membrane interactions (Chadda & Robertson 2016; Liu et al. 2010). In 
a similar way, liposomes and other nanoparticles that have surface-attached protein (or 
other) ligands can be studied using this high-resolution imaging technique. 
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5.1.3 Experimental rationale 
Despite the longstanding existence of liposome technology in drug delivery applications, 
there have been no ligand-directed liposome formulations approved for clinical use to 
date. This lack of translation is due in part to the absence of molecular tools available for 
the robust quantification of ligands on the surface of liposomes, which is necessary for 
optimising liposome preparation in the preclinical context, and eventually, to 
comprehensively characterise an actively targeted liposome formulation as required for 
clinical application. The successful development of a new and accurate method to 
quantify liposome ligands should help facilitate the production of actively targeted 
liposomes and their improved preclinical characterisation. 
 
5.1.4 Aims 
This chapter tested the hypothesis that single-molecule fluorescence microscopy can be 
used to determine the number of protein ligands bound to functionalised liposomes. 
Therefore, the overarching aim of this chapter was to develop single-molecule 
fluorescence microscopy as a tool for the quantification of ligands bound to the surface 
of liposomes. Specifically, the aims of this chapter were to: 
1. Quantify the ligand density and stoichiometry of both single-ligand and dual-
ligand liposomes using single-molecule fluorescence microscopy; 
2. Determine the effect of size-exclusion chromatography and centrifugation on the 
resultant ligand density of actively targeted liposome formulations; and 
3. Determine the effect of conventional and post-insertion functionalisation 
methods on the resultant ligand density of actively targeted liposome 
formulations.  
 
5.2 Methods 
5.2.1 Labelling proteins with fluorophores 
Human recombinant plasminogen activator inhibitor-2 (PAI-2), produced in-house by 
previously published methods (Cochran et al. 2009), and trastuzumab (TZ, Herceptin®; 
Genentech, CA, USA) were labelled with CF488 or CF647 succinimidyl ester fluorescent 
dyes (Sigma-Aldrich, MO, USA) as per the manufacturer’s instructions. Absorbance at 
280 nm (protein) and 488 nm or 647 nm (dye) was used to calculate the protein 
 127 
 
concentration and degree of labelling (DOL). DOL was further confirmed by electrospray 
ionisation mass spectrometry (ESI-MS). 
 
5.2.2 Electrospray ionisation mass spectrometry 
Positive ion mass spectra of unlabelled and labelled proteins were acquired on a 
quadrupole time of flight mass spectrometer (Micromass Q-TOF Ultima; Waters, MA, 
USA) fitted with a Z-spray ionisation source. Samples in phosphate-buffered saline (PBS; 
pH 7.4) were exchanged into deionised water containing 0.1% formic acid and made up 
to a final concentration of approximately 10 μM. The mass spectra were acquired with a 
capillary voltage of 2.6 kV, a cone voltage of 50 V, a source block temperature of 40 °C, 
and a resolution power of 5000 Hz. Caesium iodide was used for external calibration. 
Mass was calculated using MassLynx MS V4.1 (Waters, MA, USA). 
 
5.2.3 Liposome preparation 
Liposomes were prepared using the thin film hydration method as described previously 
(Uster et al. 1996). Dipalmitoylphosphatidylcholine (DPPC), cholesterol, 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[(polyethylene glycol)-2000] (mPEG2000-DSPE) 
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene 
glycol)-2000] (mal-PEG2000-DSPE) (Avanti Polar Lipids, AL, USA) in a 20:10:0.8:0.2 
molar ratio (conventional (CO) method), or DPPC, cholesterol and mPEG2000-DSPE in a 
20:10:0.6 molar ratio (post-insertion (PI) method), were dissolved in 
chloroform/methanol (2:1 v/v). For colocalisation experiments, liposomes were labelled 
with octadecyl rhodamine B chloride (R18; Invitrogen, CA, USA) by adding R18 to the 
chloroform/methanol solution in a 160:1 molar ratio (liposome phospholipid:R18). 
Organic solvents were removed by rotary evaporation and subsequent freeze-drying to 
form a lipid film.  
 
Phospholipids were reconstituted in degassed HEPES buffer (115 mM NaCl, 20 mM 
HEPES, 2.4 mM K2PO4, 1.2 mM CaCl2, 1.2 mM MgCl2; pH 7.4) at a concentration of 20 
mM. Once reconstituted, liposomes were passed once through a 0.22 µm polyvinylidene 
fluoride (PVDF) membrane (Merck Millipore, MA, USA) and then serially extruded 11 
times through a 0.1 µm PVDF membrane using a syringe-driven extruding apparatus 
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(Avanti Polar Lipids, AL, USA) at a temperature of 50°C (above the phase-transition 
temperature of DPPC). Liposomes were analysed by dynamic light scattering (DLS) to 
determine particle diameter using a Zetasizer APS (Malvern Instruments, Malvern, UK). 
Liposomes were surface-functionalised with CF647 labelled PAI-2 and CF488 labelled 
PAI-2 or TZ using either the CO method or the PI method (Fig. 5.2) (Iden & Allen 2001). 
 
For the CO method, preformed liposomes were incubated with thiolated CF dye labelled 
PAI-2 or TZ (at a molar ratio of 3333:1 liposome phospholipid:protein) for 2 h at room 
temperature. For the PI method, micelles composed of 0.8 mM mal-PEG2000-DSPE and 
0.2 mM mPEG2000-DSPE were prepared as per previously reported methods (Moreira et 
al. 2002), and CF dye labelled PAI-2 or TZ was added to the micelles (at a molar ratio of 
10:1, mal-PEG2000-DSPE:protein) to form functionalised micelles. Functionalised 
micelles were added to preformed liposomes and heated to 60°C for 1 h to facilitate the 
post-insertion of micelle lipids into the outer leaflet of the liposomes. Following the 
liposome functionalisation steps, unbound protein was removed from liposomes via either 
size exclusion chromatography (SEC) using Sepharose CL-4B (Sigma-Aldrich, MO, 
USA) or repeated centrifugation at 20,000 x g for 1.5 h at 4°C. Liposomes were 
resuspended in HEPES buffer (pH 7.4) for single-molecule fluorescence imaging. 
 
 
Figure 5.2: Conventional and post-insertion methods for ligand conjugation. The conventional 
method involves incubation of preformed liposomes with thiolated proteins (represented by green and 
magenta stars), which attach covalently to the liposome surface via terminal maleimide functional 
groups. The post-insertion method involves attaching thiolated proteins to maleimide-functionalised 
micelles, which are then incubated with preformed liposomes at 60°C to facilitate the transfer of 
micelle phospholipids with covalently attached proteins into the outer leaflet of the liposome bilayer. 
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5.2.4 Intensity measurements for labelled proteins 
Microscope coverslips were thoroughly cleaned to remove any hydrophobic and 
hydrophilic contaminants that could cause background fluorescence from the glass. They 
were first sonicated for 30 min in ethanol (Chem-Supply, SA, AUS) and then rinsed with 
deionised water. Subsequently, they were sonicated for 30 min in 1 M potassium 
hydroxide (KOH; Sigma-Aldrich, MO, USA) and rinsed with deionised water again. 
After these sonication steps were repeated, the coverslips were dried with N2 (Tanner & 
van Oijen 2010). CF dye-labelled proteins were diluted to a concentration of 
approximately 10 pM and immobilised on the surface of the cleaned microscope coverslip 
for visualisation on an inverted microscope (Nikon Eclipse Ti-E) with a CFI Apo Total 
Internal Reflection Fluorescence (TIRF) 100X oil-immersion TIRF objective (NA 1.49, 
Nikon). The green- and red-labelled proteins were excited at 1.5 W cm–2 with 488 nm 
(Coherent, Sapphire 488-200 CW) and 647 nm (Coherent, Obis 647-100 CW) lasers, 
respectively (Fig. 5.1). The signals were separated via dichroic mirrors (Photometrics, 
DVΛ Multichannel Imaging System) and appropriate filter sets (Chroma). The imaging 
was performed with an EMCCD camera (Photometics, Evolve 512 Delta). 
 
For each measurement, at least two coverslips were used. For each coverslip, multiple (5-
10) fields of view were imaged. Using ImageJ (National Institutes of Health, USA) with 
in-house built plugins, the integrated intensity for single CF dyes over time was calculated 
after applying a local background subtraction. Using a change-point step-fitting 
algorithm, the intensity distributions for a single CF fluorophore were calculated (Fig. 
5.3B) (Duderstadt et al. 2016; Watkins & Yang 2005). The histograms obtained were fit 
with either a Gaussian or Poisson distribution function using MATLAB 2014b to give a 
mean intensity of 3 ± 0.1 x 103 for CF647 (Fig. 5.3C) and 1.2 ± 0.6 x 104 for CF488. To 
measure the number of fluorophores per protein, the initial fluorescence intensity per 
protein was divided by the intensity of a single fluorophore. 
 
5.2.5 Measurement of protein density on liposomes 
To determine the average number of proteins per liposome, liposomes were imaged under 
the same conditions as the proteins, and the fluorescence intensity per liposome was 
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calculated analogously. The number of proteins per liposome was obtained by dividing 
the liposome intensities by the intensity of a single protein. 
 
5.2.6 Data analysis 
All data analysis, including the generation of graphs and statistical tests, was performed 
using GraphPad Prism software (version 7), unless stated otherwise. Data are presented 
as the mean ± standard deviation (s.d.) or standard error of the mean (s.e.m.) as stated. 
Pairwise comparisons were made using Student’s t-test, and multiple comparisons were 
made using one-way ANOVA with Tukey’s post-test. 
 
5.3 Results 
5.3.1 Imaging CF647-labelled PAI-2 
To first visualise PAI-2 using single-molecule fluorescence microscopy, the 45 kDa 
protein was labelled with a small red fluorophore (CF647) and imaged using TIRF 
microscopy, which allowed for the selective excitation of only the fluorescent species on 
the coverslip surface and imaging of fluorescence from surface-immobilised proteins with 
high contrast and low background (Fig. 5.3A). The intensity of the signal of every 
individual protein was measured over time (Fig. 5.3B, black line). The fluorescence 
intensity trajectories showed a stepwise decay towards zero due to photobleaching of the 
fluorophores attached to the protein. As the height of a single step corresponds to the 
intensity of a single fluorophore, the number of fluorophores per protein was determined 
by counting the number of steps. Analysis of numerous spots enabled a distribution to be 
fitted for the number of fluorophores per protein and for the fluorescence intensity per 
fluorophore. The intensity of a single fluorophore was determined using an unbiased 
change-point step-fitting algorithm (Fig. 5.3B, red line) (Duderstadt et al. 2016). The 
mean intensity of a single CF647 fluorophore was 3 ± 0.1 x 103 (mean ± s.e.m., n = 962) 
(Fig. 5.3C). By dividing the total intensity per protein by the intensity of a single 
fluorophore, it was calculated that there are 1.5 ± 0.4 (mean ± s.d., n = 291) CF647 
fluorophores per protein (Fig. 5.3D), with the width of the distribution in line with that 
expected for a Poisson distribution. The measurements were repeated using the same 
batch of protein measured in subsequent experiments, which found 2.0 ± 0.6 fluorophores 
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per protein (data not shown). ESI-MS analysis found an average of 3 fluorophores per 
protein for CF647-labelled PAI-2 (Appendix F). 
 
 
Figure 5.3: Single-molecule imaging of CF647-labelled PAI-2. (A) Representative field of view of 
CF647-labelled plasminogen activator inhibitor-2 (PAI-2) proteins immobilised on a cleaned 
coverslip. (B) Example fluorescence intensity trajectories of individual proteins (black line) and 
individual steps identified using a change-point algorithm (magenta line). (C) Histogram of the 
intensity of a single CF647 fluorophore (fitted with a Gaussian distribution): 3 ± 0.1 x 103 (mean ± 
s.e.m., n = 962). (D) Histogram of the number of CF647 fluorophores per protein (fitted with a Poisson 
distribution): 1.5 ± 0.4 (mean ± s.d., n = 291). 
 
 
5.3.2 Imaging CF647-labelled PAI-2-functionalised liposomes 
To quantify the number of PAI-2 proteins attached to liposomes using single-molecule 
fluorescence microscopy, liposomes were functionalised with CF647-labelled PAI-2 via 
the PI method and visualised using TIRF microscopy under the same conditions that were 
used to image the CF647-labelled PAI-2. To confirm that the fluorescence signal 
observed in the imaging experiments originated from proteins bound to single liposomes, 
liposomes were pre-labelled with the fluorophore R18 so that the encapsulated R18 acted 
as a marker for liposomes that had an intact lipid bilayer (Serro et al. 2012). Using optics 
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that split the image into a yellow and a red channel, the R18-labelled liposomes and 
attached CF647-labelled PAI-2 proteins were visualised simultaneously but each on 
different areas of the camera sensor to visualise the R18 fluorescence and the signal from 
the red-labelled proteins, with a merge of the two signals revealing colocalisation as 
indicated by white spots (Fig. 5.4A, top panel). Analysis of these images revealed that 
88% of R18-labelled liposomes had at least one CF647-labelled PAI-2 protein attached. 
The number of proteins per liposome was determined by dividing the average CF647 
fluorescence intensity per liposome by the intensity of a single CF647-labelled PAI-2 
protein, obtained previously (Section 5.3.1). The protein density was calculated to be 11 
± 4 (mean ± s.d.) proteins per liposome (Fig. 5.4B). DLS analysis of the liposomes 
indicated a liposome diameter of 153 ± 56 nm (mean ± s.d.) and a polydispersity index 
of 0.041 ± 0.017 (mean ± s.d.) (Fig. 5.4C). R18-labelled liposomes prepared in parallel 
using non-maleimide-functionalised micelles did not show colocalisation with CF647-
labelled PAI-2 when imaged by single-molecule fluorescence microscopy (Fig. 5.4A, 
bottom panel).  
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Figure 5.4: Imaging CF647-labelled PAI-2-functionalised liposomes. (A) Liposomes labelled with 
octadecyl rhodamine B chloride (R18) (left) and CF647-labelled plasminogen activator inhibitor-2 
(PAI-2) (middle) were imaged simultaneously (n = 14 fields of view, ~30 liposomes per field of view). 
A merge of the two channels (right) showed a high degree of colocalisation (white spots). Liposomes 
prepared in parallel using non-maleimide-micelles showed no colocalisation with protein signal (n = 
14 fields of view, with ~10 liposomes per field of view). (B) Histogram of the number of proteins per 
liposome, fitted with a Poisson distribution (black line): 11 ± 4 (mean ± s.d.). (C) Histogram of 
liposome diameter measured by dynamic light scattering, fitted with a Gaussian distribution (black 
line): 153 ± 56 (mean ± s.d.). Bars represent the mean ± s.d. (n = 3). 
 
 
5.3.3 Inhibitory activity of CF647-labelled PAI-2 liposomes 
A fluorogenic urokinase plasminogen activator (uPA) activity assay was performed to 
determine whether quantification of PAI-2 by single-molecule imaging would enable 
appropriate liposome sample dilution in the assay to achieve inhibition of uPA activity 
by the PAI-2-functionalised liposomes. The assay was performed for the CF647-labelled 
PAI-2-functionalised liposome sample before and after single-molecule quantification at 
a molar ratio of 2:1 PAI-2:uPA. PAI-2 concentration of the liposome sample was 
informed by either estimation based on preparation parameters (1.78 µM) or by single-
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molecule data (45 nM). The single-molecule quantification (proteins per particle) 
combined with liposome concentration (particles per mL) as determined by nanoparticle 
tracking analysis (NTA; Chapter 2, Section 2.2.3.2) enabled calculation of the average 
PAI-2 protein concentration of the liposome sample. 
 
The result of the assay performed before single-molecule quantification indicated no 
significant difference between the PAI-2 liposome treatment and positive control 
(uninhibited uPA), indicating no measurable inhibitory effect of the PAI-2 liposomes 
(Fig. 5.5A). When single-molecule quantification was performed on the sample to guide 
the concentration of sample to be used in the assay, the PAI-2 liposome sample showed 
significant (P < 0.01) inhibitory activity relative to the positive control (Fig. 5.5B), 
indicating that PAI-2 bound to liposomes retained inhibitory activity against uPA when 
combined with uPA at a true molar ratio of 2:1, as informed by single-molecule 
fluorescence imaging. 
 
 
Figure 5.5: Activity-based profiling of PAI-2-functionalised liposomes. The inhibitory activity of 
plasminogen activator inhibitor-2 (PAI-2)-functionalised liposomes was determined using a 
fluorogenic urokinase plasminogen activator (uPA) assay. (A) Prior to determination of PAI-2 ligand 
density via single-molecule imaging, estimation of PAI-2 concentration was 1.78 µM. This estimate 
was used to dilute the liposome sample to give a 2:1 PAI-2:uPA (inhibitor:enzyme) molar ratio. (B) 
After single-molecule imaging was performed, a PAI-2 concentration of 45 nM was indicated for the 
liposome preparation, which was used to dilute the liposome sample to yield a 2:1 molar ratio of PAI-
2:uPA. Data are the mean ± s.d. (n = 3). ** = P < 0.01, ns = not significant. 
 
 
5.3.4 Ligand stoichiometry of dual-functionalised liposomes 
To explore the ability of single-molecule fluorescence imaging to quantify small 
differences in protein density, the stoichiometry of two fluorescently-labelled proteins 
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was varied during the preparation of a series of dual-functionalised liposomes and their 
ratio quantified. To negate potential confounding effects that could arise from using two 
different proteins, such as protein size and reactivity, PAI-2 was labelled with either 
CF647 or CF488 (0.9 kDa; intensity of a single CF488 fluorophore 1.2 ± 0.6 x 104 (mean 
± s.e.m., n = 796); 4.5 ± 2.2 (mean ± s.d., n = 104) fluorophores per protein) to enable 
imaging of the two differently labelled (i.e. red and green) proteins. Liposomes were 
functionalised via the PI method using red-labelled (CF647) and green-labelled (CF488) 
PAI-2 at molar ratios of 1:1, 2:1, 5:1 and 10:1 (red:green) while keeping the total amount 
of protein constant for each liposome preparation. The two proteins were visualised 
simultaneously using dual-colour imaging and the protein density was determined as 
above. At a 1:1 molar ratio, 51 ± 2 % of the total number of proteins per liposome had a 
red label and 49 ± 2 % had a green label. Analysis of the other preparations revealed that 
changing the ratios of the two labelled proteins during preparation similarly altered the 
ratios of proteins incorporated into the liposome, as quantified by single-molecule 
fluorescence microscopy (Fig. 5.6A). This relationship was linear, with an R2 value of 
0.9655 (Fig. 5.6B). Imaging of the 1:1 dual-functionalised liposomes showed high levels 
of colocalisation of red and green spots (white spots), indicating that a high proportion of 
liposomes were indeed dual-functionalised (Fig. 5.6C). 
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Figure 5.6: Ligand stoichiometry of dual-functionalised liposomes. (A) Histograms of the 
measured fraction of red-labelled (magenta) and green-labelled (green) proteins per liposome, where 
1:1 (n = 146), 2:1 (n = 111), 5:1 (n = 232) and 10:1 (n = 137) molar ratios of red to green proteins 
were used during liposome preparation. Black lines represent Gaussian fits to the data. (B) Measured 
ratio of the fraction of red-labelled proteins over the fraction of green-labelled proteins as a function 
of the molar ratio used during preparation (mean ± s.e.m.). The errors in the molar ratio are pipetting 
errors calculated from the manufacturer-published imprecision ranges of the pipettes used to add the 
micelle volumes to the liposomes during preparation. (C) Representative field of view showing merge 
of red and green channels of the 1:1 liposome sample, with colocalisation indicated by white spots. 
 
 
5.3.5 Centrifugation of liposomes to remove unbound ligands 
Size-exclusion chromatography (SEC) is a commonly used but low-throughput method 
for functionalised liposome preparation, whereas alternative methods, such as high-speed 
centrifugation, may be an option to streamline the production process of functionalised 
liposomes for preclinical testing. In Chapter 2, high-speed centrifugation was tested as a 
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method to efficiently remove unconjugated PAI-2 protein from PAI-2-functionalised 
liposome samples. The results indicated that free PAI-2 protein could be removed from 
liposomes, with a high recovery of liposomes in the sample following repeated 
centrifugation. However, the effect of repeated high-speed centrifugation on PAI-2 
protein attachment to the liposome in the final formulation remained unknown. To test 
the effect of this method on the final degree of PAI-2 attachment to liposomes, dual-
functionalised PAI-2 liposomes were prepared and functionalised via the PI method as 
per Section 5.3.4 using a 1:1 molar ratio of CF647-labelled PAI-2 and CF488-labelled 
PAI-2. Following the functionalisation step, any unconjugated PAI-2 was removed from 
the liposomes using either SEC or repeated high-speed centrifugation (5 cycles for 90 
min at 20,000 x g). Single-molecule imaging of the two final liposome samples revealed 
similar numbers of red and green proteins attached to the liposomes (Fig. 5.7). The total 
number of attached PAI-2 proteins per liposome was 10.8 and 14.8 for SEC and 
centrifugation liposomes, respectively. 
 
 
Figure 5.7: Size-exclusion chromatography and centrifugation of liposomes. Liposomes 
functionalised with both CF647-PAI-2 and CF488-PAI-2 in a 1:1 molar ratio were purified using 
either size-exclusion chromatography (left) or repeated centrifugation at 20,000 x g (right) to remove 
any unbound PAI-2. Single-molecule fluorescence microscopy of the liposomes was performed to 
quantify the number of CF647-labelled PAI-2 proteins and CF488-labelled PAI-2 proteins attached to 
the purified liposomes. The black lines represent Gaussian fits to the data. Values are means ± s.e.m. 
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5.3.6 Characterisation of PAI-2-TZ dual-functionalised liposomes 
Quantification of ligand density and stoichiometry on the surface of dual-functionalised 
liposomes is important to optimise preparation parameters and select the most appropriate 
method of ligand conjugation to the liposome surface, to enable the production of a dual-
ligand targeted liposome that is optimally effective in its intended application. In the 
context of tumour targeting, liposomes bearing two different targeting ligands need to be 
able to bind successfully to their respective target cell receptors to enable liposome 
internalisation into the target cell. However, the current lack of methodology to determine 
the number and ratio of two different ligands on the surface of liposomes means that the 
development and optimisation of dual-functionalised liposome formulations is limited. 
To explore the utility of single-molecule quantification in the characterisation of novel 
clinically relevant ligand-directed liposomes, dual-ligand liposomes were prepared via 
both the CO and the PI methods of liposome functionalisation (Fig. 5.1). PAI-2 and 
trastuzumab (TZ, Herceptin®; 145 kDa) were labelled with red and green CF 
fluorophores, respectively, and conjugated to preformed liposomes using a 1:1 molar ratio 
of PAI-2:TZ. DLS showed a small but significant increase in liposome diameter 
following functionalisation for PI, but not CO, liposomes (Appendix G). Single-molecule 
fluorescence imaging and data analysis of the dual-functionalised liposomes were 
performed as outlined in Section 5.3.4. Using single-molecule imaging, the ratio of PAI-
2 to TZ of the dual-functionalised liposomes was 17 ± 18 (n = 115) for liposomes prepared 
via the CO method and 2.1 ± 2.5 (n = 167) for liposomes prepared via the PI method (Fig. 
5.8). Imaging of the samples indicated that liposomes prepared via the PI method showed 
higher levels of colocalisation than the CO method. 
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Figure 5.8: Imaging of PAI-2-TZ dual-functionalised liposomes. (A) Representative field of view 
during single-molecule imaging of plasminogen activator inhibitor-2 (PAI-2)/trastuzumab (TZ) 
liposomes prepared via the conventional (left) and post-insertion (right) methods. (B) Histograms of 
the number of proteins per liposome. The black lines represent Poisson distribution fits to the 
histograms. Due to the large number of PAI-2 proteins in the conventional sample, heterogeneities 
within the sample broadened the histogram and obscured the Poisson distribution. Therefore, this 
histogram was fitted with a Gaussian distribution. 
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5.4 Discussion 
The quantification of ligands attached to the surface of liposomes is important for the 
comprehensive characterisation, production optimisation and quality control of ligand-
functionalised liposome formulations. The overarching aim of this chapter was to use 
single-molecule fluorescence microscopy as a tool for the quantification of ligands bound 
to the surface of liposomes, which was ultimately successful. In this chapter, the 
quantification of proteins attached to the surface of liposomes was achieved for the first 
time using single-molecule fluorescence imaging to count the photobleaching steps of 
fluorescently labelled proteins bound to liposomes. Liposome and protein signals showed 
a high degree of colocalisation, indicating that proteins were bound to intact liposomes 
and that proteins could be visualised successfully using the single-molecule fluorescence 
microscope. The average number of attached proteins per liposome was determined to be 
11 ± 4, and imaging of dual-functionalised liposomes revealed stoichiometries of two 
attached proteins in accordance with the molar ratios of protein added during preparation. 
Single-molecule quantification indicated that centrifugation of liposomes slightly 
increased the final ligand density of liposomes relative to SEC due to the selection of a 
highly monodisperse population of liposomes in a particular size range, as expected. 
Single-molecule imaging revealed that the PI method generated dual-functionalised 
liposomes with a more equal representation of two differently sized protein ligands than 
the CO method, demonstrating the ability of the former method to enable superior control 
of the final liposome protein densities (Allen & Cullis 2013). Overall, this chapter has 
demonstrated the utility of single-molecule fluorescence imaging in the quantification of 
the density and stoichiometry of ligands attached to the surface of liposomes, which 
enables superior characterisation of functionalised liposomes in the preclinical testing 
context. 
 
The lipophilic dye R18 has been previously used in single-molecule fluorescence imaging 
experiments (Otterstrom et al. 2014) and was used in this work to visualise intact 
liposomes and image proteins conjugated to liposomes, rather than imaging free proteins 
in the sample. Liposomes prepared without maleimide-PEG were used to confirm that 
only covalently attached proteins colocalised with liposomes in imaging experiments. 
The lack of observed colocalisation (Fig. 5.4) demonstrates that non-specific binding of 
PAI-2 proteins to liposomes is minimal, as would be expected given the mechanism of 
 141 
 
covalent conjugation of ligands to the liposome surface (Iden & Allen 2001) and given 
that the methods used for purification were suitable. The fluorescence intensity of the 
R18-labelled liposomes was variable during imaging and this coincided with a mix of 
larger and smaller spots observed in the field of view (Fig. 5.4). Given that the R18 
molecule partitions in lipid membranes and more R18 molecules can associate with the 
bilayers of larger liposomes, this correlation is expected. Similarly, the calculated average 
number of attached PAI-2 proteins per liposome was variable, ranging from 3 to 17 
proteins. When the same batch of liposomes was analysed by DLS to determine the 
average liposome diameter of the sample, the relative width of the liposome size 
distribution (0.36) was found to correlate with the relative width of the distribution of the 
number of proteins per liposome (0.37) as determined by single-molecule imaging (Fig. 
5.4). This suggests that the width of the distribution for the number of proteins per 
liposome is a result of the heterogeneity in liposome size, as larger liposomes have a 
greater number of attached proteins than smaller liposomes due to the greater number of 
mal-PEG moieties available for ligand conjugation to the liposome surface (Allen et al. 
1995). 
 
The addition of a 1:1 molar ratio of red-labelled and green-labelled PAI-2 to the 
liposomes during the liposome preparation step resulted in a 1:1 measured ratio via single-
molecule imaging in the liposome formulation (Fig. 5.6). This observation indicated that 
the two different fluorophores did not affect protein attachment to the liposome surface, 
and that the two proteins were incorporated into the liposome in the same 1:1 ratio as their 
input stoichiometry in the formulation process. In contrast to preliminary experiments in 
which a 1:4 ratio of maleimide-PEG:methoxy-PEG was used in the liposome formulation, 
resulting in an average of 2-3 attached proteins per liposome (data not shown), the 
maleimide-PEG:methoxy-PEG ratio was changed to 4:1 for the ratiometric experiment in 
order to increase the total available sites for protein conjugation. Increasing the number 
of total proteins bound to the liposome surface enabled better detection of the variation 
between the different protein ratios used and a more robust calculation of ratios. This 
change resulted in the attachment of 8-12 proteins per liposome, corresponding to an 
approximate 4-fold increase in attached protein when the maleimide concentration was 
also increased 4-fold. The increased total protein of the liposomes was particularly 
important for the 10:1 liposome sample due to the fact that only dual-functionalised 
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liposomes were analysed (i.e. only liposomes that had at least one red-labelled and one 
green-labelled protein attached), resulting in a much lower number of dual-functionalised 
liposomes available in the sample for analysis than for the 1:1 sample. This explains the 
larger calculated error in the measured ratio of the 10:1 sample (Fig. 5.6). Nonetheless, 
the ratiometric experiment showed a linear correlation between input and measured ratio 
as determined by single-molecule fluorescence imaging, highlighting the ability of the 
single-molecule method to quantify small changes in protein attachment in dual-
functionalised liposomes. 
 
In Chapter 2, high-speed centrifugation was explored as an alternative to the 
conventionally used but low-throughput SEC to remove unconjugated PAI-2 from PAI-
2-functionalised liposomes. Centrifugation is commonly used to remove unencapsulated 
soluble drug and other small molecules from liposomes (Yalcin et al. 2018), as liposomes 
and other nanoparticles pellet under conditions of high speed centrifugation, while soluble 
small molecules remain in solution for removal. Following centrifugation of dual-ligand 
liposomes to remove unconjugated red- and green-labelled PAI-2, single-molecule 
quantification determined that the total number of attached proteins was higher for 
centrifuged liposomes relative to size-exclusion purified liposomes (14.8 and 10.8 
proteins, respectively) (Fig. 5.7). However, the ratio of the two attached proteins was 
similar to liposomes purified using SEC. While it is encouraging that repeated high-speed 
centrifugation did not remove the proteins from the liposome surface, the small difference 
in protein attachment observed between the two methods is likely due to the fact that 
centrifugation selects for larger liposomes. As larger liposomes pellet before smaller 
liposomes when centrifuged, the distribution of the liposome population is narrowed with 
each centrifugation step as the larger pelleted liposomes are recovered and the smallest 
liposomes that remain in solution are removed in the wash steps. Indeed, in Chapter 2 it 
was noted that the average diameter of a liposome sample increased from 148.0 nm to 
153.9 nm following repeated centrifugation, with 77.1% retention of particles following 
centrifugation (Chapter 2, Table 2.3).  
 
In the case of ligand-functionalised liposomes, larger liposomes containing more 
phospholipid groups and liposome constituents have a greater number of maleimide-PEG 
functional groups in the liposome bilayer and therefore have a greater number of proteins 
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attached to the liposome surface. Since centrifugation selects for larger liposomes with 
greater numbers of attached proteins, the centrifuged sample of liposomes had a higher 
average number of proteins per liposome. This observation is also supported by the R18 
liposome experiment (Section 5.3.2), which found a direct correlation between average 
liposome size and total number of attached PAI-2 proteins. Therefore, centrifugation did 
not appear to remove conjugated PAI-2 from the surface of liposomes, although the final 
liposome population obtained was slightly altered for this reason. While the 
centrifugation method is high-throughput, allows for the production of multiple different 
liposome preparations in series and results in a high recovery of liposomes (Chapter 2, 
Section 2.3.7), the inherent selection towards larger liposomes and resultant narrowing of 
the final liposome distribution should be considered as a factor in the production process. 
 
Single-molecule fluorescence microscopy was used to compare the effect of the 
conventional and post-insertion functionalisation methods on the resultant ligand density 
of actively targeted liposome formulations. Previous research has indicated that there are 
no significant differences between single-functionalised liposomes produced via the two 
methods in terms of uptake or cytotoxic effect in vitro and in vivo (Iden & Allen 2001). 
However, the effect of these functionalisation methods on dual-functionalised liposomes 
has not been determined due to the lack of methodology to quantify the density and 
stoichiometry of two different proteins attached to the surface of liposomes. In this 
chapter, PAI-2/TZ dual-functionalised liposomes prepared using two different 
functionalisation methods revealed notable differences in the final composition of the 
liposomes as measured by single-molecule fluorescent imaging (Fig. 5.8). When a 1:1 
molar ratio of PAI-2 and TZ was used in the conventional preparation method, the 
calculated number of attached PAI-2 proteins per liposome was 17 times higher than the 
number of TZ antibodies. In contrast, the incorporation of PAI-2 and TZ was more 
balanced (~2:1 PAI-2:TZ) when the post-insertion method was used to prepare the 
liposomes. 
 
The differences between the two liposomes are unsurprising when the differences 
between the two functionalisation methods are considered (Fig. 5.2). The conventional 
method involves incubation of a small protein (45 kDa) and a large antibody (150 kDa) 
with preformed liposomes, where differences in protein size (i.e. steric hindrance on rates 
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of reaction) and reactivity (i.e. the number of available sites for conjugation) may affect 
their equal incorporation into the liposomes. The incorporation of these two proteins of 
different sizes introduces a degree of competition between them for binding to the 
maleimide-PEG at the liposome surface. For conventional liposomes, it was observed that 
the degree of colocalisation of the two proteins (indicating dual-functionalised liposomes) 
was lower than that of post-insertion liposomes, which may indicate that the presence of 
the larger TZ antibody at the liposome surface caused a degree of steric hindrance to PAI-
2 attachment, resulting in fewer dual-functionalised liposomes and a larger proportion of 
liposomes with only TZ attached (i.e. TZ-functionalised liposomes). 
 
In contrast, the post-insertion method showed a high degree of colocalisation between 
PAI-2 and TZ, indicating that a greater number of dual-functionalised liposomes were 
successfully produced using this method. The post-insertion method negates the effects 
of protein differences through the simultaneous insertion of two separate preformed 
protein-functionalised micelles into the liposomes (Iden & Allen 2001). This means that 
each protein is given the opportunity to covalently attach to all available micelle 
maleimide-PEG groups without competition from the other protein before all groups are 
then transferred into the liposome outer leaflet. Theoretically, this would result in 
liposomes with a more even distribution of the two proteins at the liposome surface, and 
this is corroborated by the single-molecule quantification method used in this chapter. 
The quantification of PAI-2 and TZ at the surface of liposomes as outlined in this chapter 
provides a rationale for the use of the post-insertion method in the production of dual-
functionalised liposomes, in particular for those that have two (or more) very disparate 
proteins attached in terms of their size and/or reactivity. This aspect is relevant to the 
clinical setting, where liposomes used to target heterogeneous tumour cell populations 
would likely bear two different targeting ligands (Chapter 1, Sections 1.4 and 1.6.3). 
Therefore, the application of single-molecule quantification enables optimisation of the 
preparation protocol in order to allow for a better control of the stoichiometry of the two 
ligands at the liposome surface. 
 
Single-molecule fluorescence imaging enabled, for the first time, quantification of the 
average number of PAI-2 proteins per liposome for PAI-2-functionalised liposomes, 
which enabled a more accurate determination of the PAI-2 concentration of liposome 
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samples. The analysis of liposomes by nanoparticle tracking analysis (Chapter 2, Section 
2.2.3.2) allowed the determination of liposome concentration (number of particles per 
mL), and this value combined with the single-molecule quantification (number of PAI-2 
proteins per particle) enabled the calculation of the average PAI-2 protein concentration 
of the liposome sample, which was 45 nM. Prior estimation of the average PAI-2 protein 
concentration of the liposome sample without the single-molecule data and based only on 
preparation parameters, including estimated sample loss and dilution factors, indicated a 
PAI-2 concentration of 1.78 µM. The fluorogenic uPA activity assay was performed for 
the CF647-labelled PAI-2-functionalised liposome sample both before and after single-
molecule quantification at a molar ratio of 2:1 PAI-2:uPA, with the PAI-2 concentration 
of the sample informed by either estimation or single-molecule data. Prior to single-
molecule quantification, the assay indicated no significant difference between the PAI-2 
liposome treatment and positive control (uninhibited uPA), indicating no measurable 
inhibitory effect of the PAI-2 liposomes (Fig. 5.5). When single-molecule quantification 
was performed on the sample to guide the concentration of sample to be used in the assay, 
the PAI-2 liposome sample showed significant (P < 0.01) inhibitory activity relative to 
the positive control, indicating that PAI-2 bound to liposomes retained inhibitory activity 
against uPA when combined with uPA at a true molar ratio of 2:1, as informed by single-
molecule fluorescence imaging. This highlights the ability of single-molecule 
quantification to enable more accurate determination of the effect of liposome ligand 
density on liposome ligand function, as reflected in a sensitive functional assay. 
 
To further demonstrate the applicability of single-molecule fluorescence microscopy as a 
quantification tool for ligand-targeted nanomedicine development, future work could 
utilise the methods reported here to demonstrate correlations between the number of 
targeting ligands at the liposome surface and functional cellular effects. For example, 
single-molecule quantification of liposome ligand density could help determine the 
optimal number of ligands for maximum receptor binding, target cellular uptake and 
therapeutic effect, or could determine the functional effects of targeted liposomes 
produced by different methods. Previous studies have demonstrated that the modulation 
of liposome ligand density, achieved by changing the starting maleimide-PEG 
concentration of the formulation, affects cellular binding and uptake (Chu et al. 2016; 
Gayong et al. 2016; Li, H et al. 2016). The single-molecule method described here could 
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be used in future work to further confirm such findings, and also to elucidate additional 
characteristics of ligand-directed liposomes. For example, the method could be used to 
determine inner and outer leaflet labelling of liposomes produced by the post-insertion 
method where heat is used, since it is possible that proteins may insert into the inner 
leaflet of the liposomes and therefore not be available for cell targeting. The 
quantification of inner and outer leaflet labelling of liposomes could be elucidated by 
single-molecule imaging using dyes (e.g. pH-sensitive dyes) as per previously reported 
methods (Otterstrom et al. 2014). 
 
The single-molecule quantification technique reported in this chapter appears to be an 
accurate and high-throughput method, with the ratiometric experiment demonstrating the 
reproducibility of the method across different batches of liposomes. The number of 
fluorophores attached per protein (degree of labelling) using the same protein sample was 
measured in independent experiments, which found no variation between the calculated 
values. PAI-2 protein labelled with CF647 dye was determined to have 1.5 ± 0.4 
fluorophores per protein, and when this measurement was repeated several months later 
with the same labelled protein, the single-molecule method found 2.0 ± 0.6 fluorophores 
per protein (data not shown). In addition, single-molecule measurements from two 
different coverslips for the same batch of liposomes found 11.0 ± 2.2 and 13.0 ± 2.1 PAI-
2 proteins per liposome (data not shown). As described in Section 5.2.5, the single-
molecule method requires determination of the degree of fluorescent labelling of the 
protein via single-molecule imaging in addition to imaging of the functionalised 
liposomes. This procedure is straightforward, only needs to be done once for a newly 
labelled ligand, and can be done at the same time as imaging of the liposome samples. 
Once determined, multiple liposome samples that have been functionalised with that 
ligand can then be imaged and the data analysed using established protocols. Data 
acquisition can easily be further scaled up and automated, and the analysis pipeline can 
readily be converted to an automated process to improve the throughput of the method 
(Monachino et al. 2017). 
 
While the work presented in this chapter explored the quantification of a small protein 
ligand and a whole antibody on the surface of liposomes, in principle, the single-molecule 
approach reported in this thesis could also be applied to other surface ligand types and 
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nanoparticle systems. Quantification of other commonly used nanoparticle ligand types, 
such as antibody fragments, small peptides and aptamers, is possible, provided that the 
ligands can be fluorescently labelled for single-molecule imaging. Indeed, previous 
studies have utilised single-molecule imaging for quantifying fluorescently labelled 
peptides (Liu et al. 2010). Single-molecule fluorescence imaging techniques have been 
used to quantitatively characterise peptide-binding to lipid bilayers in order to understand 
the structure and function of membrane-bound proteins (Fox et al. 2009). More recently, 
single-molecule imaging was used to visualise the three-dimensional motions of 
membrane peptides in supported lipid bilayers by taking advantage of the surface-induced 
fluorescence attenuation of single emitting fluorophores (Li, Y et al. 2016). In addition to 
liposomes, single-molecule imaging could also be utilised in the quantification of ligands 
attached to the surface of other types of nanoparticles (Shashkova & Leake 2017), as 
previous research has shown successful application of single-molecule fluorescence 
microscopy analysis with various nanoparticle types, such as solid lipid nanoparticles 
(Zoubari et al. 2017), polymeric nanoparticles (Langdon et al. 2015), micelles (Cheng et 
al. 2013) and dendrimers (Younghoon et al. 2013). Such studies further support the 
suitability of single-molecule fluorescence microscopy for the characterisation of a wide 
variety of ligand types for ligand-functionalised nanoparticle development. 
 
The single-molecule quantification method reported in this chapter is not without 
limitations. For example, the formation of a protein corona around the surface of 
systemically administered nanoparticles represents a potential problem for the ability of 
functionalised liposomes to successfully bind to their target cells in vivo. Quantifying 
non-specific protein adsorption to the surface of nanoparticles to determine the effect of 
this on nanoparticle functionality cannot be achieved using the single-molecule approach 
as this method simply counts the number of fluorescently labelled ligands covalently 
attached to the liposome surface. Proteins in biological media that may adsorb to the 
liposome surface and ‘shield’ ligands by forming a protein corona would not change the 
number of ligands covalently bound to the liposome, only (potentially) the functional 
activity of the ligands, which the single-molecule imaging method does not measure. How 
the liposome ligand density changes after exposure to biological media is a question that 
cannot be answered by single-molecule imaging, but it is an important question for the 
nanomedicine field more broadly. Therefore, the development of additional 
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characterisation methods for ligand-functionalised liposomes within the biological 
context is necessary to facilitate successful preclinical evaluation and clinical translation. 
 
5.5 Conclusion 
The work presented in this chapter demonstrates the practical utility of single-molecule 
fluorescence microscopy to quantify the number of protein ligands bound to the surface 
of liposomes, which represents a key step forward in the characterisation and evaluation 
of actively targeted nanotherapies. Using this technique, ligand quantification was 
achieved for single-ligand and dual-ligand liposomes, and the methods used to prepare 
and functionalise actively targeted liposomes were successfully characterised for their 
effect on resultant liposome ligand attachment. By enabling the quantification of surface-
bound ligands, this single-molecule imaging technique can be used to optimise liposome 
preparation protocols, assist with the scale up of liposome preparation processes, and 
allow for batch-to-batch quality control in a preclinical or commercial production setting. 
Therefore, the comprehensive characterisation of preclinical ligand-functionalised 
liposomes using single-molecule fluorescence imaging may help improve the preclinical 
development of novel actively targeted liposomal drug delivery systems for cancer 
therapy and facilitate the translation of such nanotherapies from the laboratory through to 
clinical use. 
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Chapter 6: 
Conclusions and Future Directions 
 
 
 
 
 
 
 
 
 
Dual-targeted drug-loaded liposomes 
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6.1 Introduction 
The development of more effective treatments for metastatic breast cancer remains an 
important area of research since it is a global health problem and there is currently no 
cure for metastatic disease. The urokinase plasminogen activator system has been 
recognised to play an important role in the ability of cancer cells to escape the primary 
site of the tumour and colonise other parts of the body. This system is particularly relevant 
in breast cancer metastasis, including in the human epidermal growth factor receptor 2 
(HER2)-positive subtype and the triple-negative breast cancer (TNBC) subtype, both of 
which have an aggressive disease profile and poor prognosis. Hence, targeting this system 
using novel approaches may be effective in the treatment of metastatic breast cancer. 
Plasminogen activator inhibitor-2 (PAI-2) has previously been used to target the 
urokinase plasminogen activator receptor (uPAR) and deliver cytotoxins to breast cancer 
cells. The work described in this thesis aimed to build upon this concept by attaching 
PAI-2 to the surface of PEGylated liposomes containing the potent cytotoxin N-
alkylisatin (N-AI), for increased and selective drug delivery to uPAR-positive breast 
cancer cells. Therefore, the work presented in this thesis explored the preparation, 
characterisation, in vitro evaluation and in vivo evaluation of novel N-AI-loaded PAI-2-
functionalised liposomes for targeting uPAR in breast cancer. 
 
6.2 N-AI PAI-2 liposomes can be prepared by conventional methods 
In order to facilitate the uPAR-mediated uptake of N-AI-loaded liposomes into breast 
cancer cells, previously reported methods were optimised to create novel N-AI-loaded 
liposomes that were surface-functionalised with PAI-2. Novel N-AI-loaded PAI-2-
functionalised (N-AI PAI-2) liposomes were successfully prepared and characterised. N-
AI PAI-2 liposomes were 141.1 ± 5.0 nm in diameter, were monodisperse (polydispersity 
index of 0.086 ± 0.030) and had a zeta potential of –4.66 ± 0.52 mV. The liposomes 
contained N-AI at a concentration of 2.2 mM, significantly enhancing the aqueous 
solubility of N-AI for drug delivery applications. PAI-2 conjugation to the surface of N-
AI-loaded liposomes was confirmed using size-exclusion chromatography and Western 
blotting. A PAI-2 inhibitory activity assay confirmed that PAI-2 attached to the surface 
of liposomes remained active against urokinase plasminogen activator (uPA) after 
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conjugation, making N-AI PAI-2 liposomes suitable for further in vitro and in vivo 
evaluation against breast cancer cells. 
 
The methods used to prepare N-AI PAI-2 liposomes could be further improved to 
facilitate high-throughput production for subsequent testing and analysis. The continual 
development of new methods and technologies to prepare liposomes is expected to help 
facilitate their clinical development. In order to meet the demands for the large-scale 
preparation of liposomes as required for clinical use, microfluidic approaches have 
recently emerged as a way to produce large quantities of liposomes of a uniform size and 
consistent physicochemical properties, which may be a way forward for efficient and 
cost-effective liposome preparation (Jahn et al. 2004).  
 
Recent technological developments have contributed to a shift away from conventional 
covalent coupling methods of attaching ligands to the surface of liposomes and towards 
the specific engineering of antibodies and aptamers for cellular targeting applications. 
The use of short-chain antibody fragments as targeting ligands, as opposed to whole 
antibodies, is a promising strategy for creating actively targeted liposomes, as the ligands 
can be engineered to optimise binding affinity and other physical properties for improved 
tumour cell targeting and uptake. As antibody fragments are smaller than whole 
antibodies, the immunogenicity may be lower and the in vivo circulation time of the 
resultant targeted liposomes more appropriate (i.e. more prolonged) for tumour targeting 
(Cheng & Allen 2010). Protocols to develop bispecific immunoliposome formulations 
using two different single-chain FV fragments on the liposome surface to target two 
different tumour cell populations have been reported, where each ligand shows a retention 
of binding activity for its target receptor (Mack et al. 2012). Multivalent liposomal 
therapeutic antibody constructs that bind to more than one antigen have been reported 
(Chiu et al. 2007), as well as PEGylated hyper-branched polymers bearing two different 
targeting ligands (Pearce et al. 2016). 
 
The use of bispecific antibodies bound to the surface of liposomes may facilitate the 
recognition of multiple antigens to achieve the same effect attained with conventionally 
prepared dual-ligand liposomes (Howard et al. 2016). The successful development of a 
liposome with a single surface-attached bispecific antibody that can recognise and bind 
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to both endoglin and fibroblast activation protein demonstrates the feasibility of this 
approach in dual-targeting (Rabenhold et al. 2015). These approaches allow for more 
control in the stoichiometry of the two targeting ligands (i.e. always 1:1) compared to the 
traditional conjugation of two separate ligands, and for this reason may aid the production 
and regulatory processes required for clinical use of actively targeted liposomes. Such 
developments in antibody engineering mean that future nanoparticle-based drug delivery 
strategies can more easily permit targeting of multiple cell types, including genetically 
distinct tumour cells, but also key cells of the tumour microenvironment that are known 
to play a role in supporting tumour growth and spread, including immune cells and cancer 
stem cells (Angelova et al. 2017). 
 
6.3 N-AI PAI-2 liposomes are cytotoxic to breast cancer cells 
The cellular uptake, localisation and cytotoxicity of N-AI PAI-2 liposomes were 
successfully evaluated in vitro using breast cancer cells grown in monolayers and as 
multicellular tumour spheroids. As the binding of extracellular PAI-2 to uPAR-bound 
uPA results in the receptor-mediated endocytosis of the PAI-2/uPA/uPAR complex, PAI-
2 can be used as a targeting ligand for the intracellular delivery of covalently attached 
cytotoxin to uPAR-positive tumour cells (Cochran et al. 2011). The cellular uptake of 
fluorescently labelled PAI-2 liposomes into MDA-MB-231 breast cancer cells (uPAR-
positive) was significantly increased (P < 0.01) relative to MCF-7 breast cancer cells 
(uPAR-negative), as measured by flow cytometry. Confocal microscopy confirmed the 
uptake of PAI-2 liposomes and localisation within the cytoplasm and lysosomes of cells. 
N-AI PAI-2 liposomes showed a potent cytotoxic effect against both MCF-7 and MDA-
MB-231 cells grown in 2D (IC50 values of 31.84 ± 8.20 µM and 5.40 ± 1.14 µM, 
respectively) and in 3D as multicellular tumour spheroids (IC50 values of 40.2 ± 4.0 µM 
and 60.4 ± 7.1 µM, respectively), which supports the use of uPAR as a therapeutic target 
and warranted further evaluation of N-AI PAI-2 liposomes in vivo. 
 
The gradual movement away from simplistic monolayer and monoculture cell models and 
towards the utilisation of models that better recapitulate in vivo tumours, including 
computer simulated models (Dionysiou et al. 2006), ex vivo multicellular tumour spheroid 
models (Jiang et al. 2017), co-culture models (Lee et al. 2014), biomimetic microfluidic 
tumour microenvironment models (Tang et al. 2017) and patient-derived xenografts 
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(Shafaee & Ellis 2017), will allow for the inclusion of some aspects of tumoural 
heterogeneity and factor in the contribution of the tumour microenvironment in the 
evaluation of novel nanotherapies. As current in vitro models do not reproduce the 
complex vascular network, hypoxia, interstitial fluid pressure and fluid shear observed in 
the in vivo tumour microenvironment (Li & Lu 2011), a key limitation of multicellular 
tumour spheroid models for testing new drug-loaded nanotherapies is that these static 
models do not account for transport across the vascular endothelium (Maeda 2015). The 
development and validation of in vitro models that recapitulate aspects of the enhanced 
permeability and retention (EPR) effect is an emerging field of research. Static 3D co-
culture models comprised of vascular network structures and tumour spheroids can be 
used for incorporating the effect of vascularisation in drug testing experiments 
(Swaminathan et al. 2017). Microfluidic-based platforms can be used for monitoring 
nanoparticle delivery in a 3D environment that recapitulates circulation, extravasation 
and delivery to the tumour across the interstitial space (Li et al. 2018). These models also 
enable the examination of tumour cell and vascular cell interactions and how these 
interactions affect drug delivery, which is an important aspect of evaluating novel 
liposome formulations (Tang et al. 2017). These approaches are expected to help guide 
nanotherapy research in its early stages and provide a more accurate understanding of the 
expected efficacy should the formulation progress to in vivo studies or clinical trials. 
 
6.4 PAI-2 enhances the tumour accumulation of liposomes in vivo 
Following the in vitro evaluation of N-AI PAI-2 liposomes, the biodistribution, 
pharmacokinetic profile and anti-tumour efficacy of the liposomes were explored in vivo 
using mouse models of breast cancer. N-AI PAI-2 liposomes were found to have a plasma 
circulation half-life of 5.82 hours, with clearance predominately via the spleen, yet 
significantly increased tumour uptake of N-AI PAI-2 liposomes relative to N-AI 
liposomes was observed. No significant differences were noted in primary or metastastic 
anti-tumour growth in two mouse models of TNBC. Further research is needed to clarify 
if and how the potency of N-AI as a cytotoxin can be translated into an anti-tumour growth 
effect by targeting uPAR-positive tumour cells in vivo using PAI-2-functionalised 
liposomes. 
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Tumour targeting by liposomes is primarily mediated by the enhanced permeability and 
retention (EPR) effect, which is dependent on a number of factors, including interstitial 
fluid pressure and vascularity of the tumour, as well as the physical properties of the 
liposome formulation (Nichols & Bae 2014). It is well established that liposomes need to 
be relatively small and have a long circulation time to take advantage of the EPR effect 
for tumour targeting (Perche & Torchilin 2013). While Doxil® is comprised of liposomes 
of approximately 80-100 nm in diameter (Soundararajan et al. 2009), other clinically used 
liposome formulations for cancer therapy are slightly larger in size, including Onivyde™ 
with a mean diameter of 110 nm, and Myocet® with a diameter of 150-250 nm (Bulbake 
et al. 2017). Endosomes, which are 50-150 nm in diameter, show promise in drug delivery 
applications, but their utility faces the same challenges as liposomes with regards to 
clearance from the plasma and poor tumour targeting specificity (Si et al. 2019). Notably, 
the high tumour accumulation of Doxil® in humans is due in large part to the very long 
circulation half-life (up to 45 hours) of the formulation, which is comprised of PEGylated 
liposomes to reduce the rate of plasma clearance (Gabizon et al. 1994). Neutral or 
negatively charged liposomes (as in the case of Doxil®) have been shown to be better 
suited for drug delivery to solid tumours as they associate less with angiogenic blood 
vessels than positively charged liposomes, and are therefore more likely to extravasate 
(Krasnici et al. 2003). To increase the specificity of tumour targeting, ligand-targeted 
liposomes can be combined with the application of pH, temperature or magnetic field 
triggers to enable the controlled release of drug cargo at the tumour site and reduce off-
target effects (Han et al. 2016). While there are general optimal liposome properties for 
tumour targeting, liposomes should be designed for the specific tumour type to be 
targeted, with consideration of the tumour microenvironment and the EPR effect 
(Rosenblum et al. 2018). 
 
The development of animal models that recapitulate the EPR effect at a level more 
analogous to the human condition would be of benefit in the initial evaluation of novel 
targeted nanotherapies. Further research is required to better understand the EPR effect 
and elucidate the differences in this phenomenon between animal and human tumours, 
and between different tumour types, in order to increase translation of nanoparticle-based 
therapeutics into the clinic (Lammers et al. 2016). This could be achieved via imaging 
methods, such as the radionuclide imaging of liposomes to determine their fate in vivo 
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(van der Geest et al. 2016). Intravital imaging techniques can be used to assess the depth 
of nanoparticle (and drug cargo) penetration into the tumour and the movement of 
nanoparticles away from the major blood vessels that vascularise the tumour (Puttick et 
al. 2015; Zhao, Y et al. 2017). Single photon emission computed tomography (SPECT) 
and positron emission tomography (PET) can also be used to quantify the in vivo 
distribution of nanoparticles, including the accumulation of nanoparticles at the tumour 
site, in a non-invasive manner (Harrington et al. 2001). 
 
The use of models that recapitulate intratumoural heterogeneity is important in the 
evaluation of dual-ligand liposomes designed to target multiple tumour cell receptors. 
Patient-derived xenografts are more representative of the clinical situation as they capture 
some elements of intratumoural heterogeneity, as well as the diversity observed between 
patients with cancer (Gomez-Cuadrado et al. 2017). In addition to intratumoural 
heterogeneity, the interpatient heterogeneity observed in cancer also warrants the 
development and utilisation of patient-derived xenografts and patient-derived cell lines 
to more accurately assess patient responses to novel therapies, particularly in cases where 
resistance to currently used therapies is frequently observed (Shafaee & Ellis 2017). 
Additionally, the use of tumour models in immunocompetent animals is important given 
the known effect of the adaptive immune system on tumour growth and metastasis 
(Kitamura et al. 2015). The increasing use of such models lends itself to the improved 
assessment of targeted therapies in the context of cancer treatment (Budhu et al. 2014).  
 
6.5 Single-molecule imaging can be used to quantify liposome ligands 
Due to the lack of robust methods to quantify liposome ligands, single-molecule 
fluorescence microscopy techniques were successfully developed to quantify the density 
and stoichiometry of protein ligands attached to the surface of targeted liposomes. As 
reported in Chapter 5, single-molecule imaging confirmed that PAI-2 molecules were 
attached to the liposome surface, with an average of 11 ± 4 PAI-2 molecules per liposome. 
This was the first direct confirmation and quantification of PAI-2 attached to the surface 
of liposomes and marks an important first step in utilising these high resolution 
technologies in nanomedicine-based therapeutics development (Pujals et al. 2019). The 
method enabled the quantification of ligands after liposomes had been purified using two 
alternative methods and revealed the effects of these methods on the resultant liposome 
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ligand density. It was also demonstrated that the post-insertion method is more favourable 
for creating dual-ligand liposomes than the conventional method, as single-molecule 
imaging was able to quantify the density and ratio of PAI-2 and trastuzumab ligands 
attached to clinically relevant dual-functionalised liposomes. Therefore, this work has 
demonstrated the utility of single-molecule fluorescence imaging in the quantification of 
the density and stoichiometry of ligands attached to the surface of liposomes, which 
enables superior characterisation of functionalised liposomes in the preclinical testing 
context. 
 
Future work using single-molecule fluorescence imaging could help to elucidate 
additional characteristics of ligand-directed liposomes. For example, the quantification of 
ligands by single-molecule imaging could determine inner and outer leaflet labelling of 
liposomes produced by the post-insertion method, since it is possible that ligands may 
insert into the inner leaflet of the liposomes and not be available for cell targeting. The 
quantification of inner and outer leaflet labelling of liposomes could be elucidated by 
single-molecule imaging using pH-sensitive dyes as per previously reported methods 
(Otterstrom et al. 2014). The work described in this thesis explored differences in the 
ligand density of liposomes produced specifically by the conventional and post-insertion 
methods, but the single-molecule imaging method could also be used to explore the 
functionalisation of liposomes produced by a range of methods, in addition to controlling 
for batch-to-batch variability in liposome production. 
 
Single-molecule quantification can be used to help address the issues surrounding the 
standardisation of liposome characterisation in the broader field of nanomedicine research 
(Faria et al. 2018). There are currently no FDA guidelines or associated documentation 
outlining the requirements for the determination of target ligand density on liposomes or 
other nanoparticle-based formulations. Approximations for ligand density and the number 
of ligands per nanoparticle have been determined by making assumptions, such as that 
the nanoparticle is spherical, contains a certain number of functional groups and that the 
bioconjugation reaction is 100% efficient. Notably, the ligand density of single-chain 
anti-HER2 antibodies conjugated to the surface of doxorubicin-loaded liposomes (MM-
302) has never been quantified, as traditional methods for characterisation were not 
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applicable to functionalised liposomes (Hendriks et al. 2013; Nellis, Ekstrom, et al. 2005; 
Nellis, Giardina, et al. 2005). 
 
To further demonstrate the applicability of single-molecule fluorescence microscopy as a 
quantification tool for ligand-targeted nanomedicine development, future work could 
utilise the methods reported here to demonstrate correlations between the number of 
targeting ligands at the liposome surface and functional cellular effects. For example, the 
single-molecule quantification of liposome ligand density could help determine the 
optimal number of ligands for maximum receptor binding, target cellular uptake or 
therapeutic effect, or could determine the functional effects of targeted liposomes 
produced by different methods. Previous studies have demonstrated that the modulation 
of liposome ligand density, achieved by changing the starting maleimide-PEG 
concentration of the formulation, affects cellular binding and uptake (Chu et al. 2016; 
Gayong et al. 2016; Li, H et al. 2016). The single-molecule method described here could 
be used in future work to further confirm such findings. 
 
Given the utility of single-molecule imaging in the characterisation of ligand-directed 
liposomes, the method reported in this thesis could be further developed to make the 
quantification process more high-throughput. Data acquisition could be further scaled up 
and automated, and the analysis pipeline could readily be converted into an automated 
process (Monachino et al. 2017). To further improve the method, a fluorescent antibody 
detection system could be used to bypass the need to pre-label ligands with fluorescent 
dyes. This would allow characterisation and analysis of liposomes at any point during or 
after their production. The recent development of a high-resolution optical nanoscopy 
technique to determine the number and distribution of functional moieties on the surface 
of nanoparticles without the need for fluorescent labelling is another promising method 
for characterising actively targeted liposomes in the preclinical setting (Delcanale et al. 
2018). 
 
6.6 Conclusion 
The first clinically approved liposome, Doxil®, has been in use for over 20 years and is 
still used as an effective treatment for several cancers. However, the liposome field has 
not yet evolved into translating effective targeted liposomes. Ligand-directed liposomes 
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have the potential to increase the selectivity of therapy, and dual-ligand liposomes may 
additionally address intratumoural heterogeneity to overcome patient resistance to 
targeted therapies. The work described in this thesis demonstrated the successful 
development and characterisation of a novel ligand-directed uPAR-targeted liposome 
containing the potent anti-mitotic cytotoxin N-AI for the treatment of metastatic breast 
cancer. Cellular uptake and cytotoxicity of the liposomes were demonstrated in vitro 
against breast cancer cell lines varying in uPAR expression. In vivo, increased tumour 
uptake was demonstrated for ligand-directed liposomes relative to non-ligand directed 
liposomes, although no obvious anti-tumour benefit was observed in the models 
described. A single-molecule fluorescence microscopy method was successfully 
developed to enable future characterisation of ligand-directed liposomes to help guide 
their production and evaluation in the preclinical setting. 
 
Together, the findings in this thesis support the rationale for targeting uPAR-positive 
breast cancer cells using N-AI-loaded PAI-2-functionalised liposomes. The results also 
provide a basis for the further development of dual-ligand liposomes that can target 
heterogeneous tumour cells within the HER2-positive and TNBC subtypes, in which 
uPAR has been shown to play a key role in driving metastasis. Despite the hurdles left to 
overcome in the production, evaluation and translation of ligand-directed liposomes 
towards clinical use in the context of cancer therapy, the utility of liposome technologies 
is promising. The continued development of better methodologies and models to 
comprehensively characterise novel ligand-directed liposomes and assess the likelihood 
of their performance in humans, including the recapitulation of intratumoural 
heterogeneity, will likely improve the translation of novel targeted nanotherapies from 
preclinical models through to the clinic. 
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Appendix A: Absorption spectra of N-AI and liposome phospholipid 
 
The concentration of N-alkylisatin (N-AI) encapsulated in liposomes could not be 
determined by UV-vis spectrophotometry and interpolation from a N-AI standard curve 
as the liposome phospholipid interfered with the peak absorbance of N-AI at 310 nm and 
435 nm (Fig. A1). 
 
 
Figure A1: Liposome phospholipid interference with N-AI absorption spectrum. The 
phospholipid of empty liposomes interferes at 310 nm and 435 nm, the two peak absorption 
wavelengths for N-AI. 
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Appendix B: HPLC standard curve for N-AI quantification 
 
The concentration of N-alkylisatin (N-AI) loaded into liposomes was determined by high 
performance liquid chromatography (HPLC), which showed an N-AI concentration of 2.2 
mM, equating to 43.1% drug loading (% w/w) based on the starting amount of N-AI used 
in the liposome preparation. Concentration was determined by interpolation from an N-
AI standard curve (Fig. B1). 
 
 
Figure B1: HPLC standard curve for quantifying N-AI encapsulated in liposomes. 
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Appendix C: Quantification of PAI-2 by Western blotting 
 
A plasminogen activator inhibitor-2 (PAI-2) standard curve was successfully constructed 
using Western blotting and densitometry, which showed a linear relationship (Fig. C1). 
 
 
Figure C1: Western blot standard curve for quantification of PAI-2. (A) Various amounts of PAI-
2 were run on a SDS-PAGE gel and then transferred to a nitrocellulose membrane for detection by 
Western blotting. (B) Quantification of PAI-2 bands using densitometry shows a linear relationship. 
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Appendix D: Toxicology of N-AI-loaded liposomes in mice 
 
Toxicology studies performed by the Targeted Cancer Therapeutics Laboratory 
(University of Wollongong) have shown that N-alkylisatin (N-AI)-loaded liposomes are 
non-toxic in mice, with up to 100 mg/kg total dose of liposomal N-AI showing no adverse 
effects (Fig. D1). 
 
 
Figure D1: Toxicology testing of empty and N-AI-loaded liposomes in mice. Mice were treated 
with either a single bolus dose or multiple doses (indicated by arrows) of N-AI-loaded liposomes or 
empty (EMP) liposomes at an equivalent phospholipid concentration and weight change was 
monitored over time. 
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Appendix E: Final cohort organ weights in PK/BD study 
 
To determine the pharmacokinetic and biodistribution (PK/BD) profiles of N-AI-loaded 
non-functionalised liposomes (N-AI) and N-AI-loaded PAI-2-functionalised liposomes 
(N-AI PAI-2) in tumour-bearing mice, liposomes were labelled with tritiated cholesteryl 
hexadecyl ether (3H-CHE) to enable the detection of liposomes in plasma and tissues by 
liquid scintillation counting. Mice treated with N-AI and N-AI PAI-2 liposomes showed 
no significant differences in the average final weight of the kidneys, liver, spleen and 
lungs (Fig. E1). 
 
 
Figure E1: Final organ weights at experimental endpoint. At the end of each experimental time 
point, mice were euthanised by CO2 inhalation, and the (A) kidneys, (B) liver, (C) spleen and (D) 
lungs were removed in whole and weighed. Values are the mean ± s.d. (n = 24). n.s., not significant 
(P > 0.05). 
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Appendix F: ESI-MS of CF647-labelled PAI-2 
 
To visualise PAI-2 using single-molecule fluorescence microscopy, PAI-2 was labelled 
with a small red fluorophore (CF647, ~836 g/mol). Electrospray ionisation-mass 
spectrometry (ESI-MS) revealed up to 6 fluorophores per protein (average of 3) for 
CF647-labelled PAI-2 (Fig. F1). 
 
 
Figure F1: ESI-MS of CF647-labelled PAI-2. (A) Unlabelled PAI-2 and (B) CF647-labelled PAI-
2. Masses refer to the molecular weight of unlabelled PAI-2 (~45 kDa) with varying numbers of 
attached CF647 (~0.836 kDa) molecules. Masses were generated using MassLynx V4.1 (Waters, MA, 
USA). 
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Appendix G: Diameter of CO and PI dual-functionalised liposomes 
 
Liposomes functionalised with CF647-labelled PAI-2 and CF488-labelled trastuzumab 
(TZ) were prepared via the conventional (CO) or post-insertion (PI) method. Liposomes 
were analysed by dynamic light scattering before and after the functionalisation step to 
determine average liposome diameter. When the PI method was used, a significant 
increase in diameter (P < 0.05) was observed following functionalisation (Fig. G1). There 
was no significant increase in liposome diameter following functionalisation via the CO 
method. 
 
 
Figure G1: Diameter of liposomes before and after dual-functionalisation. A diameter increase 
was observed for liposomes prepared via the post-insertion (PI) method, but not for the conventional 
(CO) method, after functionalisation (funct). * = P < 0.05, n.s. = not significant (P > 0.05). 
 
 
 
 
 
 
